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ABSTRACT
THE MOLECULAR BASIS OF CASPASE-9 INACTIVATION
BY PKA AND C-ABL KINASES
FEBRUARY 2018
BANYUHAY PANINGBATAN SERRANO, B.S., UNIVERSITY OF THE PHILIPPINES
LOS BAÑOS
M.S., UNIVERSITY OF THE PHILIPPINES LOS BAÑOS
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Jeanne A. Hardy
Caspases are the cysteine proteases that facilitate the fundamental pathway of
programmed cell death or apoptosis. The activation and function of these powerful enzymes are
tightly regulated to ensure the faithful execution of apoptosis and prevent untimely cell death.
Many deadly human diseases such as cancer, neurodegeneration and autoimmune disorders have
been associated with defective activation and faulty regulation of caspases. As such, caspases are
considered as attractive drug targets, which when properly controlled, can lead to effective
therapeutics for apoptosis-related diseases. Thus, comprehensive investigations of the structure,
function and regulation of caspases are necessary to understand the complex mechanisms by
which caspases are controlled in order to harness their potential for therapeutic purposes. This
dissertation details the studies on the regulation of caspase-9 by phosphorylation mediated by the
kinases PKA and c-Abl. Complementary approaches of biochemistry, structural biology and cell
biology were utilized to elucidate the divergent mechanisms by which these kinases inhibit
caspase-9 function. A critical residue was revealed to be a hotspot for inactivation upon PKA
phosphorylation, utilizing two different mechanisms to silence caspase-9 activity. In addition, a
novel site of phosphorylation by c-Abl that leads to inactivation was uncovered and is unique to
caspase-9. These findings contribute to the growing information about caspases and kinases that
will aid in the development of therapeutic strategies for apoptosis-related diseases.
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CHAPTER I
INTRODUCTION

Apoptosis or programmed cell death is a conserved cellular pathway that serves as a
mechanism for multicellular organisms to undergo normal development, achieve homeostasis and
protect itself from cells that are in excess, not in use, damaged and/or potentially harmful to the
organism. At the center of this pathway are enzymes called caspases that coordinate the intricate
cascade of reactions to faithfully execute apoptosis. As specialized proteases, caspases display
exquisite specificity towards their substrates, altering substrate structure and function in an
irreversible manner. By inactivating or otherwise altering the function of a circumscribed number
of key substrates, caspases can control cell fate. Ultimately, it is the activity of the powerful
caspases that is responsible for the morphological changes that the cell undergoes during
apoptotic cell death. Because caspases play a crucial role in inducing cell death, their expression
and activation must be subject to tight regulation in order to maintain the balance between cell
death and survival. The long list of diseases associated with caspase dysfunction indicates the
severe consequences of their inappropriate activation and improper or lack of regulation in the
apoptotic pathways. Thus, caspases are considered to be attractive drug targets which, when
properly harnessed can lead to effective therapeutics for apoptosis-related diseases.
Apoptosis: Death for Survival
Apoptosis is central to the development and homeostasis of multicellular organisms. This
irreversible pathway is sensitive to cellular signals that decide whether a cell must die or not.
These death signals are then transduced via a series of biochemical reactions that commences in
the activation of caspases that finally cleave specific intracellular protein substrates to start
cellular destruction. Apoptosis is an active and deliberate kind of cell death, proceeding in an
orderly and efficient manner. This tight and precise control manifests in its perhaps most distinct
feature, which is the ability of cells undergoing apoptosis to avoid eliciting inflammatory
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responses, keeping neighboring cells intact. Morphological changes following apoptosis include
chromatin condensation, DNA fragmentation, cell shrinkage and membrane blebbing. The dying
cell is then rapidly eliminated by phagocytosis without prompting inflammation in the
surrounding areas.
The proper execution of apoptosis is critical to cellular and tissue homeostasis. Defects in
its regulation have been implicated in a plethora of life-threatening diseases. Insufficient and
suppressed apoptosis is considered a classic hallmark in many types of cancer, autoimmune
disorders and persistent viral infections. In contrast, degenerative diseases that destroy cells such
as Alzheimer’s, Huntington’s, as well as ischemia resulting from stroke and post-menopausal
osteoporosis are known to exhibit an excessive degree of apoptosis. (reviews1–4). The ability to
modulate cell death and survival is thus recognized for its immense therapeutic potential. In the
past few decades key participants in the apoptotic pathways have been identified and extensively
interrogated as potential targets for regulating apoptosis.
The Apoptotic Pathways
Depending on the nature of death signal that the cell receives, there are two pathways by
which apoptosis can proceed - the extrinsic, or death receptor pathway, and the intrinsic, or
mitochondrial pathway (Figure 1). The two pathways converge with the activation of the
executioner caspases, which ultimately cut hundreds of their specific protein targets to amplify
the cascade of cellular destruction.
In the extrinsic pathway, ligand binding of tumor necrosis factor (TNF) family such as
Fas, and TNF-related apoptosis-inducing ligand (TRAIL) ligands causes these death receptors to
cluster and recruit an adaptor protein Fas-associated death domain (FADD) and multiple
procaspase-8 molecules, forming a death-inducing signaling complex (DISC). The DISC serves
as a platform to increase the local concentration of procaspase-8 molecules, allowing its transprocessing and activation. Once active, caspase-8 cleaves and activates procaspases -3, -6 and -7
(reviews 5,6).
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Figure 1.1. The Apoptotic pathways.
The extrinsic pathway is activated by death ligand-binding, such as FasL or TNF-α, while the intrinsic
pathway is induced by mitochondrial stress such as DNA damage, hypoxia or build-up of reactive
oxygen species. Upstream caspases or initiators, caspase-8 and/or caspase-9 mediate the extrinsic and
intrinsic pathways, respectively. Both pathways converge with the activation of downstream or
executioner caspases -3, -6 and -7, thereby committing the cell to its demolition.

The intrinsic or mitochondrial pathway is activated as a response to cellular stress such as DNA
damage, toxins, hypoxia and activation of oncogenes, causing the outer mitochondrial membrane
to be compromised. This allows cytochrome c to leak out of the mitochondria into the cytosol
where it forms a heptameric complex with the apoptotic protease activation factor-1 (Apaf-1).
This platform then recruits procaspase-9 molecules form the apoptosome assembly7,8 where
caspase-9 molecules are activated. Highly active caspase-9 then becomes incredibly efficient in
cleaving and activating the executioner caspases,9 which in turn amplify the downstream
apoptotic signals. Although it seems that the two pathways are distinct from each other, crosstalk
does occur, resulting in feedback loops between pathways, as well as serving as linkages that
redirect caspases to participate in other signaling pathways.
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Caspases: The Core of the Apoptotic Machinery
Caspases are considered to constitute the core of the apoptotic machinery. Depending on
where they act in the apoptotic pathways, caspases are classified as either initiators, which
operate upstream such as caspases -2, -8 and -9, or executioners such as caspases -3, -6 and -7,
which facilitate downstream cleavage of hundreds of substrates in the apoptotic cascade10,11
(Figure 1.1). Caspases are essentially molecular scissors that derive their name from the cysteine
active site residue that they utilize in their chemistry and from their specificity to cleave after
specific aspartate residues found within a defined recognition sequence. All caspases contain the
catalytic dyad of a cysteine thiol and a neighboring histidine imidazole to perform hydrolysis of a
target peptide bond (Figure 1.2A).
Figure 1.2. Chemistry and architecture of
caspases.
(A) The His in the catalytic dyad promotes
the nucleophilicity of Cys in the active site,
which then performs a nucleophilic attack on
the peptide backbone of the target protein
substrate.
(B) Schematic representation of the structural
domains of caspases. Caspases contain a core
domain, which is composed of the large and
small subunits connected by an intersubunit
linker (ISL). At the N-terminus is a
prodomain (Pro) preceding the core of the
enzyme. The active site cysteine resides in
the large subunit. All caspases have cleavage
sites in the intersubunit linker. Most
caspases, particularly executioners, have a
cleavage site between the prodomain and the
large subunit. Cleavage sites are indicated by
arrows.
(C) Structure of a substrate-bound caspase
dimer (PDB ID: 1F1J) showing the active site
loops (L1, L2, L3, L4, from one monomer
and L2’ from the other monomer) and the
Cys-His catalytic dyad (shown as spheres).
The prodomain in all available crystal
structures of caspases is mobile and has not
been observed crystallographically, so was
modeled in this figure as light green dashed
lines.
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Structurally, all caspases contain the highly homologous protease or core domain that is
further subdivided into a large (17-20 kDa) and a small (10-12 kDa) subunit that are held together
by an intersubunit linker (ISL) (Figure 1.2B). The N-terminus is a stretch of residues that
comprise the prodomain (Pro), with the initiator caspases having longer and structured
prodomains than the executioners. Initiator caspases such as caspase-8 and -9 are monomeric
following synthesis on the ribosome, while executioners dimerize immediately upon ribosome
release. Mature caspases exist as homodimers, having the two monomers aligned in a head-to-tail
fashion (Fig. 1.2C). The two small subunits adjacent to one another make hydrophobic
interactions that form the dimer interface. At the center of the structure is a sheet of 12 contiguous
β-strands (six from each monomer) that are surrounded by several α-helices and a few short βstrands. The substrate-binding pocket that contains the active site is composed of four protruding,
dynamic loops (L1, L2, L3, L4) sampling different conformations and are reorganized and
stabilized upon substrate binding. A stabilizing element is the interaction of loops L4 and L2 from
one half of the dimer with the N-terminus of the small subunit (loop L2’) of the other half (Figure
1.2C). These loop interactions have been shown to be critical for caspase activity12, and has been
exploited to develop strategies to trap caspases into an inactive state that is incompetent to bind
substrate.
The activity of caspases ultimately determines cell fate and any inopportune activation or
inhibition is extremely detrimental to the cell. Because highly active caspases are lethal, they are
synthesized and stored in their inactive zymogen forms (procaspases). The requirements for
activation of executioner caspases are quite distinct from those of initiators. During zymogen
activation, executioner caspases require cleavage at the intersubunit linker in order to be
maximally active. These cleavage events are primarily carried out by initiator caspases, but could
also be achieved by self-proteolysis. In contrast, initiator caspases are recruited to multimeric
scaffolds such as the DISC (for caspase-8)13, PIDDosome (for casp-2)14 and the apoptosome (for
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caspase-9)7,15,16 for activation. Dimerization has also been shown to be paramount to caspase
activity (reviews17,18).
Targeting caspases to either inhibit or activate them is an efficient way to prevent or
accelerate cell death. Caspases are extremely selective proteases in the sense that they have strong
preference to cut after specific aspartate residue in their substrates, but do not cut after all
aspartates haphazardly. They are notably unlike other proteases that randomly cleave at any
available site bearing a recognized amino acid. Caspases are signaling proteases and are not
designed for degradation of substrates. They cut only at one or sometimes two sites. These
specific substrate modifications lead to either have them gain or lose function. The most
conserved region in the structure of caspases is the active site. The substrate-binding pocket has
evolved to retain specific residues that stringently recognize an aspartate in the P1 position of the
peptide, but this cleavage preference has been shown to extend to include glutamate and
phosphoserine

under

specific

circumstances19–21.

The

P4-P3-P2

residues

must

make

complementary interactions with other residues in the catalytic pocket for tighter binding and
cleavage. While the residues that compose the P1 pocket are highly conserved the P4, P3 and P2
pockets vary significantly between caspases.
The vast number and the range of protein substrates that undergo caspase cleavage, as
well as the discrepancies between cleavage preferences in vitro and intracellularly prompted the
idea that caspases possess exosites that serve as determinants of substrate recognition and
processing (Figure 1.3A). Recently, caspase-7 was revealed to possess a lysine-rich exosite patch
that facilitates faster cleavage of its substrate, poly(ADP ribose) polymerase 1 (PARP)22. In
addition to exosites, data are emerging that caspases have allosteric sites (Figure 1.3B) that can
act as switches when targeted by small molecules such as FICA and DICA in caspase-723, metalbinding such as zinc in caspase-624 and -925 and peptides as in the case of caspase-626. Allosteric
inhibitors generally function by trapping caspases into a conformational state that is incapable of
binding substrate (Figure 1.3B). These exosites and allosteric sites are now acknowledged to be
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excellent

target

regions,

because

while

modifying the active site serves to efficiently
and robustly inactivate caspases, it does not
confer any specificity towards a particular
caspase-substrate pair. Allosteric and exosite
regions, especially those that are found to be
unique to a specific caspase, could provide the
needed specificity when directed for caspase
inhibition or activation.
Natural Regulators of Caspase Activation
and Function
The whole ensemble of apoptosisrelated proteins must work in a precise and
Figure 1.3. Exosites and allosteric regions
control caspases function.
(A) Caspases possess exosites that aids in
recognition and binding of a cognate substrate.
Blocking the exosite results in either
unproductive binding or no binding of the
target substrate.
(B) In the absence of any inhibitor or substrate,
caspases predominantly exist in the zymogen
state (top). Binding of a compound to the active
site reorganizes and orders the loop bundle,
shifting the equilibrium in its active state
(middle). An allosteric inhibitor (such as FICA
and DICA for caspase-7) binding distal to the
active site drives back the equilibrium to the
zymogen state (bottom).

organized manner for apoptosis to function
normally.

As

critical

mediators

of

the

apoptotic pathways, it is only fitting that
caspase activity is tightly controlled. One can
imagine the lethal or deleterious consequences
when caspases are either missing/kept inactive
or

overexpressed/constitutively

active.

Knockout versions of mice that are deficient in

specific caspases either result in perinatal lethality or have developmental defects (review27). A
number of cancers28,29 and neurodegenerative diseases30,31 have been attributed to dysregulated
activity and inappropriate expression of caspases. Fortunately, constant check-and-balance
mechanisms have evolved to achieve timely activation and inhibition of caspases.
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Upstream of the caspase activation
cascade are Bcl-2 family proteins that are
either pro- or anti-apoptotic (Figure 1.4).
Many of the Bcl-2 family proteins are
harbored inside the mitochondria and upon
receiving an intracellular signal, these family
members compete to enable the mitochondrial
release of cytochrome c. Pro-apoptotic Bcl-2’s
Figure 1.4. Pro- and anti-apoptotic proteins
control the intrinsic pathway.

(BAX and BAK) induce or facilitate release of
cytochrome c while anti-apoptotic Bcl-2’s do

the opposite. IAPs (inhibitor of apoptosis proteins) are the first line of defense that keep caspase
activation in check either by directly interacting with caspases or by facilitating ubiquitination
and consequently proteasomal degradation of caspases (review32). Other cellular proteins
identified to contribute to caspase regulation include heat shock proteins (Hsps) which have been
observed to directly interact with caspases33–35 (for review:

32,36,37

) and alternatively spliced

caspase variants that generally act as dominant negatives38. In addition, adaptor proteins
containing binding motifs compete for interaction with caspase activating scaffolds/complex,
thereby regulating caspase activation.
It is also now becoming clear that caspases have evolved to be sensitive to changes
brought about by post-translational modifications (PTMs). Phosphorylation, nitrosylation,
ubiquitination and oxidative modification of caspases have been linked to both suppression and
induction of apoptosis (reviews39,40). Caspases are highly susceptible to modifications, and in
most cases these reported PTMs result in dramatic alteration of their function. The ability of other
proteins to modify the caspase structure and consequently transform its function is a promising
avenue for co-regulation of caspases and cognate enzymes, and sensitive regions or sites arising
from these PTMs can be exploited for precise control of caspase function.
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Among the PTMs in caspases,
phosphorylation

is

perhaps

the

most

documented and well-explored. Although
the apoptotic pathways do not directly
involve kinases in the signaling cascade,
activities of relevant kinases have been
determinants of the cell’s susceptibility to
death.

All

apoptotic

caspases

harbor

phosphorylation sites (Figure 1.5), and while
numerous cell-based studies have identified
the

relevant

caspase-kinase

pairs

and

Figure 1.5. Reported phosphorylation sites in
caspases.
Apoptotic caspases are phosphorylated at multiple
sites in their structure. Cleavage sites at the linker and
between the prodomain and large subunit are indicated
by arrows.

mapped their roles in the context of apoptosis, molecular details of the mechanisms of inhibition
or activation that these phosphorylation events confer to caspases are still lacking. It is notable
that these phosphorylation sites reside in different regions within the caspase structure, thus it is
highly likely that these regions are potential allosteric sites and exosites that can be exploited to
modulate the function of a specific caspase. An excellent model to interrogate the diverse
mechanisms of caspase phosphoregulation is that of the initiator caspase-9, whose great extent of
phosphorylation on all its domains could provide insights as to how phosphorylation precisely
influences caspase structure, activation and function.
The Initiator, Caspase-9
Caspase-9 is the initiator caspase that mediates the intrinsic apoptotic pathway. It is
synthesized as a 46-kDa zymogen that has a long prodomain called the caspase recruitment
domain (CARD) (res. 1-138) which, unlike in executioner caspases, does not get cleaved off
during zymogen activation8,16,41 due to its critical function of mediating caspase-9’s recruitment to
the apoptosome. The core of the enzyme is composed of the large subunit (res. 139-315) followed
by a long linker (res. 316-330) and a small subunit (res. 331-416). The catalytic dyad of C287 and
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H237 resides in the large subunit. There are
three

possible

cleavage

sites

in

the

intersubunit linker- E306, D315 and D330
(Figure 1.6A). The majority of self-cleavage
occurs at D315 with little observed cleavage
at E306. D330 is a cleavage site for caspase3, which is cleaved when the feedback loop
present

between

caspase-3

and

-9

is

activated.
Although predominantly present as
a monomer, the crystal structure of a
CARD-deleted caspase-9 (ΔCARD casp-9)
suggests that its active form is a dimer42.
Interestingly, the structure (PDB ID:1JXQ)
reveals that the two catalytic domains in the
dimer have different conformations (Figure
1.6B). One active site is catalytically
competent while the other is not, resting in
what is called an “inactive” active site.
Moreover, the loop bundle in this inactive
catalytic site resembles the conformation of
the

loops

assumed

by

the

caspase-7

zymogen, hence it is incompetent to bind

Figure 1.6. The caspase-9 structure.
(A) Domain organization of caspase-9 and location
of reported phosphorylation sites within the
caspase-9 structure, with cognate kinases indicated.
(B) Structure of substrate-bound, dimeric, fulllength caspase-9 showing the active site loops (L1,
L2, L3, L4 and L2’), phosphorylation sites (in
spheres) and the active site catalytic dyad (shown as
sticks) which is competent in only one monomer.
There is no existing structure of full-length caspase9; this structure was modeled using available crystal
structures of the CARD-deleted caspase-9 (PDB ID
1JXQ) and the complex between caspase-9 CARD
and Apaf-1 CARD (PDB ID 3YGS). The region
between the CARD and large subunit was modeled
as grey coils, as it is not present in any available
crystal structures of caspase-9.

substrate in this arrangement. The presence
of this catalytically incompetent active site
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was shown to be a result of alleviating steric clashes at the dimer interface should the site assume
an active conformation, and not simply an artifact of crystal contacts42.
Multiple Levels of Caspase-9 Activation
The activation of executioner caspases mainly lies in the intra-chain cleavage of the
prodomain and the intersubunit linker. Thus their activation is a direct consequence of the action
of initiator caspases. Unlike executioners wherein dimerization and cleavage renders them fully
active, initiator caspases, particularly caspase-9, are activated in a different manner, primarily
because there are no upstream proteases to cleave them. Caspase-9 does undergo self-processing,
but this does not seem to convert caspase-9 into its fully active state43,44. In addition, caspase-9
activity seems to be influenced more by intra- and inter-domain interactions than by cleavage.
This is supported by the observed increase in activity as protein domains are added stepwise to
interact with the caspase-9 catalytic core, which is the simplest unit to generate caspase-9
constructs that possess maximal intrinsic (basal) activity. The presence of the CARD increases
the activity of caspase-9 by ~20%, and is further enhanced five-fold in the presence of Apaf-1
CARD. The primary mode of caspase-9 activation is its recruitment to the apoptosome, in which
it achieves its maximal activity, rendering it extremely efficient in cleaving downstream caspases
and other substrates (Figure 1.7).
The apoptosome is a heptameric complex of Apaf-1, cytochrome c and d/ATP. Through
homotypic interactions between Apaf-1 CARD and caspase-9 CARD, caspase-9 gets
incorporated into the apoptosome where it undergoes auto-catalytic processing and activation.
When bound to the apoptosome, caspase-9 activity is increased by 1000-fold, prompting the idea
that caspase-9-bound apoptosome is the holoenzyme form of caspase-9. The fact that caspase-9
reaches its full activity in the apoptosome prompted many models of its activation (reviews45,46).
The induced proximity model suggests that the apoptosome serves as a platform to increase the
local concentration of procaspase-9 that results in trans-autoprocessing. However, this does not
explain why cleaved/processed caspase-9 is not fully active. The observation that caspase-9 is

11

Figure 1.7. Levels of caspase-9 activation.
Caspase-9 is predominantly monomeric, but requires oligomerization, minimally dimerization, for
activity. An increase in activity is facilitated by protein-protein interactions with Apaf-1 CARD.
Caspase-9 achieves full activity by interacting with full-length Apaf-1, which together with cytochrome
c, forms the apoptosome for caspase-9 binding. The structure of full-length caspase-9 was modeled
using the CARD-deleted caspase-9 structure (PDB ID: 1JXQ) and caspase-9 CARD in complex with
Apaf-1 CARD (PDB ID: 3YGS). The caspase-9 bound apoptosome was based on the structure reported
by Cheng, et al, 201648)

predominantly monomeric but requires dimerization to be active led to the proximitydimerization model: caspase-9’s recruitment to the apoptosome leads to increase in local
concentration and allows them to dimerize – and would also explain the ∆CARD caspase-9
crystal structure of being a catalytically active dimer. Another model is centered on the activating
caspase-9 by induced conformational changes in its active site as it is bound to the apoptosome.
These changes may possibly be brought about by interactions of the apoptosome to the
dimerization interface of caspase-9 thereby stabilizing the active loops, or by facilitating different
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oligomerization states of caspase-9. Recent near-atomic cryo-EM structures47,48 and biochemical
studies49 on caspase-9-bound apoptosome have provided a clearer picture of how caspase-9 is
poised to undergo activation in the apoptosome. Both models posit that proximity-driven
dimerization and induced conformational changes in caspase-9 upon apoptosome binding are
consistent with recent structures of the apoptosome.
While the canonical mode of caspase-9 activation lies in the apoptosome, caspase-9 has
also been observed to undergo activation by alternative mechanisms that are independent of the
apoptosome. This stems from observations that under certain cellular conditions such as viral
infection50 and lysosomal cell death51, caspase-9 undergoes cleavage and activation without Apaf1 or cytochrome c. Caspase-9 was also found to be present and activated in the “dependosome”, a
high-molecular weight complex composed of adaptor proteins (DRAL and TUCAN) and an E3
ubiquitin ligase (NEDD4)52,53, in a manner analogous to that of the apoptosome.
Intracellular Regulation of Caspase-9
Disturbance in the normal activation of caspase-9 has been linked to a number of
apoptosis-related diseases and thus caspase-9 is considered a therapeutic target. In certain cancers
and viral infections, caspase-9 has been observed as either poorly expressed or has diminished
activity. Very low or no expression levels of caspase-9 and caspase-7 are evident in colonic
carcinoma cells54 and caspase-9 expression was suggested to be a prognosticator of adverse
carcinoma55. In testicular cancer cells, caspase-9 activation fails and confers greater resistance to
apoptosis56. In degenerative diseases such as amyotrophic lateral sclerosis (ALS), caspase-9 was
found to be highly abundant and active57 in spinal cords of ALS subjects. Thus, due to the central
role of caspase-9 in apoptosis, it is heavily regulated in the cell to guarantee its proper and timely
activation.
The many layers by which caspase-9 can be activated allow for multiple levels of its
regulation. This multi-level regulation ensures that caspase-9 function is modulated with high
fidelity, even providing fail-safe mechanisms in case one mode of activation goes awry.
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However, this also causes caspase-9 activation to be particularly susceptible to various
intracellular imbalance or assaults in the apoptotic pathways. Nevertheless, from a therapeutic
viewpoint, one advantage of this multi-level regulation of caspase-9 is that it provides several
potential nodes for therapeutic intervention to specifically control caspase-9 function.
Caspase-9 endogenously experiences tight control by a number of mechanisms (Table
1.1). Mature caspase-9 is inhibited by XIAP by having its BIR3 domain interact with the small
subunit of caspase-9 thereby preventing its dimerization58. An isoform caspase-9b that lacks the
catalytic domain acts as a dominant negative factor and was found to interfere with caspase-9
CARD:Apaf-1 CARD binding

59

. Another CARD-containing protein that competes for Apaf-1

binding is TUCAN (tumor up-regulated CARD-containing antagonist of caspase-9), which is
found to be overexpressed in many types of cancer including breast, gastric and colon cancer 60,61.
Zinc, which only recently has emerged as a relevant apoptotic regulator, has been reported to bind
and inhibit caspase-962,63. Caspase-9 also undergoes post-translational modifications. Nitrosation
of the active site cysteine leads to its failure to self-activate64–66. Interestingly, ubiquitination of
caspase-9 has opposing effects, depending on the polyubiquitin linkage. XIAP also acts as an E3
ubiquitin ligase, appending K47-linked ubiquitin chains that leads to proteasomal degradation of
caspase-9. In contrast, the E3 ligase NEDD4 mediates K63-linked ubiquitination and this
apparently leads to a more stable caspase-9 in the dependosome and results in its activation52,53.
As previously mentioned, caspase-9 is extremely sensitive to phosphorylation, imparting another
level of regulation which is the main focus of this dissertation.
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Table 1.1. Natural regulators of caspase-9.
Regulation

Regulator

Result

Oligomerization

Self
Apaf-1/cytochrome c

Activation
Activation

Dimerization
Holoapoptosome formation

Protein binding

XIAP
Caspase-9b isoform
TUCAN/CARD8

Inhibition
Inhibition
Inhibition

Prevents dimerization
Competes for Apaf-1 CARD binding
Competes for Apaf-1 CARD binding

Metals

Zinc

Inhibition

Binds to active site and allosteric site

Nitrosation

NO

Inhibition

Modifies active-site cysteine

XIAP

Inhibition

NEDD4

Activation

K48-linkage; leads to proteasomal
degradation
K63-linkage; stabilizes caspase-9 in the
dependosome

Kinases

Inhibition
(mostly)

Ubiquitination

Phosphorylation

Mechanism

Many/diverse

Phosphorylation of Caspase-9 Alters the Apoptotic Response
Caspase-9 is extensively phosphorylated. Eleven sites, spanning all domains, are
reportedly phosphorylated by at least nine different kinases67 (Figure 1.6A). The high degree of
phosphorylation in caspase-9 highlights the various checkpoints that caspase-9 experiences
during apoptosis as it is poised to undergo self-activation and perform cleavage of executioner
caspases. Phosphorylation of caspase-9 has been implicated in insufficient apoptosis in Downs
syndrome68 and affects survival of breast and ovarian cancer cells69. The first report of its
phosphorylation is by Akt70 or protein kinase B (PKB), a serine-threonine kinase involved in
apoptotic suppression. Since then, caspase-9 has been reported as a target of kinases that are
involved in cell cycle (CDK169, CK271), cellular stress (PKC-ζ72, c-Abl73, Akt70) and extracellular
signals (ERK1,274 and DYRK1A75) . Cell-based studies on caspase-9 revealed that these kinases
inhibit apoptosis by preventing caspase-9 from self-processing and activation69,74,75, sometimes
despite the release of cytochrome c76.
The catalytic core of caspase-9 has the highest number of phosphorylation sites of all
domains of caspase-9. The most studied phosphorylation site in caspase-9 is T125. This residue
lies in the potentially flexible linker between the CARD and the large subunit. It is

15

phosphorylated by four different kinases (ERK 1 and 2 of the MAPK pathway, DYRK1A,
CDK1) that have been implicated in cancer and tumorigenesis. In fact, phosphorylation of this
residue has been found to be a hallmark of gastric carcinomas77. Akt/PKB, which was shown to
phosphorylate S196 is involved in signaling pathways that respond to growth factors, thus is an
important regulator of cell proliferation. Akt kinase transfected in HEK cells prevented caspase-3
from activating, thus suppressing cell death70. In cell extracts treated with okadaic acid, a
phosphatase inhibitor, caspase-9 was reported to be phosphorylated at S144 by an atypical PKC
isoform, PKCζ, upon inducing hyperosmotic shock using NaCl or sorbitol72. In this case, caspase9 failed to undergo processing and apoptosis was restrained in HEK293 cells. In many types of
cells elevated levels of cAMP have been found to confer resistance to apoptosis. The link
between the cAMP elevation and apoptosis is the activation of cAMP-dependent protein kinase
(PKA), which inhibits caspase-9 activation by phosphorylating it at three sites- S99, S183 and
S195. However, it was reported that direct phosphorylation of these three sites is dispensable to
caspase inhibition; instead it was suggested that PKA phosphorylates Apaf-1 and prevents it from
oligomerizing and recruiting cytochrome c78. Intriguingly and in contrast to the inhibitory effect
of kinases mentioned above, c-Abl is reported to promote caspase-9 processing at Y153 upon
araC (DNA replication inhibitor)-induced apoptosis. Cells expressing a knockout of this site,
Y153F, failed to undergo apoptosis even after araC treatment or exposure to UV radiation73.
Divergent Mechanisms of Caspase-9 Control by Phosphorylation
It is clear that caspase-9 activity is particularly sensitive to phosphorylation, given the
extent of its phosphorylation and the number of kinases that recognize it as a substrate. In the past
decade, advancement in proteomics have identified phosphorylation sites in caspases-9 and in
other caspases, but naturally, it has been difficult to perform wide-scale annotations under
different cellular conditions. And while cell-based studies have been instrumental in determining
the phenotypic consequence of either promotion or suppression of apoptosis upon
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phosphorylation of caspase-9, to date there has been insufficient information on the molecular
details to pinpoint the mechanism of phosphoregulation. Given the immense therapeutic potential
of targeting caspase-9, knowing the precise molecular details of its phosphoregulation is
absolutely essential if that mechanism is to be harnessed to specifically control caspase-9.
There are multiple aspects to caspase-9 phosphorylation that warrant deeper
investigation. First, it is noteworthy that phosphorylation sites in caspase-9 are not clustered in
one region, but rather are spread over different regions in caspase-9 structure (Figure 1.6B). All
domains of caspase-9 - the CARD, catalytic core and intersubunit linker - are phosphorylated.
Thus, phosphorylation of one site may confer a different mechanism of regulation to caspase-9,
especially considering the fact that there are multiple levels to exert control within the caspase-9
activation cascade. We have recently observed a dual mechanism of inactivation of caspase-7 by
the kinase PAK2, wherein phosphorylation at S30 prevents procaspase-7 binding to and
processing by caspase-9, and phosphorylation at S239 in the mature form directly blocks
substrate binding79. Second, given that there are multiple sites phosphorylated by a single kinase,
it is important to discriminate which site directly imposes a functional effect on caspase-9 upon
phosphorylation, and which are simply “bystander” or redundant residues. Such is the case for
caspase-9 phosphorylation by PKA, ERK1,2 and CK2 (Figure 1.6A) where more than one site is
phosphorylated by each kinase. Are all sites required to be phosphorylated to inactivate caspase9, or does a single residue serve as a predominant phosphoregulator of caspase-9’s catalytic
activity? While the concept of “bystander” or “silent” phosphorylation is replete in kinase
literature, non-observance of functional effects should be carefully interpreted. As caspase-9’s
activity is influenced by a variety of factors, the absence of a direct inhibition to the
catalytic/proteolytic activity of caspase-9 upon phosphorylation does not necessarily mean that
phosphorylation has no other influence on caspase-9 structure and function. Third, it is apparent
from the great extent of phosphorylation in caspase-9 that phosphorylation is a major and critical
regulator of its function. It is therefore fitting to ask whether there are more sites of
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phosphorylation in caspase-9 that are yet to be uncovered, in what cellular context and how
would it alter the apoptotic pathways. Finally, crosstalk between caspase-9 and its cognate
kinases has not been thoroughly interrogated. Caspases and kinases are in constant molecular
dialogue that allows for their co-regulation. Most caspases cleave the very kinase that
phosphorylates them, resulting in either gain- or loss-of-function, or localization of the kinase
into a different cellular compartment, thus tipping the balance between cell death and survival.
Given that at least nine different kinases phosphorylate caspase-9, it is conceivable that this
caspase-kinase interplay would play a more significant role in mediating the apoptotic response.
This dissertation focuses on addressing these molecular questions about caspase-9
phosphoregulation by employing sound and complementary studies of biochemistry, structural
biology and cell biology. Specifically, Chapter II investigates the single-site, dual-mechanism of
caspase-9 inhibition by PKA, a ubiquitous kinase that is involved in cellular signaling but whose
aberrant expression and activity has been observed in many cancer cell types. Chapter III delves
deeper into the hierarchical nature of caspase-9 activation by interrogating the physical
interactions between the caspase-9 CARD and its catalytic domains that affects caspase-9
stability, and how phosphorylation by PKA perturbs these interactions. In Chapter IV we identify
a novel site of phosphorylation in caspase-9 by c-Abl, a kinase that has both pro-apoptotic and
anti-apoptotic/pro-survival roles, and elucidate the mechanism of inactivation.
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CHAPTER II
PHOSPHORYLATION BY PROTEIN KINASE A DISASSEMBLES
THE CASPASE-9 CORE

Majority of this chapter is published: Serrano, B.P. and Hardy J.A. Phosphorylation by Protein
Kinase A Disassembles the Caspase-9 Core. Cell Death and Differentiation. In press (2018).

Abstract
Caspases, the cysteine proteases which facilitate the faithful execution of apoptosis, are
tightly regulated by a number of mechanisms including phosphorylation. In response to cAMP,
PKA phosphorylates caspase-9 at three sites preventing caspase-9 activation and suppressing
apoptosis progression. Phosphorylation of caspase-9 by PKA at the functionally relevant site
S183 acts as an upstream block of the apoptotic cascade, directly inactivating caspase-9 by a twostage mechanism. First, S183 phosphorylation prevents caspase-9 self-processing and directly
blocks substrate binding. In addition, S183 phosphorylation breaks the fundamental interactions
within the caspase-9 core, promoting disassembly of the large and small subunits. This occurs
despite S183 being a surface residue distal from the interface between the large and small
subunits. This phosphorylation-induced disassembly promotes the formation of ordered
aggregates around 20 nm in diameter. Similar aggregates of caspase-9 have not been previously
reported. This two-stage regulatory mechanism for caspase-9 has not been reported previously
but may be conserved across the caspases.
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Introduction
Caspases are specialized enzymes that coordinate the intricate cascade of reactions to
faithfully execute apoptosis. Caspases irreversibly cleave protein substrates causing gain or loss
of function, thereby committing the cell to its demise. Caspases display exquisite specificity
towards substrates, generally preferring to cleave after an aspartate, glutamate1,2 and in some
cases phosphoserine3. Apoptotic caspases are classified as either initiators (caspase-2, -8 and -9)
or executioners (caspase-3, -6 and -7). Uncontrolled activation of caspases is lethal, so caspases
are synthesized and held as inactive zymogens (procaspases) prior to apoptosis induction.
Activation generally relies on either recruitment to an activating scaffold (initiators) or cleavage
at the intersubunit linker forming a mature caspase (executioners) (for review4). Most procaspases
are homodimeric proteins that contain a highly homologous protease core, which can be cleaved
into two large and two small subunits. While executioner caspases are constitutive dimers,
initiator caspases exist in equilibrium between monomeric and dimeric states, with caspase-9
existing predominantly a monomer5,6. Upon activation, the highly dynamic loops comprising the
active site undergo conformational rearrangements to bind and cleave substrates, thereby
initiating cell death. Ultimately, caspase activity is intrinsic to apoptosis, so caspase expression
and activation is tightly regulated. This is achieved by a number of mechanisms which exert
control at various checkpoints in the cell. Improper regulation of caspases is associated with
diseases ranging from cancer to neurodegeneration (for review7–9). Thus, caspases are considered
attractive drug targets for apoptosis-associated diseases.
Phosphorylation is a central regulator of apoptosis (for review10–12). Although apoptosis is
unlike other classic signaling pathways because it does not directly utilize kinases, the related
activity of kinases can determine a cell’s susceptibility to death. All apoptotic caspases are kinase
substrates and caspases usually cleave the very kinases that phosphorylate them. Efforts to map
kinase-caspase co-regulation and competition are ongoing (for review10,12–14), however, a more
complex landscape of co-regulation becomes evident with the observation that some caspases
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have multiple phosphorylation sites involving several kinases. Thus, although cell-based studies
are fundamental in identifying cognate kinases and in determining the functional endpoint as
either caspase inhibition or activation, biochemical and structural studies are essential in
identifying critical residues and elucidating molecular details of diverse regulatory mechanisms
arising from phosphorylation.
Among the apoptotic caspases, caspase-9 appears to be most sensitive to
phosphorylation, which is mediated by a number of kinases activated in response to specific
cellular signals (for review15). For example, in many cell types elevated cAMP levels have been
found to confer protection from apoptosis16–19 due to sustained Protein Kinase A (PKA) activity,
which phosphorylates caspase-9 at three specific sites – S99, S183 and S195 – leading to failure
of caspase-9 activation and eventual suppression of apoptosis20. Intriguingly, however,
phosphorylation of these sites was reported to be dispensable in directly inhibiting caspase-9 and
it was instead suggested that PKA acts on a more upstream substrate such as Apaf-1 to prevent
caspase-9 activation. This observation seems to evoke silent or bystander phosphorylation in
caspase-9, and while non-functional phosphorylation does occur in other proteins21,22, the idea
that PKA phosphorylates all three sites without any functional consequence seems to differ from
what is known about the sensitivity of caspase activity to phosphorylation. Recent studies from
our group23,24 and others25 have revealed that caspase activity is directly affected by
phosphorylation both orthosterically and allosterically. In addition, the high conservation of
phosphorylation sites across species15 underscores the likelihood that phosphorylation yields
functional effects, as functional phosphorylation sites evolve more slowly than non-functional
sites22. Given the complexity of having three PKA phosphorylation sites, it is important to
differentiate sites critical to inhibition from non-functional sites and is paramount for unraveling
the dynamic control of caspase-9 activity by phosphorylation.
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Here we identify S183 as the functionally relevant site that leads to direct inhibition of
caspase-9 upon phosphorylation by PKA. Phosphorylation of the caspase-9 zymogen renders it
incompetent to bind substrate, whereas phosphorylation of the mature form destabilizes the
interactions within the caspase-9 core leading to its disassembly and formation of ordered
aggregates. Understanding the multi-level mechanisms by which phosphorylation controls
caspase-9 should provide new avenues to tap caspase-9’s therapeutic potential in apoptosisrelated disease.

Results
Phosphorylation of caspase-9 by PKA directly results in inhibition
All three reported sites of phosphorylation are located in the CARD (caspase activation
and recruitment domain) plus large (CARD+Lg) region of caspase-9 (Figure 2.1A). S99 is in the
highly flexible linker between the CARD and the large subunit. S183 sits just below Loop 1 (L1)
in the vicinity of the substrate-binding groove and S195 is at the bottom of the α1 helix (Figure
1B). Building on the report that PKA directly phosphorylates caspase-920, we tested whether PKA
activity affects caspase-9 function by assessing the ability of procaspase-9 to undergo selfprocessing in the presence of PKA and ATP. Procaspase-9 possesses a low level of basal
activity5,26,27 that allows in trans cleavage, under favorable conditions, to generate a mature,
active caspase-9. Even in homogeneous preparations of wild-type (WT) procaspase-9, the
intersubunit linker is rapidly cleaved, generating the CARD+Lg and small (Sm) subunits (Figure
2.2A). Addition of PKA with ATP greatly attenuated the rate of procaspase-9 self-cleavage
(Figure 2.2A).
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Figure
2.1.
Sites
of
PKA
phosphorylation in caspase-9.
(A) Domain architecture of caspase-9
showing the caspase activation and
recruitment domain (CARD) (yellow
green) and the protein core composed of
the large (dark green) and small (light
green) subunits connected by an
intersubunit linker with three cleavage
sites indicated by arrows: E306 (minor,
self cleavage), D315 (major, self
cleavage, and by caspase-8) and D330
(by caspase-3). The sites of PKA
phosphorylation are indicated by .℗ S99
is in the CARD while both S183 and
S195 are in the large subunit.
(B) Structure of the caspase-9 dimer with
phosphorylation sites (yellow spheres)
noted. There is no structure of fulllength caspase-9, so this model was built
based on the CARD-deleted caspase-9
structure (aa 138-416; PDB ID: 1JXQ)
and the caspase-9 CARD structure (aa 195; PDB ID: 3YGS) from a dimeric
complex with Apaf-1 CARD. The region
containing S99 is not present in either
structure and is potentially highly
disordered, so it was modeled as a dark
gray coil. S99 is in the CARD; both
S183 and S195 are located in the α1
helix.
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To quantify the extent of inhibition, we assayed the activity of caspase-9 WT upon
phosphorylation using the fluorogenic peptide substrate Ac-LEHD-AFC. Caspase-9 activity
decreased two-fold when incubated with active PKA (Figure 2.2B), suggesting that PKA
significantly inhibits caspase-9 function. In vitro phosphorylation using PKA and [γ-32P]ATP
showed phosphorylation of the CARD+Lg region of caspase-9 (Figure 2.2C) as expected, with a
corresponding marked inhibition of caspase-9 activity (Figure 2.2D). This sensitivity of caspase-9
to phosphorylation is reversible. When treated with lambda protein phosphatase (λPP), we clearly
observed the removal of phosphates from caspase-9 (Figure 2.2C). More importantly, caspase-9
activity was relieved of inhibition upon dephosphorylation (Figure 2.2D). This ability of caspase9 being to be inactivated and reactivated by phosphorylation and dephosphorylation underscores
the idea that this modification acts as a direct molecular regulator.
S183 is the critical residue leading to caspase-9 inactivation upon PKA phosphorylation
To pinpoint the single residue most responsible for inhibition, we generated
unphosphorylatable alanine variants and correlated their phosphorylation states (Figure 2.2E)
with caspase-9 inhibition (Figure 2.2F). All single alanine variants were phosphorylated only in
the CARD+Lg region, and while S99A and S195A were highly inhibited by phosphorylation,
S183A activity was less affected by phosphorylation. Among the double unphosphorylatable
variants (S99A/S195A, S99A/S183A, S195A/S183A), only S99A/S195A, in which only S183
can be phosphorylated, displayed inhibition similar to phosphorylated WT.
Having all three sites unphosphorylatable (S99A/S183A/S195A) resulted in low levels of
non-specific phosphorylation, especially with the appearance of a band corresponding to a
phosphorylated small subunit (Figure 2.2E). This extra, non-specific phosphorylation had no
substantial influence in caspase-9 activity, since only background levels of inhibition for the triple
alanine mutant were observed. These results clearly suggest that S183 is the dominant site
responsible for the inhibition due to PKA phosphorylation.
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Figure 2.2. Phosphorylation of caspase-9 by PKA results in significant inhibition of caspase-9.
(A) Active PKA inhibits self-processing of procaspase-9. Full-length (FL) procaspase-9 WT rapidly undergoes
self-cleavage to generate the CARD+Large (Lg) and Small (Sm) subunits as assessed by Coomassie-stained SDSPAGE analysis. Addition of PKA and ATP to procaspase-9 slows the rate of self-cleavage, so that caspase-9
remains predominantly in the full-length, uncleaved form even after 4 h incubation.
(B) Addition of active PKA to cleaved caspase-9 WT results in a two-fold decrease in caspase activity after 2 h as
measured by the hydrolysis of the fluorogenic caspase-9 substrate Ac-LEHD-AFC, suggesting that PKA treatment
leads to inhibition. Percent caspase-9 activity is normalized against activity in the absence of PKA. Data shown are
means (± SEM) of three independent trials on three separate days.
(C) Caspase-9 is phosphorylated by PKA only in the CARD+Lg region, as detected by autoradiography after in
vitro phosphorylation using [γ-32P] ATP for 4 h. There is no visible phosphorylation in the Sm subunit. PKA is
phosphorylated during overexpression in bacteria73, so it does not get efficiently labeled by [γ-32P] ATP. Treatment
of PKA-phosphorylated caspase-9 with λ protein phosphatase (λPP) results in dephosphorylation as manifested by
loss of signal in the autoradiogram (labeled here and in the succeeding figures as 32P).
(D) Phosphorylation of caspase-9 is reversible. Caspase-9 phosphorylated by PKA is inhibited. Treatment of
phosphorylated caspase-9 with λ protein phosphatase (λPP) relieves the inhibition. Percent inhibition for
phosphorylated caspase-9 (with both PKA and ATP present) was normalized against activity in the nonphosphorylated form (with PKA but no ATP present). Data shown are means (± SEM) of three independent trials
on three separate days.
(E) Unphosphorylatable alanine variants (single, double and triple alanine substitutions at phosphorylated serines)
and catalytic site-inactivated variant C287A were subjected to in vitro phosphorylation by PKA for 4 h. Double
alanine variants show (observed by Coomassie-stained SDS-PAGE analysis in the first of each pair of panels)
decreased levels of phosphorylation as the weaker intensity of the bands in the autoradiogram (second of each pair
of panels). The triple alanine variant shows only weak, non-specific phosphorylation in the small subunit,
indicating that all three sites S99, S183 and S195 are phosphorylated by PKA.
(F) Inhibition by phosphorylation of WT caspase-9 and alanine variants. Only when S183 is available to be
phosphorylated (WT, S99A, S195A and S99A/A195A) does caspase-9 experience significant inhibition. All S183A
variants are insensitive to PKA-mediated inhibition. The catalytic parameters of alanine variants are indicated in
Table 1. Percent inhibition for phosphorylated caspase-9 (with both PKA and ATP present) was normalized against
activity in the non-phosphorylated form (with PKA but no ATP present). Data shown are means (± SEM) of three
independent trials on three separate days.
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PhosphoS183 caspase-9 and the phosphomimetic S183E are completely inactive
Due to low levels of non-specific phosphorylation observed in vitro, we prepared
versions of caspase-9 that are unambiguously phosphorylated at only one site. We used a
genomically recoded E. coli method28 to genetically encode site-specific phosphoserine
incorporation during protein production. Three versions of caspase-9 that displayed
phosphoserine only at S99, S183 or S195 (phosphoSer99, phosphoSerS183 and phosphoSerS195,
respectively) were produced. All phosphocaspase-9 variants, as well as unphosphorylated WT
caspase-9, were predominantly in the zymogen form (Figure 2.3A). WT caspase-9 and both
phosphoSer99 and phosphoSer195 were able to self- process, while phosphoSer183 remained in
its full-length/zymogen form (Figure 2.3A), suggesting that phosphoS183 limits caspase-9
activity. Consistent with the ability to self-process, phosphoS99 and phosphoS195 showed
LEHDase activity, whereas phosphoS183 had no measurable activity (Figure 2.3B), clearly
demonstrating that phosphorylation at S183 inactivates caspase-9.
Although the phosphocaspase variants are the biologically relevant forms, the yield of
phosphoserine-incorporated caspase-9 was extremely low. To obtain sufficient quantities to
enable thorough interrogation of the effects of phosphorylation on caspase-9 function and
structure, we generated phosphomimetic variants in which glutamate was substituted for
phosphoserine. Following expression, S99E was observed in the mature, cleaved form and was
catalytically active, with a modest three-fold reduction of activity as compared to the WT (Figure
2.3C, 2.3D).
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Figure 2.3. Caspase-9 phosphorylated at S183 and phosphomimetic S183E are inactive.
(A) Uncleaved zymogen versions of caspase-9 (WT and phosphocaspase, indicated with ℗ preceding the
phosphoserine residue) purified from E. coli C321.ΔA which allows site-specific incorporation of phosphoserine,
were subjected to self-cleavage for 2 h and assessed by Coomassie-stained SDS-PAGE analysis. Only caspase-9
specifically labeled at S183 (phosphoS183) did not self-process, indicating that its activity is inhibited. PhosphoS99
and S195 were able to self-process with kinetics similarly to WT caspase-9.
(B) LEHDase activities of phosphocaspase-9 variants. Activity was measured after 2 h to allow selfcleavage/activation of phosphocaspase-9. PhosphoS183 exhibited no LEHDase activity. Data shown are means (±
SEM) of three independent trials on three separate days.
(C) Phosphomimetic S183E was expressed as full-length, uncleaved caspase-9, unlike WT and phosphomimetics
S99E and S195E which were expressed in a mature, cleaved state following expression, as assessed by Coomassiestained SDS-PAGE analysis. The constitutively two-chain (CT) version of caspase-9 is generated from the
independent translation of the CARD+Lg and Sm subunits. CT WT and CT S183E are the cleaved forms of caspase9.
(D) Catalytic parameters for caspase-9 phosphomimetic variants. Only the phosphomimetic S183E has a dramatic
effect on caspase-9 activity in both full-length, uncleaved and CT versions. Data shown are means (± SEM) of three
independent trials on three separate days.

S195E was also in the mature, cleaved state and had WT-like activity. In contrast, the S183E
substitution adversely affected caspase-9 activity. In addition to retaining a zymogen form, it was
also catalytically incompetent to turn over substrate (Figure 2.3C, 2.3D). The expression and
activity profiles of the phosphomimetics were consistent with what we observed for the
phosphocaspase counterparts, indicating that they are robust phosphomimetics.
While cleavage is not an absolute requirement for caspase-9 activation, we sought to test
whether the loss of activity of S183E is due to its zymogen nature, or due to the intrinsic changes
brought about by the phosphomimetic mutation. S183E expressed from a constitutively two-chain
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(CT) construct, in which the CARD+Large region is translated independently from the small
subunit, yields the mature, cleaved form (Figure 2.3C). Even in this mature version, CT S183E
was still catalytically inactive (Figure 2.3D) with a 5-fold or greater increase in KM and
approximately 100-fold decrease in kcat, suggesting that both substrate binding and catalytic
ability are impacted. Overall, S183E shows a 1000-fold less efficient kcat/KM than WT caspase-9.
S183A, which retains similar size and is uncharged like a serine residue, is active, albeit
exhibiting a 10-fold lower catalytic efficiency than WT, primarily due to its decreased kcat (Figure
2.3D). The triple alanine mutant S99A/S183A/S195A also shows only a 10-fold decrease in
kcat/KM (Table 2.1). This suggests that phosphorylation or glutamate substitution, which results in
a dramatic 1000-fold decrease in activity, is the major cause of inhibition, rather than simply
generic sensitivity of the S183 site. These data strongly suggest that phosphorylation of S183
directly impairs substrate binding.

Table 2.1. Catalytic parameters1 for caspase-9 alanine variants using substrate Ac-LEHD-AFC.
KM

kcat

103 x kcat / KM

(µM)

(s-1)

(µM-1s-1)

S99A

768 ± 100

0.64 ± 0.04

0.83

S195A

681 ± 71

1.22 ± 0.05

1.8

S99A/S195A

469 ± 41

1.03 ± 0.03

2.2

S99A/S183A

1203 ± 100

1.16 ± 0.05

0.96

S195A/S183A

1318 ± 107

1.17 ± 0.05

0.89

726 ± 71

0.20 ± 0.01

0.26

Caspase-9 variant

S99A/S183A/S195A
1

Values are mean (± SEM) of three trials done on three separate days.
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Phosphorylation at S183 disorients a conserved S1 arginine leading to impaired substrate
binding
S183 resides just below Loop 1 (L1) which, together with L3, L4, L2 and L2’, form the
active site loop bundle. L1 contains the highly conserved and critical R180. R180 plays two
important roles. It directly binds substrate P1 residues and it orients R355, the most critical
residue for substrate recognition, which makes bidentate interactions with substrate. The proper
positioning of R180 is primarily due to an H-bond with the hydroxyl side chain of S183, with
another set of H-bonds provided by their amide backbones (Figure 2.4A). These interactions
ideally situate R180’s guanidinium group to interact with the P1 aspartate in the substrate,
keeping it in position for the active site residues to perform catalytic cleavage (Figure 2.4B).

Figure 2.4. Model for caspase-9 inhibition by phosphomimetic S183E and phosphoS183.
(A) Structure of caspase-9 dimer (PDB ID IJXQ) highlighting the substrate-binding groove. Critical
interactions between S183 (yellow sticks) and the conserved S1 subsite R180 (green sticks). R180 is an
important residue that makes contacts with P1 aspartate in the substrate (light gray sticks).
(B) Models for inhibition of caspase-9 by S183E and phosphorylation at S183. Substitution at S183 by
glutamate or phosphoserine are predicted to result in a steric clash with R180, thus disorienting the
active site loops
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The inability of S183E and phosphoS183 to bind substrate appears to stem from a steric clash
between E183 or phosphoS183 and R180 (Figure 2.4B). The additional bulk and extra charge
coming from these groups should cause R180 to become displaced from the S1 pocket,
consequently disorienting the active site loop bundle, thus making caspase-9 incompetent to bind
substrate. This model is consistent with the behavior of S183A which, although incapable of
being an H-bond acceptor to R180, provides enough space to allow R180 attain the proper
conformation to interact with the substrate, and thus exhibits activity, albeit a decreased one. This
mechanism of inhibition of substrate binding is also consistent with the kinetic data for S183E
(Figure 2.3D) and phosphoS183 (Figure 2.3B) in which both are completely inactive.
Phosphomimetic S183E impacts recognition by caspase-8
A hallmark of caspases is their involvement in complex cleavage cascades requiring that
various caspases recognize and cleave other caspases. Caspase-9’s canonical function is to cleave
executioner caspases, but it is also cleaved and activated by caspase-8 (at D315) 29,30 and caspase3 (at D330)31–33. We assessed the changes brought about by the phosphomimetic in the ability of
other caspases to cleave caspase-9. For these experiments it is important that the intrinsic ability
of S183E be understood. Whereas WT caspase-9 fully self-processes immediately, the full-length
S183E phosphomimetic was completely devoid of self-processing activity (Figure 2.5A) so any
processing can be attributed to caspases other than caspase-9.
S183E, like the full-length catalytically inactive variant C287A, was susceptible to
cleavage by caspase-3 (Figure 2.5B, 2.5D) but remained completely inactive even after cleavage
(Figure 2.5C), consistent with what was observed for CT S183E which was inactive in its mature
form. Although caspase-8 was not as efficient as caspase-3 in cleaving caspase-9, it was striking
that S183E remained mostly in its full-length form after incubation with caspase-8, suggesting
that S183E transforms caspase-9 into a non-optimal substrate of caspase-8 (Figure 2.5D) and may
represent another layer of regulation of caspase-9 by phosphorylation at S183. Phosphorylation of
caspase substrates has been reported to alter their susceptibility to caspase cleavage (for
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review10). This effect, whether promotion or protection against cleavage, is commonly observed
when phosphorylation is directly adjacent to the caspase cleavage site. In this case, however,
S183 and the cleavage site D315 in the linker are distal in sequence (Figure 2.1A). Thus it is
possible that the long linker of caspase-9 (which is not ordered in any crystal structure) has a
conformation bringing it in the vicinity of S183 where phosphorylation alters the ability of
caspase-8 to cleave and activate caspase-9. Alternatively, S183E could be negatively influencing
the interface between caspase-9 and caspase-8, perhaps by exploiting an allosteric mechanism or
by disrupting a possible exosite on caspase-9 required for interaction with caspase-8.

Figure 2.5. S183E impacts recognition by caspase-8.
(A) WT and S183E uncleaved zymogens were incubated for 8 h to allow self processing. S183E shows
no self-processing activity as assessed by SDS-PAGE analysis.
(B) S183E is cleaved by caspase-3 at D330. The catalytic-site substituted C287A and S183E
phosphomimetic are cleaved in a similar manner by caspase-3 at D330 as assessed by SDS-PAGE
analysis. Since C287A and S183E are both catalytically inactive, the cleavage products (CARD+Lg and
Sm) result from the activity of caspase-3. In contrast, WT caspase-9 can self-process, resulting in a
small subunit spanning residues 316-422 (Sm316-422) or can be cleaved by caspase-3, resulting in a small
subunit spanning residues 331-422 (Sm331-422).
(C) The catalytic-site inactivated variant C287A, the S183E phosphomimetic or WT caspase-9 were
incubated for 2 h with caspase-3 to allow processing and then tested in an LEHDase activity assay.
S183E does not gain activity even after cleavage by caspase-3. Data shown are means (± SEM) of three
independent trials on three separate days.
(D) The catalytic-site inactivated variant C287A or the S183E phosphomimetic were incubated for 6 h
with caspase-3 or caspase-8 to observe processing.. Whereas C287A is fully processed by both caspase3 and caspase-8, S183E is only cleaved by caspase-3. S183E remains almost uncleaved after incubation
with active casp-8, suggesting that S183E is a poor substrate for caspase-8.
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CT S183E breaks the interaction between the large and small subunits
The catalytic core of a caspase-9 monomer
is formed from the regions that become the large
and small subunits after cleavage5,34 (Figure 2.1B).
The strong association between caspase large and
small

subunits

is

maintained

by

critical

interactions that form and stabilize the core of both
monomeric and dimeric caspase-9. In dimeric
caspase-9, six β strands from each monomer
associate edge-to-edge to form one contiguous 12stranded β sheet across the dimer interface held
together tightly by a series of hydrophobic
residues on both the large and small subunits5.
Although the subunits are expressed independently
of each other in the CT version of WT caspase-9,
they associate and assemble to form a properly
folded protein composed of one small and one
large subunit. This tight association between
subunits usually manifests through their co-elution
on an ion exchange gradient during protein
purification,

coupled

with

co-varying

band

intensities of the subunits visible in a Coomassiestained

denaturing

gel.

This

behavior

was

observed for CT WT caspase-9, where peak
fractions corresponded to the co-elution of the
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Figure 2.6. S183E breaks interactions
within the core of caspase-9.
(A) Anion exchange chromatogram (bottom)
and Coomassie-stained gel of peak fractions
(top) for CT WT caspase-9. CARD+Lg and
Sm subunits co-elute and corresponding band
intensities co-vary along the salt gradient
during an anion exchange column, suggesting
tight interaction of the subunits in the
caspase-9 core.
(B) Anion exchange chromatogram (bottom)
and Coomassie-stained gel of peak fractions
(top) for CT S183E. The independent elution
of the Sm subunit from the CARD+Lg
indicates dissociation of core subunits of
S183E.

CARD+Lg and Sm subunits along a salt gradient and the subunit band intensities on a denaturing
gel clearly co-varied (Figure 2.6A). This suggests that CT WT is well-behaved and properly
folded, as supported by the data that it has the same catalytic efficiency as the FL WT (Figure
2.4D). In contrast, CT S183E CARD+Lg and Sm subunits eluted separately on an anion exchange
column (Figure 2.6B). This separate elution of subunits implies that S183E breaks the
interactions between the large and the small subunits, making the protein unstable. We also
observed that traditional caspase purification schemes were not suitable to purify CT S183E, as
we always obtained impure protein, thus CT S183E was purified from inclusion bodies and
refolded (see Methods). In both approaches, purified CT S183E displayed no caspase activity,
likely due to loss of or weakening of interactions between the large and small subunits of caspase9.
Phosphorylation of S183 unfolds and disassembles the caspase-9 core
The fact that S183E decreased the interactions between the large and small subunits
suggests that phosphorylation of S183 could have a similar effect. We used caspase-3 to cleave
full-length (FL) versions of caspase-9 phosphomimetics to assess the impact of cleavage of a
phosphorylated zymogen on stability of the caspase-9 core. Caspase-3 natively cleaves caspase-9
at D330; in vitro this occurs efficiently even at very low concentrations (Figure 2.7A). FL C287A
and FL S183E showed distinct migration on a native gel (Figure 2.7B) with no significant
aggregation nor any additional bands for each protein, suggesting that the protein samples
retained their native, properly folded states. Upon cleavage by caspase-3, C287A’s mobility only
shifted slightly. In striking contrast, cleaved S183E exhibited a dramatic shift in mobility on a
native gel (Figure 2.7D). Since protein mobility in native gels depends on the conformation as
well as the charged state of a protein, this significantly altered mobility of cleaved S183E implies
a shift in conformation to one distinct from a properly folded, cleaved caspase-9.

38

Figure 2.7. S183E is highly destabilized upon cleavage.
(A) Full-length (FL) S183E phosphomimetic and C287A catalytic site-inactivated variant are cleaved
by caspase-3 (casp-3) in the same manner and with similar efficiencies as assessed by denaturing
Coomassie-stained SDS-PAGE.
(B) FL C287A, FL S183E and cleaved WT caspase-9 showed similar, compact migration along the
native (non-denaturing) Coomassie-stained agarose gels, indicative of properly-folded proteins.
(C) Thermal melting curves generated from differential scanning fluorimetry using SYPRO® orange.
Both FL C287A and FL S183E showed typical melting transitions. FL S183E’s stability is less than
that of FL C287A and comparable to that of a cleaved WT caspase-9 (Table 2.2). Data shown are the
mean of three independent trials. Fluorescence values were normalized against the lowest and highest
values in each data set.
(D) Caspase-3-cleaved S183E exhibits a dramatic shift in mobility on a Coomassie-stained native
agarose gel relative to casp-3-cleaved C287A caspase-9.
(E) Thermal melting curves of caspase-3-cleaved C287A and S183E. Caspase-3-cleaved C287A
shows a melting transition similar to uncleaved C287A. No melting curve is observed for caspase-3cleaved S183E. Data shown are means of three independent trials. Fluorescence values were
normalized against the lowest and highest values in each data set.
(F) FL phosphomimetic variants and FL S183A were prepared in the background of the C287A
mutation to prevent self-cleavage. All caspase-9 variants were cleaved by caspase-3 in the same
manner as assessed by denaturing Coomassie-stained SDS-PAGE.
(G) Coomassie-stained native agarose gel of FL phosphomimetic variants and FL S183A. Compact
migration on the native gel suggests these caspase-9 variants are properly folded.
(H) Thermal melting curves of full-length phosphomimetic variants and S183A. All variants
displayed normal melting transitions. Data shown are means of three independent trials. Fluorescence
values were normalized against the lowest and highest values in each data set.
(I) Cleavage by caspase-3 of phosphomimetic variants and S183A did not significantly alter
mobilities on a Coomassie-stained native agarose gel. Only caspase-3-cleaved S183E showed a
significant shift in mobility, indicating a substantial change in the folded state of the protein.
(J) Thermal melting curves of caspase-3-cleaved phosphomimetic variants and S183A. All variants
displayed normal melting transitions, except for casp-3-cleaved S183E. Data shown are means of
three independent trials. Fluorescence values were normalized against the lowest and highest values
in each data set.
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The stability of S183E before and after cleavage was assessed by a thermal shift assay by
differential scanning fluorimetry (DSF). Both FL C287A and FL S183E exhibited typical melting
curves, indicating that they are properly folded (Figure 2.7C). It is notable, however, that the FL
S183E is less stable than FL C287A (Table 2.2). After cleavage by caspase-3, no drastic changes
in the melting transitions of C287A were observed, however, cleaved S183E was severely
destabilized and no melting transition was observed (Figure 2.7E). The magnitude of the initial
fluorescence was also very high, suggesting that cleaved S183E was already in an unfolded or
molten globule state at the start of the thermal denaturation.

Table 2.2. Melting temperatures2 (Tm) obtained from thermal shift assay of caspase-9 full-length and
caspase-3-cleaved variants.
Caspase-9 variant

2

Tm (˚C)
Full-length (FL)

Cleaved by caspase-3

C287A

46.2 ± 0.1

40.6 ± 0.5

S183E

42.5 ± 0.2

no fit

S99E/C287A

46.7 ± 0.6

39.0 ± 0.3

S195E/C287A

46.5 ± 0.2

41.4 ± 0.2

S183A/C287A

44.7 ± 0.1

38.6 ± 0.2

WT (cleaved)

42.5 ± 0.3

not done

Values are mean (± SEM) of three trials done on three separate days.

We likewise tested whether the corresponding phosphomimetics of the two other sites
(S99 and S195) would impart instability to caspase-9 upon cleavage by caspase-3. We also
sampled S183A to discriminate the effect of a stringent (glutamate) from a conservative (alanine)
modification on stability. The phosphomimetics and S183A were constructed in the background
of C287A to remove the ability to self-process. Caspase-9 S99E/C287A, S195E/C287A and
S183A/C287A (Figure 2.7F) all showed properties of properly-folded proteins as demonstrated
by their distinct migration on a native gel (Figure 2.7G) and by exhibiting typical protein melting
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curves (Figure 2.7H, Table 2.2). Upon cleavage by caspase-3, none of the three variants showed
dramatic shifts in either gel mobility (Figure 2.7I) or melting transitions (Figure 2.7J). Strikingly,
amongst all the caspase-9 variants, a dramatic mobility shift and unusual melting curve were
again only observed for cleaved S183E. Moreover, phosphorylation at S183 by PKA
recapitulated what we observed for cleaved S183E. Using S183A and S99A/S195A to direct
phosphorylation to S99/S195 or S183, respectively, we found that only when S183 is
phosphorylated by PKA is the mobility shift similar to cleaved S183E (Figure 2.8). This
demonstrates that phosphorylation at S183 destabilizes the caspase-9 monomer, and subsequent
cleavage at the linker causes the core subunits to dissociate, rendering caspase-9 non-functional.

Figure 2.8. Phosphorylation of caspase-9 by PKA at S183 results in destabilization similar to
caspase-9 S183E.
(A) Mature, cleaved forms of caspase-9 unphosphorylatable alanine variants were incubated with
PKA and ATP to direct phosphorylation specifically at S99 and S195 or at S183. No impact on
mobility was observed upon Coomassie-stained denaturing SDS PAGE.
(B) Mobility shifts of unphosphorylated (no ATP) and phosphorylated (+ ATP) S183A or
S99A/S195A caspase-9 following non-denaturing native agarose gel electrophoresis after 15 min
or 1 h of phosphorylation. After 1 h of phosphorylation, S99A/S195A (conditions promoting S183
phosphorylation) exhibited a drastic shift in migration, similar to what was observed in cleaved
S183E, indicating that S183 phosphorylation destabilizes caspase-9 leading to a shift in the
conformation.

41

Caspase-3-cleaved S183E caspase-9 forms ordered aggregates
Destabilized and partially unfolded globular proteins are known to have an increased
propensity to aggregate in vitro35. We reasoned that the unfolded nature of S183E following
cleavage could potentially render caspase-9 prone to aggregation. The tendency of cleaved S183E
to form aggregates was assessed by monitoring Thioflavin T (ThT) fluorescence in vitro. A large
increase in ThT fluorescence was observed for cleaved S183E (Figure 2.9A). In contrast, there
was little to no increase in fluorescence observed for FL S183E, and cleaved or FL C287A.
Cleaved S183E was found exclusively in the insoluble fraction, while most of cleaved C287A
remained in the soluble fraction (Figure 2.9B). This magnitude of increase in ThT fluorescence,
as well as the rapid kinetics of aggregate formation, strongly indicate that cleaved S183E forms
aggregates which assume a regularity in structure, particularly an assembly or stacking of βsheets, since amorphous or early aggregates are not known to bind ThT36,37.
The size and morphology of the aggregates were visualized by transmission electron
microscopy (TEM). The shape of the aggregates varied from circular to elongated clusters that
also ranged in size from 10-40 nm (round) and 40-80 nm (elongated) (Figure 2.9C, Figure 2.10).
At 400,000x magnification, the microscope was able to resolve individual units that are
approximately 2-5 nm in diameter, which corresponds to the diameter of caspase-9 monomers,
which are 2.5 nm in diameter. Moreover, it appears that the aggregates were assembled from
proteins arranged adjacent to one another. Although not sufficient to form fibrils, this
arrangement appears to confer enough structural regularity to form ordered aggregates that bind
ThT.
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Figure 2.9. Cleaved S183E forms ordered aggregates.
(A) In situ ThT fluorescence monitored for 12 h. Only caspase-3-cleaved S183E showed significant
increase in ThT fluorescence, suggesting that it forms higher order oligomers or aggregates. Very
little increase in ThT fluorescence was observed for FL S183E or cleaved C287A. Data shown are
means (± SEM) of three independent trials done on three different days.
(B) SDS-PAGE analysis by Coomassie staining of the pellet (P) and supernatant (S) fractions of FL
caspase-9 C287A or S183E after 12 h of cleavage by caspase-3. The caspase-9 CARD+Lg and Sm
subunits fractionated mostly into the soluble supernatant for cleaved C287A, while for cleaved
S183E, the subunits are found exclusively in the insoluble/ pellet fraction.
(C) TEM images of aggregates of cleaved S183E. Individual units (e.g. caspase-9 monomers) appear
to form ordered aggregates (enlarged images). The scale bar is 40 nm wide and 10 nm for selected
enlarged images; all images are magnified 400 000x.
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Figure 2.10. TEM images of negatively stained aggregates of cleaved S183E.
Sample TEM images collected from various grids. The scale bar is 40 nm wide; all images are
magnified 400,000x.

Cell-Based Studies to Interrogate Phosphorylation of Caspase-9 Intracellularly
Our in vitro phosphorylation results clearly demonstrated that phosphorylation of S183
leads to dramatic inhibition of caspase-9 activity. We recognized the importance of showing the
biological relevance of S183 phosphorylation. An ideal experiment would be to knock-out
endogenous caspase-9 in cells and individually introduce wild-type (WT) caspase-9 and the
unphosphorylatable variants S183A, S99A/S195A, and S99A/S183A/S195A. Upon expression,
endogenous PKA would be activated by treatment with a cAMP analog or an activator of
adenylate cyclase to induce the synthesis of cAMP. The phosphorylation states of each variant
can be assessed by immunoblot against phosphoserine after immunopull-down with a caspase-9
antibody. The LEHDase activities of cell lysates can then be measured and correlated to the
phosphorylation state of caspase-9.
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While it appears that these experiments are straightforward, it is quite important to take
note that the caspase-9 variants do not have WT-like activities (Figure 2.3D, Table 2.1). In fact,
the activities of S183A and the triple mutant S99A/S183A/S195A is decreased to only ~10% of
the WT enzyme. Thus the maximum enzyme activity that can be measured from cells transfected
with S183A or the triple mutant will almost be close to background. In addition, the extent of incellular phosphorylation must also be taken into consideration, since only a certain fraction of the
caspase-9 pool is usually phosphorylated (refer to Chapter IV, Figure 4.13B). These factors must
be carefully considered, otherwise interpreting the results will be quite confounding and
conclusions derived from those interpretations will be misleading. Nevertheless, we decided to
pursue these cell-based experiments to support and strengthen our model that S183
phosphorylation in caspase-9 is functionally and biologically relevant.
Instead of knocking out caspase-9 in cells,
we used a caspase-9-deficient cell line, Jurkat JMR.
This particular Jurkat clone was resistant to
etoposide-induced cell death, which was found to be
a consequence of the absence of caspase-967,68. We
confirmed from immunoblot using an anti-caspase-9
antibody that JMR does not express any endogenous
caspase-9 (Figure 2.11), and was a good cell line to
transfect with caspase-9 variants.
Prior to transfection, it is imperative to

Figure 2.11. Jurkat JMR cells are deficient
in casp-9.
Immunoblot of lysates of Jurkat JMR cells
show that JMR cells are casp-9- deficient. As
controls, HEK293T cells were used to verify
the antibody against caspase-9 and caspase-3.
Caspase-3 is present in both JMR and
HEK293T.

ensure that PKA is present and can be activated in JMR. JMR cells were treated either with a
common cell-permeable cAMP analog, 8-BrcAMP, or with Forskolin, which is an activator of
adenylate cyclase that synthesizes cAMP. In order to check that PKA is specifically activated,
cells were pre-treated with a PKA-specific inhibitor, H8969. Immunoblot against the catalytic
domain of PKA shows that PKA is expressed in JMR (Figure 2.12). More importantly, JMR was
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amenable to PKA activation by treatment with
Forskolin. Using an antibody that specifically
recognizes phosphorylation of PKA substrates
with a defined consensus sequence, it was
observed that Forskolin strongly induced the
phosphorylation of these substrates compared
with 8-BrcAMP. Phosphorylation of PKA
substrates was diminished when cells were pretreated with H89, a PKA inhibitor, indicating

Figure 2.12. PKA is activated by Forskolin
and inhibited by H89.
JMR cells were treated with Forskolin (30 µM
for 20 min) or 8-BrcAMP (1 mM, 30 min). For
PKA inhibition, cells were initially treated with
H89 (20 µM, 20 min) prior to Forskolin or 8BrcAMP treatment.

that phosphorylation was specific PKA activation in JMR cells.
JMR cells were transfected to transiently express WT caspase-9 and the catalytic siteinactive variant C287A. Low transfection efficiencies were observed (Figure 2.13A), which were
not unusual for Jurkat cell lines. However, it appears that the expression of WT caspase-9 was
toxic to JMR cells. After 48 h of transfection, cells began to form unusually large clumps and
exhibited morphologies of dying cells (Figure 2.13B). This was confirmed by Trypan Blue
staining of dead cells. After 48 h, only about 40% of cells in WT-transfected JMR cells were
alive (Figure 2.13C). It is then highly likely that transfection of any active variant of caspase-9
into JMR cells would also be toxic. This would be a reasonable outcome, since JMR cells which
were previously caspase-9-deficient could be more sensitive to caspase-9 activity especially when
overexpressed. While others have managed to introduce WT caspase-9 into JMR cells to generate
a stable caspase-9-expressing cell line68, our efforts were not as successful. Thus, even by scalingup both transfection and cell culture to have enough material to work with, it would be extremely
difficult to interpret whether any change in caspase-9 activity in PKA-active and PKA-inactive
cells is due to its phosphorylation, since JMR with WT caspase-9 would have already induced
apoptosis prior to PKA activation.
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Figure 2.13. Transfection of active, wild-type (WT) caspase-9 leads to cell death in JMR cells.
Jurkat JMR cells were transfected with vector only or 3x-FLAG-tagged caspase-9 variants (catalytic siteinactivated C287A or wild type). 48 h post transfection, cells were counted, washed with PBS, and lysed.
(A) Caspase-9 C287A is moderately expressed in Jurkat JMR, whereas active WT caspase-9 is weakly
expressed.
(B) Cell morphology of vector-, C287A- and WT caspase-9-transfected Jurkat JMR. Cells transfected with
WT caspase-9 exhibit morphology of unhealthy and dying cells. Cells were visualized using ZOE
fluorescent imager (BioRad) in bright-field mode.
(C) Relative amount of live/healthy JMR cells 48h after transfection. % live cells was measured by Trypan
Blue staining and counted using the TC20 automated cell counter (BioRad).

These results underscore the challenges in conducting and interpreting caspase functional
assays in cells, particularly when one intends to assign a loss-of-function property to a mutation
or modification of a specific residue. Besides having necessary controls, it is critical to have prior
knowledge of the intrinsic properties, specifically activity, of any caspase variant that will be
introduced in the cell.
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Discussion
Phosphorylation is recognized as one of the global regulators of caspase function, but the
molecular basis of how this modification mediates caspase structure and function, especially of
caspase-9, is vastly understudied. Our results demonstrate that phosphorylation of caspase-9 by
PKA at S183 is sufficient to directly inactivate caspase-9 activity and hence block the apoptotic
cascade. This result agrees well with the data in the report that initially identified the three sites of
PKA-mediated phosphorylation20 however our new data on the kinetic activity of the S183
substitution variants (Table 1) substantially impacts the conclusions made in the earlier work. The
prior report20 measured DEVDase activity in cell extracts that had been depleted of caspase-9,
supplemented with either WT caspase-9 or the unphosphorylatable S99A/S183A/S195A variant
by in vitro translation and finally activated to apoptosis with cytochrome c. We surmise that the
prior work was not based on transfection due to the fact that transfection of active caspase-9 is
toxic (Figure 2.13), which prevented our exploration of the function of caspase-9 in a whole-cell
context. In the in vitro translation assays, they found that DEVDase activity in cell extracts
supplemented with either WT or the S99A/S183A/S195A variant were sensitive to the presence
of PKA, leading to the conclusion that PKA does not directly act on caspase-920. Caspase-9
shows strong LEHDase activity, but very weak DEVDase activity38. The major DEVDases
activated by cytochrome c addition in HeLa cell extracts are caspase-3 and caspase-7, so the
earlier assay20 measured the downstream activity of caspase-3 and -7 but did not directly assess
the activity of caspase-9. The implicit assumption in the experiment was that caspase-3 and -7 are
activated by the added WT or S99A/S183A/S195A caspase-9, however the intrinsic activity of
S99A/S183A/S195A caspase-9 was not reported. In our work, we have shown that the intrinsic
activity of S99A/S183A/S195A (Table 2.1) is decreased to only ~10% of WT caspase-9 activity.
Due to the inherent differences in the catalytic activity of WT and S99A/S183A/S195A caspase-9,
if caspase-9 had been responsible for activating the measured DEVDase activity, then the activity
in the cell extracts supplemented with S99A/S183A/S195A should have been only ~10% of the
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WT levels. That was not the case. The S99A/S183A/S195A DEVDase activity in the absence of
PKA was 84% of that of WT caspase-9. This strongly suggests that the DEVDase activity was
not due solely to activation by caspase-9, but was probably due to activation of caspase-3 and -7
by another factor, likely caspase-8. Thus the interpretation that PKA was not acting directly on
caspase-9 is confounded by the assumption that S99A/S183A/S195A is fully active. Our kinetic
data on the intrinsic activity of S99A/S183A/S195A allows an updated interpretation of the prior
data, which is consistent with direct inactivation of caspase-9 by PKA.
The hierarchical nature of caspase-9 activation allows phosphorylation to exert multiple
levels of regulation during the life cycle of caspase-9. It is conceivable that caspase-9
phosphorylated at S183 would still be recruited to the apoptosome since CARD:CARD
interactions are not likely disrupted, however this phosphorylated form of caspase-9 is inherently
non-activatable. It appears that phosphorylation at S183 should not favor a conformation in either
the zymogen or cleaved form that would allow caspase-9 to bind substrate, even if it were docked
as part of the apoptosome, the ultimate caspase-9 activating platform. Thus, phosphorylation at
S183 acts as a block in the initiation phase of the caspase activation cascade, by rendering
caspase-9 incapable of cleaving executioner caspases. S183 resides within the vicinity of the
active site. Other caspases such as caspase-6 and caspase-7 are similarly phosphorylated at sites
neighboring the active site loops which results in inhibition by preventing these loops to assume
an active conformation23–25. This mechanism likewise appears to be pertinent to phosphorylation
of caspase-9 at S183, thus this orthosteric nature of inhibition emerges as a common theme
among phosphorylated caspases.
It is evident from our in vitro experiments that the two other sites, S99 and S195 are
phosphorylated

by

PKA,

yet

the

phosphorylated

versions

and

their

corresponding

phosphomimetics showed little or no influence in any of the caspase-9 activities we interrogated.
One possibility is that these are simply “functionally neutral” sites that have persisted through
evolution since they do not confer any disadvantage associated with their phosphorylation21,22.
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Another possibility is that their phosphorylation may influence caspase-9 on a different level than
directly affecting its catalytic activity. Given that S99 resides within the CARD, phosphorylation
may impact either caspase-9’s recruitment or its conformational activation in the apoptosome.
S195 is highly exposed on the surface of helix α1, and phosphorylation might mediate proteinprotein interactions with other caspase-9 substrates. These possible mechanisms warrant further
studies to uncover other levels of caspase-9 phosphoregulation.
Crosstalk usually occupies the regulatory landscape involving caspases and cognate
kinases (for review10). This caspase-kinase interplay is essential in keeping the balance between
cell death and survival. Typically, caspases cleave their cognate kinase, either freeing up
regulatory elements and relieving the inhibited state, or rendering the kinase inactive (for
review10). In our in vitro phosphorylation assays, we observed no cleavage of PKA by caspase-9.
Should there be an interplay in a cellular context, a caspase cleavage site within PKA and
homotypic binding motifs present in both enzymes are requisites. However, sequence analysis
predicted no caspase-9 cleavage sites in PKA, which could indicate that the interplay is heavily
weighted towards that of caspase-9 phosphorylation and its subsequent inhibition. Moreover, the
observation that the phosphomimetic S183E greatly attenuates its cleavage by caspase-8 (Figure
4D) suggests that once phosphorylated, caspase-9 could no longer be alternatively activated by
the extrinsic pathway. Thus it appears that the impacts of phosphorylation by PKA prevails over
several modes of caspase-9 activation. PKA is overexpressed in many cancers (for review39–41)
and phosphorylation of caspase-9 to prevent its full-scale activation could be one of the
mechanisms by which unregulated PKA could promote tumorigenesis, proliferation and
transformation.
S183 appears to be a hotspot for inactivation upon phosphorylation, utilizing divergent
mechanisms to limit caspase-9 activity. In addition to directly blocking substrate binding, our
results have uncovered that S183 phosphorylation breaks the critical interactions within the
caspase-9 core causing it to change conformation. This dramatic transition is fascinating since
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S183 is not situated at the interface of the large and small subunits, hence this dissociation seems
most likely to stem from conformational strains translated from one region to another within the
caspase-9 core. We believe this to be the first report of such a mechanism for inactivation by
phosphorylation. Moreover, this phosphorylation-induced destabilization appears to affect the
mature (cleaved) form of caspase-9 more severely than the zymogen, likely due to covalentlyinduced proximity.
On one hand, we could view this in the context of caspase-9 activation in the apoptosome
where an S183-phosphorylated caspase-9 would remain non-activatable and would likely
disengage from the apoptosome because it is no longer structurally and functionally intact after
maturation. On the other hand, it is possible that caspase-9 can enter a different pathway that
allows it to assume altered conformations that could potentially confer different functions to
caspase-9 beyond its known role in activation of executioner caspases. Unfolding mechanisms
have been observed to serve as direct regulators of signaling pathways, wherein unfolding
facilitates remodeling of the active site or binding interfaces, allow disorder-to-order transitions
and vice-versa, or interconvertion between tertiary and quaternary structures (for review42,43).
Here we observed that unfolded, phosphorylated caspase-9 serves as a precursor to forming
ordered aggregates.
Accumulation of unfolded protein is a hallmark of protein aggregation diseases such as
Alzheimer’s, Huntington’s and amyotrophic lateral sclerosis (ALS) (for review44,45) and a
common feature of toxic aggregation is phosphorylation (for review46). Phosphorylation of Tau,
amyloid-β and α-synuclein has been associated with accelerated misfolding, aggregation and
toxicity47–49, and while it may be reminiscent of what we observed with the phosphorylationinduced unfolding of caspase-9, to date no disease of such type has been attributed to caspase-9
aggregation. Hence, it seems that evolution has allowed this unfolding and aggregation
mechanism of caspase-9 to persist because it does not appear to be deleterious to the cell,
potentially due to low caspase-9 titers intracellularly. Whereas amyloid-like aggregates and fibrils
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are usually associated with and causative of diseases, functional aggregates have also been
identified to be exploited in many species35,50 to play a number of valuable roles. Cell death and
inflammation pathways are known to utilize functional aggregates or higher-order structures to
amplify and propagate signals, increase local concentration, facilitate recruitment or even direct
subcellular localization51–57. Other cell death-related proteins known to assemble into higher-order
structures in vivo include caspase-158, apoptosis-associated speck-like protein containing CARD
(ASC)59, and Bax and Bak60. Thus the idea of a caspase-9 functional aggregate in the cell is not
unprecedented, and it is worthwhile to note that we observed caspase-9 aggregation under
conditions that are close to physiological. Nevertheless, whether these aggregates actually form in
vivo and what their functional roles are in the cell remain to be explored. One could only
speculate that at least for S183-phosphorylated caspase-9, these aggregates may prevent
apoptosis, yielding either protective or, more likely, proliferative effects. Regardless, this is the
first report of caspase-9 forming higher-order structures in the absence of any other protein or
recruitment platform. PKA recognition sites are present in the sequences of other caspases
including caspase-3, -6, -7, -8, and -10, although PKA-mediated regulation of these caspases has
not been reported. Given the high structural homology among caspases, it is likely that other
caspases may also form similar ordered aggregates in response to phosphorylation.
The mechanisms by which phosphorylation modulates protein structure and function are
diverse and heterogeneous; each of these mechanisms is tailored and engaged to effectively
regulate specific signaling pathways. Phosphoregulation stems from altering protein
conformations and modulating protein-protein interactions. Conformational changes range from
small or local to those that translate into larger structural rearrangements, resulting in activation
or inhibition of a protein. Typical of these phosphorylation-induced perturbations are disorder-toorder transitions and vice versa that have been reported to be common functional and stability
switches61–64. Phosphorylation also imparts change in specificity, often creating new sites for
recognition such as protease cleavage14, metal/cofactor binding and priming sites during
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sequential activation or binding (for review65,66). In addition to inducing shifts in conformational
states of proteins, phosphorylation greatly influences protein-protein interactions, and is often
responsible for transitions between oligomeric states and complexes of proteins. In the case of
caspase-9, a unique two-stage mechanism of caspase phosphoregulation is revealed. First,
phosphorylation directly blocks substrate binding and inactivates caspase-9. In addition,
phosphorylation at a site distal from the small:large subunit interface, dissociates the two
constitutively interacting chains, thereby promoting the disassembly of the caspase core leading
to inhibition. Whether this unfolding/disassembly mechanism is coupled to the assembly of
higher order caspase-9 complex or aggregates in the cell, the nature and structure of these
aggregates, and their functional or biological relevance in protection from or causation of disease
remain to be examined.

Materials and Methods
DNA constructs and E. coli strains
The caspase-9 (C9) full-length wild-type (C9FL) expression construct consists of the fulllength, C-terminal His6x-tagged human caspase-9 gene (amino acids 1-416 plus the six terminal
Histidines) in pET23b27 (gift of Guy Salvesen). The caspase-9 constitutively two-chain (C9 CT)
expression construct consists of a synthetic gene (Genscript, Piscataway NJ) in pET21b that
encodes E. coli codon-optimized human caspase-9 that is built for separate expression of the
caspase-9 large subunit (amino acids 1- 315) independently from the small subunit (amino acids
316-416 + His6x) which was under the control of a second ribosome binding site. Caspase-9
variants encoding amino acid substitutions were generated using the QuikChange site-directed
mutagenesis method (Stratagene/Agilent, Santa Clara CA). The caspase-3 wild type expression
construct consists of the full-length, C-terminal His6x-tagged human caspase-3 gene (amino acids
1-279 plus six terminal His) in pET23b70 (gift of Guy Salvesen). The gene for the catalytic
subunit of PKA in pET15b71 was expressed from a construct supplied by Susan Taylor (Addgene
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plasmid # 14921). The SepOTSλ (phosphoserine orthogonal translation system) plasmid, pBADGST-AmpR vector, and the fully recoded E. coli strain C321.ΔA28 were gifts from Jesse Rinehart
(Yale University).
Expression and Purification of Proteins
Purification of soluble caspase-9 proteins. Caspase-9 variants (except C9 CT
S99A/S183A/S195A) were transformed into BL21(DE3) strain of E. coli. The cultures were
grown in 2xYT media with 100 µg/mL of ampicillin at 37˚C with vigorous shaking until they
reached an optical density (OD600) between 1-1.2. The temperature was lowered to 15˚C and
protein expression was induced by adding 1 mM of IPTG (Anatrace, Maumee OH). Protein
expression was allowed to proceed for 3 h (except for C9 FL WT zymogen which was expressed
for only 30 min, C9FL S183A, C9FL S99A/S183A and C9FL S195A/S183A which were
expressed for 16 h) and cells were harvested by centrifugation at 4 700 x g for 10 min at 4˚C. Cell
pellets were stored at -80˚C, freeze-thawed and lysed in a microfluidizer (Microfluidics, Inc.,
Westwood MA) in lysis buffer (50 mM sodium phosphate pH 7.0, 300 mM NaCl and 2 mM
imidazole). Cell lysates were centrifuged at 30 600 x g for 50 min at 4˚C to remove cellular
debris. The supernatant was filtered through 0.45 µm PVDF (EMD Millipore, Billerica MA) filter
and loaded unto a 5-mL HiTrap Ni-affinity column (GE Healthcare, Pittsburgh PA). Proteins
were eluted using a linear gradient of 2-100 mM imidazole in lysis buffer. Protein fractions were
analyzed by SDS PAGE and fractions containing caspase-9 were pooled and diluted 8x with a
buffer containing 20 mM Tris pH 8.5 and 5 mM DTT (buffer A) and loaded onto a HiTrap Qcolumn (GE Healthcare). Proteins were eluted by a linear gradient from 0-275 mM of NaCl in
buffer A. Caspase-9 eluted in buffer A at 180 mM NaCl. Peak fractions were analyzed by SDS
PAGE for purity and were stored in -80˚C until use.
Purification of caspase-9 from inclusion bodies. Caspase-9 variants C9 CT
S99A/S183A/S195A and C9 CT S183E were transformed into BL21(DE3) strain of E. coli. The
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cultures were grown in 2xYT media with 100 µg/mL of ampicillin at 37˚C with vigorous shaking
until they reached OD600=0.8. The temperature was lowered to 30˚C and protein expression was
induced by addition of 1 mM IPTG. Protein expression was allowed to proceed for 3 h and cells
were harvested by centrifugation at 4 700 x g for 10 min at 4˚C. Cells were freeze-thawed and
lysed in a microfluidizer in a buffer containing 10 mM Tris pH 8.0 and 1 mM EDTA. The lysate
was centrifuged at 27000 x g for 1h at 4˚C. Inclusion bodies were purified from the pellet by was
washing 3x with buffer containing 100 mM Tris pH 8.0, 1 mM EDTA, 500 mM NaCl, 2%
Triton-X and 1M urea, centrifuging at 17 000 x g for 15 min between washes. The pellet was then
washed 3x with 100 mM Tris pH 8.0 and 1 mM EDTA to remove urea and performing the same
centrifugation between washes. The pellet was then resuspended in minimal volume of 6M
guanidine chloride with 20 mM β-mercaptoethanol and placed in a rotating platform for 1 hour.
The mixture was centrifuged at 20 000 x g for 20 min at 4˚C. Supernatant containing denatured
caspase-9 was added dropwise to a refolding buffer containing 100 mM Tris pH 8.0, 10%
sucrose, 0.1% CHAPS, 150 mM NaCl and 10 mM β-mercaptoethanol. Refolding was allowed to
proceed by dialyzing the solution against 10 mM Tris pH 8.0, 0.1 mM EDTA and 10 mM βmercaptoethanol. The dialysate was centrifuged at 20 000 x g for 10 min at 4˚C to remove
aggregates and the supernatant was filtered through a 0.45 µm PVDF membrane and loaded onto
a 5-mL HiTrap Q-column. The column was developed by a linear gradient from 0-250 mM NaCl.
Refolded caspase-9 eluted in a buffer containing 20 mM Tris pH 8.0, 200 mM NaCl and 5 mM βmercaptoethanol. Fractions were analyzed by SDS PAGE for purity and were stored in -80˚C
until use.
Purification of caspase-3 protein. The gene for full-length wild-type Caspase-3 in
pET23b was transformed into BL21(DE3) E. coli. Cultures were grown in 2xYT media with 100
µg/mL Ampicillin at 37˚C with shaking until OD600=0.8. Protein expression was induced by
addition of 1 mM IPTG at 30˚C for 3 h and cells were harvested by centrifugation at 4 700 x g for
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10 min at 4˚C. Cells were freeze-thawed, lysed in a microfluidizer in a lysis buffer containing 50
mM sodium phosphate pH 8.0, 300 mM NaCl and 2 mM imidazole, and centrifuged at 30 600 x g
for 50 min at 4˚C to remove cellular debris. The supernatant was loaded onto a 5-mL HiTrap Niaffinity column, washed with 50 mM imidazole and proteins were eluted with 250 mM imidazole
in lysis buffer. The eluted protein fraction was diluted six-fold with 20 mM Tris pH 8.0 with 2
mM DTT (buffer A) and loaded onto a HiTrap Q-column. Proteins were eluted by a linear
gradient from 0-500 mM of NaCl in buffer A. Caspase-3 eluted in buffer A with 250 mM NaCl.
Peak fractions were analyzed by SDS PAGE for purity and were stored in -80˚C until use.
Purification of PKA catalytic subunit. PKA in pET15b was transformed into the
BL21(DE3) strain of E. coli. Cultures were grown in 2xYT media with 100 µg/mL of ampicillin
at 37˚C with vigorous shaking until OD600=0.6. Protein expression was induced by addition of 0.5
mM IPTG at 16˚C for 12 hours. Cells were harvested by centrifugation at 4 700 x g for 10 min at
4˚C. PKA was purified as reported72 with modifications. Cells were resuspended in lysis buffer
(50 mM KH2PO4 pH 8.0 and 20 mM Tris-HCl), lysed by microfluidizer and centrifuged at 30 600
x g for 45 min at 4˚C to remove cellular debris. The supernatant was loaded onto a 5-mL HiTrap
Ni-affinity column and the column was washed with 50 mM imidazole in lysis buffer. Proteins
were eluted with 500 mM imidazole in lysis buffer, diluted 6x with a buffer containing 50 mM
KH2PO4 pH 7.15, 20 mM KCl and 1 mM DTT and loaded onto a 5-mL HiTrap Q-column. The
column was developed by a linear gradient from 20-250 mM KCl. PKA eluted in a buffer of 50
mM KH2PO4 pH 7.15, 150 mM KCl and 1 mM DTT. Fractions were analyzed by SDS-PAGE to
determine purity (Fig. S4) and were stored in -80˚C until further use.
In vitro phosphorylation and dephosphorylation of caspase-9
Autophosphorylation of PKA. PKA was incubated in kinase buffer (50 mM Tris-HCl pH
7.5, 10 mM MgCl2, 0.1 mM EDTA and 0.01% Brij 35) with 250 µM ATP at 30˚C for 30 min.
Phosphorylation of caspase-9. Caspase-9 was added to the autophosphorylated PKA
reaction and supplemented with 250 µM [γ-32P]ATP (10 µCi/µL, Perkin Elmer) and incubated for
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30 min to 4 h at 32˚C. Reactions were stopped by adding SDS-PAGE loading dye and boiling for
10 min.
Dephosphorylation of caspase-9. Lambda protein phosphatase (NEB) was used to
dephosphorylate caspase-9. 100 U of phosphatase were used for every 10 µM of phosphate
attached to caspase-9. The reaction was allowed to proceed for 1 h at 30˚C. The reaction was
stopped by addition of SDS-PAGE loading dye and boiling for 10 min. Removal of phosphates
was confirmed by loss of band intensity in the phosphorimage. Phosphorylation levels were
quantified from an ATP standard curve on the same phosphorimage (Figure 2.14). Bands were
imaged using Typhoon FLA 7000 (GE Healthcare) and quantified using ImageQuant TL software
(GE Healthcare).

Figure 2.14. ATP standard curve to determine phosphorylation levels.
(A) [γ-32P] ATP standard samples were prepared by serial dilution. 1 µL was spotted and
exposed on the same phosphorimage as the phosphorylated caspase-9 samples.
(B) Standard curve constructed from intensities of [γ-32P] ATP standards. Band and spot
intensities were quantified using ImageQuant software.

Assay for caspase-9 activity
Caspase-9 was diluted in caspase-9 activity assay buffer (100 mM MES pH 6.5, 10%
PEG 8 000, 5 mM DTT) to a final concentration of 800 nM. A substrate titration was performed
in the range of 0 - 3 mM fluorogenic substrate Ac-LEHD-AFC (Ex 365/Em 495) (Enzo Life
Sciences). Enzyme concentrations were determined by labeling the active-site using a quantitative
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inhibitor z-VAD-FMK. The rate of LEHD cleavage was measured with a fluorescence plate
reader (SpectraMax M5, Molecular Devices, Sunnyvale CA).
Caspase-9 cleavage assays
Caspase-3 (30 nM) or caspase-8 (300 nM) was diluted in their respective activity buffers
(caspase-3: 20 mM HEPES pH 7.5, 150 NaCl 5 mM CaCl2, 10% PEG 400 and 2 mM DTT;
caspase-8: 10 mM PIPES pH 7.2, 100 mM NaCl, 1 mM EDTA, 0.05% CHAPS, 10% sucrose and
2 mM DTT). Caspase-9 (3 µM) (catalytic site-inactive variant C287A or FL S183E) was added
and the cleavage reactions were incubated at 37˚C for times indicated. For self-cleavage of
caspase-9, 3 µM of caspase-9 zymogen (FL uncleaved WT caspase-9) was diluted in caspase-9
minimal activity buffer (100 mM MES, 20% PEG 400 and 5 mM DTT) and incubated at 37˚C at
each time point indicated. For cleavage of FL caspase-9 C287A phosphomimetics and FL S183E
by caspase-3 for native gel electrophoresis and thermal shift assays, 500 nM of caspase-3 was
prepared in 50 mM Tris-Cl pH 7.5, 150 mM NaCl and 2 mM DTT (cleavage buffer). Caspase-9
was then added to a final concentration of 50 µM and cleavage was allowed to proceed for 15
min at 37˚C. Reactions were stopped by adding SDS-PAGE loading dye and boiling for 10 min.
Cleavage of the full-length caspase-9 band was analyzed by SDS-PAGE and densitometry using
ImageLabTM (BioRad). For cleavage of FL caspase-9 as parallel samples for the ThT fluorescence
assay, 75 µM of caspase-9 FL C287A or FL S183E was incubated with caspase-3 (500 nM) in
caspase-3 cleavage buffer at 37˚C for 15 min. The cleavage reactions were transferred to a 96well black plate and further incubated at 30˚C for 12 h, after which the samples were centrifuged
at 18 000 x g to pellet the aggregates. The pellet was dissolved in 2% SDS and both the pellet and
supernatant fractions were analyzed by SDS PAGE.
Construction, expression and purification of site-specific phosphocaspase-9
C9FL + His6x (1-422) was subcloned into NdeI and HindIII sites of pBAD-GST-AmpR
vector to generate the plasmid C9F-pBAD. Codons that code for S99 (TCG), S183 (TCC) and
S195 (TCC) were replaced by TAG using a QuikChange mutagenesis approach to generate
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phosphocaspase-9 expression plasmids (C9pBAD-SepC9). Site-specific phosphoincorporation
was performed as reported by Pirman, et al28. Briefly, recoded E. coli (rEcoli) C321.ΔA were cotransformed with the C9pBAD-SepC9 and SepOTSλ plasmids. Cultures were grown in LB media
supplemented with 2 mM O-phospho-L-serine (Sigma) pH 7.5, 100 µg/mL Ampicillin and 25
µg/mL Kanamycin at 30˚C with shaking until an OD600 = 0.8. The temperature was lowered to
18˚C and protein expression was induced by 0.4% L-arabinose (Acros Organics, NJ) and 1 mM
IPTG for 20 h. Cells were harvested by centrifugation at 4 700 x g for 10 min at 4˚C. Cells were
lysed and caspase-9 proteins were purified as described above, except for the addition of glycerol
(5%), phosphatase inhibitors NaF (20 mM) and β-glycerophosphate (2 mM) in all purification
buffers, as well as the use of a MonoQ 5/50 GL column (GE Healthcare) for the final ion
exchange purification using a gradient of 0-300 mM NaCl. Yields of the phosphoserineincorporated caspase-9 were extraordinarily low: approximately 0.05-0.10 mg from 12L of
expression.
Native agarose gel electrophoresis
Caspase-9 (full-length and caspase-3-cleaved versions of phosphomimetics and alanine
variants) (20 µg) was mixed with 2x native gel sample buffer and loaded onto a 0.8% agarose gel
(prepared using 25 mM Tris-Cl pH 8.5 and 192 mM glycine). The gel was run for 90 min at 60 V.
Protein bands were stained with Coomassie dye, imaged and analyzed using ImageLabTM
(BioRad).
Thermal shift assay by differential scanning fluorimetry
The thermal stability of caspase-9 variants in 10 µM in 50 mM Tris-Cl pH 7.5, 150 mM
NaCl and 2 mM DTT was analyzed in the presence of SYPRO® Orange (ThermoFisher) (0.5x
final concentration) using a CFX Connect Real-Time PCR detection system (BioRad).
Measurements were performed in a 96-well plate in 50 µL reactions. The fluorescence intensity
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was monitored by increasing the temperature in 0.5˚C increments from 25 to 95˚C. Thermal
melting points (Tm) were determined by curve fitting analysis using Prism (GraphPad) software.
In situ ThT Fluorescence Assay
Caspase-9 samples (FL and caspase-3-cleaved C287A and S183E versions of caspase-9)
(75 µM) were mixed with Thioflavin T (ThT, Sigma) to a final concentration of 10 µM and
incubated at 30°C in black 96-well plates that were sealed to prevent evaporation. The total
reaction volume was 100 µL. The ThT fluorescence (Ex 450/Em 485) intensity of each sample
was recorded every 10 min using a SpectraMax M5 plate reader over the course of 12 h.
Transmission Electron Microscopy
A 50 µL sample of caspase-3-cleaved S183E (75 µM) was incubated at 30˚C for 12 h in
parallel with the ThT fluorescence samples. After 12 h, the sample was centrifuged for 10 min at
18 000 x g and the pellet was washed twice and resuspended in 25 µL nanopure water. A 3 µL
sample of a three-fold diluted suspension was embedded on an ultra thin carbon film supported
by a lacey carbon film on a 400-mesh copper grid (Ted Pella, Inc.) for 5 min. The grid was
blotted to remove excess sample and was washed twice with nanopure water. The grid was then
incubated upside-down on a drop of 2% uranyl acetate for 30 s, washed with water to remove
excess stain and dried overnight for negative stain EM analysis. A JEOL JEM-2200 FS EFTEM
(Energy Filtered Transmission Electron Microscope) operating at 200 kV was used to obtain
micrographs at 200 000x to 400 000x magnification (UMass Amherst Electron Microscopy
Center). In order to enhance contrast all images were zero-loss filtered using an energy slit width
of 20 eV.
Mammalian Cell Culture, Transfection and Preparation of Extracts
Jurkat JMR cells (gift of Douglas Green, St Jude Children’s Research Hospital) were
grown in RPMI media supplemented with 10% fetal bovine serum, 2 mM glutamine and 1 mM
HEPES. Cells were incubated at 37°C in a humidified atmosphere maintained at 5% CO2. Cells
were transiently transfected with either empty vector (p3xFLAG-CMV-14 (Sigma)) or caspase-9
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(C9 WT-3xFLAG or C9 C287A-3xFLAG) using the DNA-In Jurkat transfection reagent (MTIGlobal Stem) according to manufacturer instructions. A ratio of 5µg DNA : 10 µL reagent per
well of a 6-well plate was observed to be optimal. Fresh media was supplemented after 24 h to
support cell growth.
After 48 h of expression, transfected cells were washed with 1x PBS and lysed for 20 min
with 1x Lysis buffer containing 50 mM Tris pH 7.5, 150 mM NaCl, 1% Triton-X100 and
supplemented with 1x Halt™ protease and phosphatase inhibitor cocktail (Thermo Scientific).
Lysates were clarified by centrifugation for 30 min at 16,100 x g at 4˚C.
Activation of PKA in Jurkat JMR
JMR cultures grown to ~90% confluency were treated with 30 µM Forskolin (CST) for
20 min, or with 1 mM 8-BrcAMP (8-Bromoadenosine 3’,5’-cyclic monophosphate sodium salt)
(Sigma) for 30 min. For untreated cells, DMSO was added in place of the compounds. To
determine the selective inhibition of endogenous PKA, JMR cells were initially treated with 20
µM

H89

(N-[2-[[3-(4-Bromophenyl)-2-propenyl]amino]ethyl]-5-isoquinoline-sulfonamide

dihydrochloride) (CST) for 20 min prior to Forskolin or 8-BrcAMP treatment.
Immunoblotting
Total lysates were loaded onto a 12 % SDS-PAGE and electroblotted to a PVDF
membrane. Lysates were probed with antibodies against the following: caspase-9 (rabbit, Cell
Signaling Technologies, CST), caspase-3 (rabbit, CST) and cyclophilin A (rabbit, CST) which
served as a loading control. PKA activation was assessed by immunoblot using antibody against
PKA (rabbit, CST) and an antibody against phosphorylated forms of PKA substrates with
arginine at position -3 (mouse, CST). All primary antibodies were used at 1:1000 dilution. The
following HRP-conjugated secondary antibodies (dilution 1:50.000) were used (all from Jackson
Immunoresearch): goat anti-mouse IgG and goat anti-rabbit IgG. Bands were were detected by
enhanced chemiluminescence and visualized in ChemiDoc XRS+ (BioRad).
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CHAPTER III
CASPASE-9 CARD:CORE DOMAIN INTERACTIONS REQUIRE
A PROPERLY-FORMED ACTIVE SITE

This chapter appeared in Kristen L. Huber’s Ph.D. Dissertation “Regulation of Caspase-9 by
Natural and Synthetic Inhibitors” (2012), but has since been revised to include additional data and
interpretation of results. The majority of this chapter is under revision: Huber, K.L.*, Serrano,
B.P.* and Hardy, J.A. Caspase-9 CARD:Core Domains Interactions Require a Properly-formed
Active Site. Biochem J. (2018).
*These authors shared equally in this work.

Abstract
Caspase-9 is a critical factor in the initiation of apoptosis, and as a result is tightly
regulated by a number of mechanisms. Caspase-9 contains a Caspase Activation and Recruitment
Domain (CARD), which enables caspase-9 to form a tight interaction with the apoptosome, a
heptameric activating platform. The caspase-9 CARD has been thought to be principally involved
in recruitment to the apoptosome, but its roles outside this interaction have yet to be uncovered.
In this work we show that the CARD is involved in physical interactions with the catalytic core of
caspase-9 in the absence of the apoptosome; this interaction requires a properly formed caspase-9
active site. The active sites of caspases are composed of four extremely mobile loops. When the
active-site loops are not properly ordered, the CARD and core domains of caspase-9 do not
interact and behave independently, like loosely tethered beads. When the active site loop bundle
is properly ordered, the CARD domain interacts with the catalytic core, forming a single folding
unit. Together these findings provide mechanistic insight into a new level of caspase-9 regulation.

67

Introduction
Apoptosis or programmed cell death is a fundamental cellular process that is paramount
to cellular regeneration and tissue homeostasis in multicellular organisms. Unlike other cell death
pathways, apoptosis efficiently dismantles the cell without adverse effects on neighboring cells or
its environment. Its faithful execution is essential in avoiding a number of catastrophic disease
states and is also critical in organismal development, hence apoptosis is tightly regulated.
Caspases (cysteine aspartate proteases) are special proteases dedicated to properly carry out the
apoptotic pathways. Initiator caspases (caspase-2, -8 and -9) function upstream of the apoptotic
pathways while executioners (caspase-3, -6 and -7) mediate downstream reactions. Because
highly active caspases are lethal, they are synthesized and held as inactive zymogens
(procaspases) to avoid untimely activation of apoptosis. Apoptotic pathways are triggered upon
receipt of a death signal, either through ligand binding (extrinsic pathway) or mitochondrial
assault (intrinsic pathway). Initiator caspases are then recruited to a multi-complex activating
scaffold to undergo activation. These active initiators in turn cleave and activate downstream
executioners, thereby initiating the series of proteolytic reactions, which ultimately culminates in
cell death. Because the caspase activation cascade signals the commitment of the cell to its
demise, the activation of these suicidal enzymes is tightly controlled.
Caspase-9 is a critical initiator of the intrinsic pathway, and is responsible for activating
downstream executioners caspases -3, -6 and -7. Defects in the intrinsic pathway are
characteristic of diseases ranging from autoimmune disorders to cancer. In these diseases,
activation of caspase-9 is particularly critical

1–3

, however, because of caspase-9’s upstream role

in the intrinsic pathway, its regulation is quite distinct from that of the executioner caspases.
Caspase-9 also has structural and functional characteristics that are distinct from other caspases.
Like all caspases, the caspase-9 structure contains the highly homologous catalytic core,
composed of the large and the small subunit connected by an intersubunit linker (Figure 1). While
cleavage at the linker converts most caspases to their active form, caspase-9 is somewhat active
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even prior to cleavage of the intersubunit linker 4. Caspase-9 is also predominantly monomeric in
solution, unlike other caspases, which are constitutively dimeric. In addition, the catalytic core of
caspase-9 is preceded by a long prodomain called the Caspase Activation Recruitment Domain
(CARD). A six-helix bundle with protein binding motifs, the caspase-9 CARD facilitates proteinprotein interaction with the CARD in apoptotic protease activation factor 1 (Apaf-1), anchoring
caspase-9 to its activation platform, the apoptosome

5–7

. Caspase-9’s interaction with the

apoptosome is one of the most significant unique features of this caspase.
The apoptosome platform is formed when an intracellular stress signal leads to release of
cytochrome c from the mitochondria. Cytochrome c is then available to bind to Apaf-1, initiating
a conformational change resulting in a dATP-dependent Apaf-1 heptamerization into the
apoptosome. The apoptosome then recruits and activates caspase-9 (Figure 1.7). The molecular
details of caspase-9 activation by the apoptosome have not been fully elucidated, but binding to
the apoptosome increases caspase-9’s activity by approximately 2000-fold4. Intriguingly, even in
the absence of the apoptosome, the presence of individual domains influence caspase-9 activity.
Caspase-9 is 20% more active when caspase-9’s catalytic core remains covalently linked to the
CARD domain, as in full-length caspase-9, than when it is proteolytically removed to form the
∆CARD version of caspase-9 8 (Figure 1). The authors who made this observation suggested that
increased tangling of CARD domains leads to an increase in the dimeric fraction of full-length
caspase-9 over ∆CARD caspase-9, which accounts for this difference in activity. Addition of the
isolated Apaf-1 CARD further enhances caspase-9 activity by five-fold, in vitro 8. The greatest
increase in activity, though, occurs when full-length caspase-9, including both the CARD and
core domains, binds to the apoptosome through caspase-9 CARD: Apaf-1 CARD interactions.
Early models of the apoptosome activation of caspase-9 argued that the increased activity
is due to a change in the oligomeric state of the enzyme via increasing the local concentration of
monomeric caspase-9. Recruitment of additional molecules of caspase-9 was hypothesized to
participate as partners in dimerization 9 or facilitate dimerization amongst the apoptosome-bound
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monomers 10. This model is supported by the evidence that enhanced activity is associated with
dimerized caspase-9 molecules 11. Alternative views of the activation mechanism invoke induced
conformational changes in which the apoptosome binds to the dimerization interface of caspase-9
and stabilizes the active site region leading to a catalytically competent conformation

12

. This

conformational change model is supported by the evidence from high-resolution cryoelectron
microscopy (cryo-EM) which shows that caspase-9 is potentially monomeric in the highly active
state, bound to the apoptosome9. Recent near atomic resolution cryo-EM structures of the human
apoptosome show that a catalytic core of a caspase-9 monomer is bound to the apoptosome hub,
independent of potential caspase-9 dimers undergoing activation

13,14

. Additional studies of

caspase-9’s activation mechanism have also suggested that cleavage of its intersubunit linker
initiates dissociation from the apoptosome thus regulating the time of apoptosome activity 15.
While it is clear that caspase-9 is recruited to the apoptosome through CARD:CARD
interactions, it is not clear what prompts the release of caspase-9 from the apoptosome or how the
caspase-9 CARD influences caspase-9 function when not bound to the apoptosome. This
becomes more relevant with the observation that caspase-9 activation can be achieved without
apoptosome formation through different pathways

16–18

. If the caspase-9 CARD were

predominantly involved in tethering caspase-9 to the apoptosome, then in the absence of the
apoptosome removal of CARD should not decrease activity significantly. On the contrary, a
significant decrease in caspase-9 catalytic efficiency is observed when the CARD is removed.
This suggests that the CARD plays another role in function and regulation of caspase-9. The most
direct hypothesis is that the caspase-9 CARD interacts this the core domain directly, influencing
the structure and thus the function of the enzyme. The goal of this work is to probe and uncover
the nature of any existing CARD:caspase-9-core interactions.
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Results
The Influence of CARD on the Oligomeric State of Caspase-9
The catalytic core of caspase-9 (∆CARD) has a lower catalytic efficiency than the fulllength version of the enzyme, but the fundamental structural and physical basis of these
differences are not known. We interrogated the effect of the presence of the CARD on the
specific biophysical properties of caspase-9 to understand why the presence of the CARD domain
has a synergistic effect on function. To ensure that the caspase-9 ∆CARD and full-length reagents
used for this study were comparable to the studies that show CARD’s ability to enhance caspase9 activity, we independently measured the catalytic properties of various caspase-9 constructs.
Consistent with previous reports4,8, the ∆CARD variant of caspase-9 has a decreased catalytic
efficiency relative to the full-length version (Table 3.1). Therefore the difference in activity
observed between the two caspase-9 variants is most likely due to the presence or absence of the
CARD.

Table 3.1. Catalytic parameters3 for caspase-9 variants using substrate Ac-LEHD-AFC.
KM

kcat

103 x kcat / KM

(µM)

(s-1)

(s-1 µM-1)

Caspase-9 Full-length (C9FL)

430 ± 35

1.4 ± 0.1

3.3

Caspase-9 ∆CARD

992 ± 34

0.3 ± 0.002

0.3

Caspase-9 variant

3

Values are mean (± SEM) of three trials done on three separate days.

Caspase-9 is predominantly monomeric in solution, but when subjected to size exclusion
chromatography, proteolytic activity correlated with the small fraction of dimeric caspase-9 and
not with monomeric caspase-9, suggesting that dimerization is required for caspase-9 activity8,11.
Thus, one potential reason for the increase in the activity of full-length caspase-9 could be due to
an increase in the ratio of dimeric caspase-9 when the CARD is attached, as has been suggested
previously8. To assess this, full-length and ∆CARD versions of caspase-9 were subjected to size
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exclusion chromatography (SEC) to determine the oligomeric state of each enzyme. Both full
length and ∆CARD caspase-9 were predominantly monomeric in solution and no oligomeric
fraction could be observed in the chromatogram (Figure 3.1). Caspase-9 can be forced into a
dimeric state by binding of a covalent active-site inhibitor z-VAD-FMK. The full-length and
∆CARD caspase-9 were both capable of completely converting to their respective dimeric states
in the presence z-VAD-FMK (Figure 3.1).

Figure 3.1. CARD does not influence caspase-9 oligomerization.
Size exclusion chromatography of full-length caspase-9 (Casp-9 FL) and caspase-9 ΔCARD (Casp-9
ΔCARD) in the presence and absence of active site ligand z-VAD-FMK. Both Casp-9 FL and Casp-9
ΔCARD are capable of dimerization induced by z-VAD-FMK. The molecular weights for the
standards are marked as diamonds.
Table 3.2. Molecular weights of caspase-9 variants from Size Exclusion Chomatography.
Molecular Weight (kDa)
Caspase-9 variant
Observed
Expected4
Casp-9 ∆CARD
30
29.0
Casp-9 ∆CARD + VAD-FMK
71
58.0
Casp-9 Full-length (FL)
45
47.2
Casp-9 Full-length + VAD-FMK
136
94.4
4

Expected / Theoretical molecular weights were calculated from the protein sequence of caspase-9
variants using ExPASy ProtParam tool19.
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We observed that the molecular weight of the dimeric full-length caspase-9 was larger than
expected (136 kDa vs. 94 kDa expected) (Table 3.2), which could be due to either a significant
change in the hydrodynamic radius of dimeric full length caspase-9 or an enhanced interaction
with the negatively charged matrix in the column, as we have observed with caspase-620.
Nevertheless, these results suggest that the CARD does not appear to have a great influence on
the oligomeric state of the enzyme and thus cannot be the cause of the increased activity observed
in the presence of the CARD.
The Presence of CARD Influences Stability of Caspase-9
Another potential reason for the increased activity of full-length caspase-9 could be that
the presence of the CARD affects the protein’s stability. To assess this, both full-length and
∆CARD caspase-9 in monomeric and dimeric forms were analyzed for changes in thermal
stability by circular dichroism (CD) spectroscopy. Full-length caspase-9, which was cleaved at
the intersubunit linker between the large and small subunits, and included the CARD domain,
showed a three-state unfolding curve (Figure 3.2A). The first melting transition occurred at 48 ±
2˚C while a second occurred at 62 ± 2˚C. To determine the domain of the full-length enzyme that
unfolds at each melting transition, the catalytic core and CARD domains were expressed
independently and interrogated in a similar fashion. The catalytic core of the enzyme (∆CARD),
which was also cleaved at the intersubunit linker, corresponded to the first melting transition at 49
± 1˚C (Figure 3.2B) while the second transition corresponded to that of CARD only with a
melting temperature of 61 ± 2˚C (Figure 3.2C). These results suggest that when caspase-9 is in its
cleaved monomeric state, the presence of CARD does not affect the overall thermal stability of
the caspase-9 catalytic core and the two domains (CARD and core) of the enzyme unfold
independently.
Although caspase-9 exists in equilibrium between monomer and dimer, it is
predominantly monomeric in solution (Figure. 3.1). To assess whether the oligomeric state of
caspase-9 influences its stability, thermal denaturation studies were similarly performed on the
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Figure 3.2. Monomeric and dimeric states of caspase-9 have different unfolding properties.
Thermal denaturation profiles (left) and circular dichroism spectra (right) of various forms of caspase-9
(top schematics).
(A) Two melting transitions are observed in the cleaved full-length, monomeric, caspase-9.
(B) and (C) Thermal denaturation profile of caspase-9 core and CARD, respectively, showing that the
first melting transition in full-length, monomeric caspase-9 (A) is due to the unfolding of the core,
while the second is due to that of the CARD.
(D) Full-length, cleaved caspase-9 is dimeric in the presence of an active site ligand z-VAD-FMK.
Upon thermal denaturation, caspase-9 at this state exhibits a single melting transition, likely due either
to dimerization, or the presence of an ordered active site, or both.
(E) Dimeric, cleaved caspase-9 ΔCARD with bound z-VAD-FMK is highly stabilized by 14˚C
compared to monomeric, cleaved ∆CARD (B).
(F) Constitutive dimer (cDimer) full-length caspase-9 cleaved at the intersubunit linker exhibits two
melting transitions, suggesting independent unfolding of CARD and core domains.
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cleaved full-length and ∆CARD versions of caspase-9 when the enzyme is in a dimeric state with
an active site ligand (z-VAD-FMK) bound (Figures 3.2D and 3.2E). Both versions of caspase-9
showed an increase in thermal stability. Caspase-9 ∆CARD had a 14˚C increase in thermal
stability in the presence of active site ligand (Figure 3E), which is similar to the increase in
stability observed when caspase-7 binds active site ligand21. Full-length caspase-9 (Figure 3.2D)
showed only a 6˚C increase in thermal stability in the presence of active site ligand, more similar
to the 3˚C increase in stability observed for caspase-6 upon ligand binding22. Strikingly, in the
presence of substrate, the three-state unfolding (two melting transitions) of the full-length
caspase-9 was no longer observed (Figure 3.2A vs. 3.2D). It appears that binding a ligand to the
active site of caspase-9, which induces dimerization and ordering of the active site loop bundle,
also transitions caspase-9 to a two-state unfolding mechanism (single melting transition). In
addition, full-length caspase-9 is completely unfolded at 90˚C as observed in the circular
dichroism spectrum (Figure 3.2A, 3.2D). These data suggest that in the cleaved, dimeric and
active-site bound state, the catalytic core and the CARD of caspase-9 unfold cooperatively.
To discriminate the influence of substrate-binding from dimerization on the observed
cooperative unfolding, thermal denaturation was performed on a caspase-9 variant that exists as a
constitutive dimer (cDimer) (Figure 3.2F). This dimeric version of caspase-923 was constructed
by substituting residues in the dimer interface with those present in caspase-3, which is
constitutively dimeric. Full-length, unbound dimeric caspase-9, which was cleaved at the
intersubunit linker exhibited three-state unfolding (Figure 3.2F), suggesting that substrate binding
was responsible for the observed changes in unfolding properties. Thus, the single melting
transition observed when cleaved, full-length caspase-9 in the dimeric, active-site bound state
(Figure 3.2D) indicates that substrate binding-induced dimerization either results in the complete
unfolding of CARD, or causes the catalytic core and CARD to unfold as one cooperative unit.
Comparison of the circular dichroism spectra of the full-length, cleaved caspase-9 in monomeric
and dimeric states (Figure 3.3) show that there is no significant change overall in the secondary
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structure content. The CARD is composed of six helices24; if the CARD became unfolded in the
presence of substrate or upon dimerization, we would expect to see a significant loss in the CD
signal. Secondary structure content analyses from the CD spectra revealed that there is ~5 % loss
in helical content when full-length caspase-9 binds an active site ligand to induce dimerization
(Figure 3.3, FL monomer vs FL + VAD-FMK). The similarity in the CD spectra with and without
active site ligand suggests that the CARD remains folded and that the caspase-9 catalytic core and
CARD must be unfolding as a single cooperative unit. This observation suggests that a physical
interaction between the CARD and core domains occurs, which causes the two domains to unfold
as a single unit.

Figure 3.3. Comparison of CD spectra of caspase-9 full length (C9 FL) in monomeric and dimeric
states.
The secondary structure of caspase-9 with (+ VAD-FMK) and without (FL monomer, cDimer and cDimer
C287A) an active site ligand bound was assessed by CD. C9 FL cDimer is a constitutive dimer variant of
caspase-9. There is no significant change in the helical content of caspase-9 upon dimerization and substrate
binding. Estimation of helix content was performed using BeStSel structure prediction and fold recognition
software (http://bestsel.elte.hu/index.php)57.

An Ordered Active Site Supports CARD:Core Interactions
Caspase-9 has been shown to possess catalytic function even as an uncleaved zymogen4
possibly due to its increased intersubunit linker length. Caspase-9 possesses a longer L2 loop,
allowing L2’ some flexibility to assume a productive conformation which enables caspase-9 to
support a properly formed active site even without linker cleavage25. Therefore, the
uncleaved/zymogen form of caspase-9 can be utilized to interrogate whether the interaction
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observed between the CARD and the catalytic
core of caspase-9 is due to changes in the
active site conformation. Analysis of the fulllength monomeric caspase-9 in the uncleaved
state

(catalytic

site-inactivated

variant

C287A), resulted in a two-state unfolding
mechanism (Figure 3.4A) similar to that
observed for the cleaved, dimeric and active
site-bound

state

(Figure

3.2D).

The

monomeric, uncleaved caspase-9 zymogen
appears to support the interaction of the core
and CARD domains because they unfold as a
single unit. To further test this mechanism, we
cleaved the same caspase-9 zymogen construct

Figure 3.4. The CARD and core of caspase-9
unfold as a single unit when the intersubunit
linker is intact.
Thermal denaturation profiles (left) and circular
dichroism spectra (right) of various forms of
caspase-9.
(A) Monomeric, zymogen (uncleaved) caspase-9
(catalytic site-inactivated C287A) exhibited a
single melting transition, which suggests
cooperative unfolding of CARD and core of
caspase-9.
(B) Cleavage of the linker of (A) by caspase-3
results in independent unfolding, as manifested by
two separate melting transitions.
(C) Zymogen (catalytic site-inactivated C287A),
uncleaved caspase-9 in a constitutive dimeric
state (cDimer) shows a single melting transition.

with caspase-3. Cleavage of the intersubunit
linker by caspase-3 disrupted the interaction of
the CARD and catalytic core domains as
observed

by

the

independent

three-state

unfolding properties (Figure 3.4B), which is
similar to that of the cleaved wild-type
monomeric caspase-9. The presence of an
intact

linker

also

appears

to

support

CARD:core interactions in constitutively dimeric (cDimer) full-length caspase-9 zymogen
(C287A). This version of caspase-9 had a two-state unfolding mechanism (Figure 3.4C), similar
to that of a full-length, dimeric caspase-9 with a bound active site ligand (Figure 3.2D). Together,
these data suggest that the CARD domain and the catalytic core of caspase-9 do not physically
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interact and unfold independently in monomeric or in dimeric caspase-9 that has a disordered
active site resulting from cleavage of the intersubunit linker. In contrast, these domains physically
interact and unfold cooperatively, as a single unit, when the active site region assumes an ordered
conformation as supported by either an intact linker in both monomeric and dimeric states, or by
binding of a substrate to the active site.
Characterizing the Site of Interaction Between Caspase-9 Catalytic Core and CARD
The ∆CARD caspase-9 variant is less
active than full-length caspase-9 (Table 3.1),
suggesting that the presence of the CARD could
increase the catalytic activity of the caspase-9
core. Indeed, an increase of caspase-9 activity was
observed when CARD was incubated with
∆CARD (Figure 3.5A). This increase in activity
was not simply due to molecular crowding since
adding BSA in place of CARD did not amount to
any significant change in activity. However, this
enhancement did not reflect the full activity of
full-length caspase-9, suggesting that a covalent
tether between CARD and the catalytic core of
caspase-9 is necessary for CARD’s impact on
enzymatic activity. Since the linker between the
CARD and core domains is essential to mediate
the increase in the activity of caspase-9, we
reasoned that perhaps there were either specific

Figure 3.5. Linker between CARD and
core supports CARD:core interaction.
(A) In trans activity assay of ∆CARD
caspase-9 with CARD. The presence of
CARD enhances caspase-9 activity, but does
not recapitulate the full activity of a fulllength caspase-9. Error bars are SD from
three independent trials done on three
separate days.
(B) Thermal denaturation analysis (left) and
CD (right) f Ser-Gly linker extension variant
of caspase-9 showing the same melting
transitions as that of full-length, cleaved WT
caspase-9.
(C) Ser-Gly linker extension variant exhibits
the same kinetic behaviors as WT caspase-9.

interactions with the tether and the adjacent
domains or a length-dependence to the interaction. To test this, a five amino acid Ser-Gly
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extension was inserted within the linker between CARD and the large subunit of caspase-9’s
catalytic core (Figure 3.5B). This variant behaves like the native full-length form of caspase-9 in
both thermal stability (Figure 3.5B) and catalytic efficiency (Figure 3.5C), suggesting that a
longer and potentially more flexible linker does not negatively impact the function of caspase-9.
The cooperative unfolding observed between the CARD domain and the catalytic core of
dimeric caspase-9 implies a physical interaction between the two domains. To characterize this,
the interaction between the isolated CARD and catalytic core domains in trans was interrogated
(Figure 3.5). The catalytic core (∆CARD) in its monomeric or dimeric form (∆CARD+VADFMK) was incubated with the CARD and analyzed for an interaction between the two domains
by native gel electrophoresis (Figure 3.6A). An interaction between the two domains would result
in a band migrating with the molecular weight of the full-length enzyme during native gel
analysis. However, no visible shift in band migration was observed that would correspond to
complex formation between CARD and ∆CARD, which suggests either no interaction between
the domains, or very weak and transient interactions, or that the conditions for native gel
electrophoresis did not promote CARD:core interactions. Ni-affinity isolation assay was then
performed (Figure 3.6B) in which His-tagged ∆CARD in different states (cleaved with VADFMK-bound, cleaved with no ligand bound, or uncleaved with no ligand bound (C287A)) was
incubated with CARD (no His6x tag). Only ∆CARD with bound VAD-FMK was able to isolate
the CARD after elution out of the Ni beads, suggesting complex formation between the catalytic
core and the CARD (Figure 3.6B). In addition, fluorescent polarization/anisotropy binding
experiments showed that while FITC-labeled CARD also binds to monomeric, cleaved ∆CARD
caspase-9, tighter binding was observed with dimeric ∆CARD caspase-9 bound with an active
site ligand (+ VAD-FMK) (Figure 3.6C). Together these data are consistent with those observed
from thermal denaturation studies, where an ordered active site appears to promote CARD:core
interactions.
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Figure 3.6. Characterizing CARD-core interaction.
(A) Native gel electrophoresis showed no visible obility shift to indicate interaction between CARD and
caspase-9 core (unbound/monomeric and z-VAD-FMK-bound/dimeric).
(B) His-tagged, dimeric, VAD-FMK-bound ∆CARD was able to pull down untagged CARD by NiNTA affinity assay, suggesting interaction between CARD and catalytic core of caspase-9.
(C) Fluorescence anisotropy shows binding of FITC-labeled CARD to both monomeric and dimeric
(+VAD-FMK) ∆CARD. Error bars are SD from three trials done on three separate days.

Given the observation that the CARD and core domain physically interact, we undertook
a program designed to uncover sites where substitution of the native amino acids by alternatively
charged amino acids might disrupt interactions between the CARD and core domain. To generate
candidate sites for interaction and mutations, we performed docking studies between reported
crystal structures of the CARD (PDB ID: 3YGS)24 and the dimeric form of the caspase-9 catalytic
core (PDB ID: 1JXQ)11 using the RosettaDock server26. The top docking models were those that
avoided interactions of CARD residues involved in the caspase-9 CARD/Apaf-1 CARD complex
and avoiding unfavorable (e.g. steric) interactions between caspase-9 CARD and core. Two
models fit these criteria (Figure 3.7), both showing putative electrostatic interactions between the
CARD and the core. Model 1 predicted the interaction between negatively charged residues in α4
helix of the core with arginines of the H1 helix of CARD (Figure 3.7A). Model 2 predicted
homotypic helix to loop interactions: helices α1 and α4 in the core interacting with L1-2 (loop
between helix H1 and H2) and a small kink in H4 of the CARD (Figure 3.7B). 	
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Figure 3.7. Representative docking models of possible sites of CARD-core interactions.
Docking analysis between reported crystal structures of the caspase-9 core domain (PDB ID: 1JXQ)
and caspase-9 CARD (PDB ID: 3YGS) generated top two models depicting (A) helix to helix and (B)
loop to helix interactions of caspase-9 core with the CARD domain. Both models should not interrupt
Apaf-1 CARD- caspase-9 CARD interactions and were chosen for substitution studies that may
potentially disrupt the CARD-core interactions.
Docking studies were performed using the
RosettaDock server.

Single and combination charge swapping variations based on the docking models were
introduced in the CARD and core in an attempt to disrupt the interaction between the two
domains and thus decrease the catalytic efficiency of the caspase-9 variants. We expected that
mutations that disrupted the interaction between the CARD and core domain would decrease the
catalytic efficiency of the variant versions of caspase-9 and would be comparable to the catalytic
activity of ∆CARD (Table 3.1). Upon analysis of the charge swap effects on the catalytic
efficiency of caspase-9, a two-fold decrease in catalytic efficiency was observed for variant R7E
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(Table 3.3) which would support Model 2, the helix-to-helix binding mode of CARD to the
caspase-9 core. A similar effect was observed by the single site variant R11E which further
supports a helix-to-helix binding model of CARD and the catalytic core of caspase-9. However
the double site variant of R7E/R11E did not show an enhancement of this effect (Table 3.3). This
could indicate that R7 and R11E are included in the activating affect of CARD; however, the
combination of both these variants is not strong enough to completely eliminate the activation
property of CARD, as the catalytic efficiency of the ΔCARD version (Table 3.1) of the enzyme
was not recapitulated.

Table 3.3. Catalytic parameters5 for caspase-9 charge-swap variants.
KM

kcat

103 x kcat / KM

(µM)

(s-1)

(µM-1s-1)

none

430 ± 35

1.4 ± 0.1

3.3

R7E

CARD (H1)

693 ± 55

0.76 ± 0.2

1.1

R11E

CARD (H1)

477 ± 19

0.73 ± 0.06

1.5

R7E/R11E

CARD (H1)

469 ± 216

0.6 ± 0.2

1.3

D23R

CARD (L1-2)

337 ± 103

0.78 ± 0.2

2.3

R51E

CARD (H4)

197 ± 56

0.85 ± 0.2

4.3

E365R

Core (α4)

429 ± 67

1.2 ± 0.2

2.8

Caspase-9 variant
Wild-type

5

Region of Mutation

Values are means (± SEM) of three trials done on three separate days.

Phosphomimetic S183E Breaks CARD:core Interactions
The propensity of the CARD:core interactions to exist when caspase-9 is in a
conformation with an ordered active site suggests that any modification in caspase-9 that would
lead to a disordered active site loop bundle would disrupt these interactions. One particular
caspase-9 variant that we have shown to inactivate caspase-9 by that precise mechanism is the
phosphomimetic S183E (Chapter II). S183E was observed to have a profound effect on caspase-9
function27. S183E prevents substrate binding by displacing a specific arginine residue (R180) in
the S1 specificity pocket (Figure 2.4), resulting in the active site loop bundle to become
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disoriented. After overexpression S183E remains uncleaved and exhibits no LEHDase activity
(Figure 2.3C, 2.3D). Since S183E is in its monomeric and uncleaved form, we expected its
stability to be comparable to that of the zymogen, catalytic-site inactivated caspase-9 C287A, and
predicted it would exhibit only one melting transition upon thermal denaturation (Figure 3.4A).
However, S183E underwent two melting transitions (Figure 3.8A), corresponding to the
unfolding of the core (43˚C) and the CARD domain (64˚C). The S183E thermal denaturation
profile suggests that the interaction between the CARD and core domain has been disrupted by
the S183E substitution, leading the two domains to unfold independently. Importantly, the
melting temperature of the core is unchanged from WT caspase-9 suggesting that the core is
intact when the S183E variant is in the uncleaved zymogen conformation. The striking
observation that the CARD:core interactions were eliminated upon modification of the S183 site,

Figure 3.8. Phosphomimetic S183E disrupts CARD:core interactions.
Thermal denaturation curves (left) and CD spectra (right) of caspase-9 S183 substitution variants.
(A) Full-length, monomeric, uncleaved S183E exhibits three-state unfolding (two melting transitions),
unlike other full-length uncleaved caspase-9 variants, suggesting that S183E breaks CARD:core
interactions because the two domains unfold independently.
(B) Cleavage of S183E by caspase-3 leads to destabilization and formation of aggregates.
(C) Full-length, monomeric, uncleaved S183A (catalytic-site inactivated C287A) shows a single
melting transition, indicating an intact CARD:core interaction.
(D) Full-length, monomeric, cleaved S183A behaves similarly to full-length, monomeric, cleaved
caspase-9 that exhibits three-state unfolding.

83

suggests that S183 must sit at the binding interface between the caspase-9 core and its CARD.
However, our results from interrogating the effect of S183 phosphorylation on caspase-9 structure
(Chapter II) point to a different mechanism in which S183E imparts conformational instability to
caspase-9 in the cleaved state. All zymogen/uncleaved caspase-9 variants we interrogated were
observed to have similar thermal stabilities, whether by CD (Figure 3.4A, 3.4C, 3.10A, 3.10C) or
by DSF (Table 2.2), while S183E was observed to be less stable. This most likely contributes to
the unusual three-state unfolding of S183E upon thermal denaturation – its unstable conformation
cannot fully support CARD:core interactions. Moreover, cleaving S183E with caspase-3 to
generate a fully mature caspase-9 led to its aggregation, which was evident in both its thermal
denaturation curve that showed a decrease in thermal stability of the core (41˚C in cleaved S183E
vs. 48˚C in WT caspase-9), and CD spectrum at 90˚C (Figure 3.8B), which was typical of an
unfolded protein. These results are consistent with our observations that the core of S183E is
becomes extremely unstable upon linker cleavage, and ultimately leads to the formation of
ordered aggregates (Figure 2.7, 2.9). In addition, the CARD:core interactions appear to remain
intact in the alanine variant S183A. Full-length, monomeric S183A showed a single melting
transition in its uncleaved state (Figure 3.8C), suggesting cooperative unfolding of domains, and
two melting transitions in its cleaved state (Figure 3.8D), indicating independent unfolding of
CARD and core domains. Thus, although S183 did not emerge as a critical site of CARD:core
interactions, our model of caspase-9 inactivation by S183E by disorienting the active site loops is
in agreement with our hypothesis that a properly formed active site is crucial for the interaction
between caspase-9 core and its CARD domain.
Phosphorylation has been shown to be a robust mechanism to disrupt binding
interfaces28–30. Three reported phosphorylation sites - S9931, T107 and T12532,33 - reside in the
potentially highly flexible region between the CARD and the large subunit (Figure 1.6A, 1.6B).
Given that the linker which tethers the CARD to the catalytic core seems to be required for
increased catalytic activity (Figure 3.5C), it is conceivable that phosphorylation at this region
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could impact interactions between the CARD and core. We examined whether the
phosphomimetic versions of these residues would break the CARD:core interactions by
conducting the same thermal denaturation studies on both cleaved and zymogen/uncleaved forms.
Both S99E and T125E in monomeric, uncleaved form showed cooperative unfolding of domains,
exhibiting a single melting transition (Figure 3.9A, 3.9C), suggesting that the interaction between
CARD and core is still present and was not interrupted by these mutations. Cleavage at the linker
resulted in independent unfolding of the CARD and core domains (Figure 3.9B, 3.9D). These
results suggest that S99 and T125 sites are not within the binding interface of the CARD and
catalytic core.

Figure 3.9. Phosphomimetic variants S99E and T125E retain CARD:core interactions.
Thermal denaturation curves (left) and CD spectra (right) of caspase-9 CARD phosphomimetic
variants.
(A) and (C) Full-length, monomeric, uncleaved (constructed in the background of C287A) S99E (A)
and T125E (C) exhibit two-state unfolding (single melting transition), suggesting intact CARD:core
interactions.
(B) and (D) Full-length, monomeric, cleaved S99E and T125E behaves similarly to full-length,
monomeric, cleaved caspase-9 that exhibits three-state unfolding.
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Discussion
Full control of the caspases involved in apoptosis, inflammation and neurodegeneration
requires detailed understanding of the functions and regulatory mechanisms for each individual
caspases. Caspase-9 has a particularly unique activation mechanism including changes in its
conformational and oligomeric states and association with the apoptosome activation platform.
Furthermore, the presence of individual domains such as the caspase-9 CARD (in cis) or the
Apaf-1 CARD (in trans) have the ability to increase caspase-9 basal activity8. Altering enzymatic
activities by additional domains have been observed in other proteins including PAS (Per-ArntSim) Kinase34, Dnmt1 DNA methyltransferase35, and ADAMTS-4 (A disintegrin and
metalloproteinase with thrombospondin motifs 4)36, suggesting that this property may be of
widespread significance. Therefore studying the individual activation effects of a particular
domain provides further insights towards how caspase-9 becomes activated on the apoptosome.
Here we investigated the mechanism by which the caspase-9 CARD domain influences
caspase-9 activity. We have demonstrated that the oligomeric state of both full-length and
CARD-deleted (∆CARD) caspase-9 are similar, thus the increase in caspase-9 activity in the
presence of the CARD is not due to a shift the oligomeric state as had been previously
suggested11. We also observed that the mere presence of CARD is not responsible for the
increased enzymatic activity but requires specific interactions between the CARD and core
domain, particularly with the active site. We have observed that caspase-9 CARD:core interaction
is controlled by the folded state of the active site (Figure 3.11). Specifically, the CARD and
catalytic core domains of caspase-9 unfold independently and do not physically interact in either
monomeric or dimeric states of the cleaved enzyme because the active site is unable to form a
properly ordered substrate-binding groove and is therefore unable to support the interactions
between the CARD and caspase-9 core. In the dimeric state with a ligand bound to the active site,
these domains unfold cooperatively, as a single folding unit, indicating a physical interaction
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Figure 3.10. Model for caspase-9 conformational states in the presence of CARD domain.
Relevant conformations of caspase-9 are shown as cartoons in the upper panels. Caspase-9 in both its
uncleaved, monomeric state and cleaved, dimeric state assumes a conformation wherein an ordered
active site supports the interaction of CARD with the core of the protein, allowing cooperative
unfolding of the two domains as depicted in the lower panels. The enzyme assumes a different
conformation when this interaction is abolished either by transitioning to a cleaved monomeric or
cleaved dimeric states where the active site is disordered, or by introducing a mutation in the core (as
in S183E) that leads to its destabilization and disorder of active site loops.
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between the CARD and core domain when the cleaved enzyme dimerizes and has a properly
ordered active site that is capable of binding CARD.
The substrate-binding groove is ordered in dimeric, cleaved caspases (-1, -3, -6, -7, -8
and -9) with a bound substrate. Notably a similar ordered conformation can be formed in
uncleaved zymogen of caspase-9, due to linkage effects which allow the intersubunit linker to
buttress the L3 and L4 loops in an ordered conformation11,37 (Figure 3.10). This manifests in the
cooperative unfolding of CARD and the catalytic core of caspase-9 observed in the
zymogen/uncleaved form of full-length caspase-9, whether monomeric or dimeric, when the
intact intersubunit linker can properly order the active site even prior to cleavage. Intriguingly,
this CARD-core domain interaction is disrupted either by cleavage of the intersubunit linker by
self-processing or by caspase-3, or by a mutation in the core such as S183E, all of which prevent
the active site from assuming an ordered conformation. Thus, the CARD appears to be interacting
with the caspase-9 core in any version of caspase-9 presenting a properly formed substratebinding groove.
Our attempt to pinpoint the binding interface between the CARD and catalytic core of
caspase-9 showed that single charge swap mutations on the surface of the protein distal from the
active site were not strong enough or properly positioned to disrupt the activating affect of
CARD. A more extensive alanine scanning mutagenesis study or charge repulsion analysis
around the substrate-binding groove could further define the region of interaction between the
CARD and core domains mediated by the active-site region of the enzyme. Once the binding
interface is defined, its role in the caspase-9 activation cascade can be further interrogated, and
may serve as a potential junction to control caspase-9’s intrinsic activity.
The primary role of the CARD is to facilitate recruitment and subsequent activation of
caspase-9 in the apoptosome. Prior to our work there has been no data to suggest that there are
existing interactions between the CARD and the catalytic core of caspase-9. The role of these
interactions in the context of the caspase-9 activation via the apoptosome remains to be explored,
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but seems to be consistent with the induced conformational changes model12, wherein binding to
the apoptosome stabilizes the active site region leading to its activation. Recent cryo-EM
structures of caspase-9-bound apoptosome show that a catalytic core of caspase-9 is bound to the
apoptosome hub14,38, and mechanistic studies have also shown that the catalytic core is able to
interact with the nucleotide binding domain of Apaf-1 in the apoptosome39. Our results
complement these observations in the sense that there are regions in the catalytic core that engage
in stabilizing interactions with other proteins (in this case, the caspase-9 CARD), possibly
influencing capase-9 activity. Given our observations that CARD:core interactions influence
caspase-9 stability, it is possible that these interactions exist to stabilize caspase-9 prior to its
recruitment to the apoptosome. One can envision caspase-9 utilizing the same binding interface in
the CARD to interact with the catalytic core in the zymogen state when it is free from the
apoptosome. Once the apoptosome is formed, the caspase-9 CARD:core interaction gives way to
caspase-9 CARD:Apaf-1 CARD binding, allowing caspase-9 to be finally recruited and activated
in the apoptosome. Moreover, in light of observations that caspase-9 is activated independent of
the apoptosome to facilitate alternative pathways (both apoptotic and non-apoptotic)17,18,40, the
presence of CARD:core interactions could also serve as a mechanism to retain, modulate or even
enhance caspase-9 activity as it functions outside the apoptosome. Other human caspases
(caspase-1, -2, -4/-5, -12) also possess a CARD (review41). Among these caspases, caspase-2 is
most similar to caspase-9. It would be interesting to examine whether caspase-2 CARD is also
able to form these interactions with the catalytic core, which would suggest natural prevalence of
these interdomain interactions in caspases and not limited to caspase-9. This could also be a
relevant theme in caspase-2 activation. Although caspase-2 has been shown to be activated via
proximity-induced oligomerization via the PIDDosome42, genetic experiments have challenged
this mode of activation, since caspase-2 was observed to be activated in the absence of this
activating scaffold43,44. Alternative modes of caspase-2 activation have since been proposed
depending on the type of cellular death signals (review45); in these cases it is tempting to
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speculate that CARD:core interactions may play a role in regulating caspase-2 function, should
they be present. Interdomain interactions have been demonstrated to be critical in controlling the
different conformational states and in regulating the catalytic activity of several proteins
including the deubiquitinating enzyme USP446, phenylalanine hydroxylase47 and ERAP-1
(endoplasmic reticulum aminopeptidase-1)48.
Prior works on other caspases have suggested that regulation may be dependent on the
most unique regions within the caspase structure, the prodomain and intersubunit linker. It is well
established that the cleavage of the intersubunit linker primarily acts as an activation switch in
executioner caspases (and in some initiator caspases such as caspase-8). However, it seems that
there is no consensus as to the function of prodomain in executioner caspases. For example, while
the prodomains of caspase-3 and caspase-7 have been shown to be dispensable for activity in
vitro, it appears that in vivo, having an intact prodomain keeps the enzyme in its inactive state
until cleaved by another downstream caspase49,50. The caspase-3 prodomain has been also shown
to bind Hsp27 in monocytes, leading to inhibition of its proteolytic activation51. In caspase-6, an
intact prodomain was reported to inhibit self-cleavage at the linker region in vivo52 and both the
prodomain and linker are predicted to be highly disordered protein-binding regions53 that
dramatically affect the stability of caspase-620. In the case of caspase-9 it appears that the cleaved
state of the intersubunit linker and the interactions between the CARD (prodomain) and the
catalytic core is essential for the appropriate function that is unique to caspase-9.

Materials and Methods
Caspase-9 Expression and Purification
The caspase-9 full-length gene (human sequence) construct, encoding amino acids 1-416,
in pET23b (Addgene plasmid 11829 4) was transformed into the BL21 (DE3) T7 Express strain
of E. coli (NEB) and purified in a manner similar to that previously reported 54. The cultures were
grown in 2xYT media supplemented with ampicillin (100 mg/L, Sigma-Aldrich) at 37˚C until
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they reached an optical density (OD) at 600 nm of 1.2. The temperature was reduced to 15˚C and
cells were induced with 1 mM IPTG (Anatrace) to express soluble 6xHis-tagged full-length
protein. Cells were harvested after 3 h to obtain single-site processing at Asp315. Cell pellets
stored at -20˚C were freeze-thawed and lysed in a microfluidizer (Microfluidics, Inc.) in 50 mM
sodium phosphate pH 8.0, 300 mM NaCl, and 2 mM imidazole. Lysed cells were centrifuged at
37,000 x g to remove cellular debris. The filtered supernatant was loaded onto a 5-mL HiTrap Niaffinity column (GE Healthcare). The column was washed with a buffer containing 50 mM
sodium phosphate pH 8.0, 300 mM NaCl, and 2 mM imidazole until 280 nm absorbance returned
to baseline. The protein was eluted using a linear imidazole gradient of 2 to100 mM over the
course of 270 mL. The eluted fractions containing protein of the expected molecular weight and
composition were diluted 10-fold into a buffer composed of 20 mM Tris pH 8.5, 10 mM DTT to
reduce the salt concentration. This protein sample was loaded onto a 5-mL Macro-Prep High Q
column (Bio-Rad Laboratories, Inc.). The column was developed with a linear NaCl gradient and
eluted in 20 mM Tris pH 8.5, 100 mM NaCl, and 10 mM DTT buffer. The eluted protein was
stored in -80˚C in the above buffer conditions. Purified caspase-9 was analyzed by SDS-PAGE
and ESI-MS to confirm mass and purity. Caspase-9 variants, C287A, R7E, R11E, D23E, R51E
E365R, R7E/R11E, S183E, S183A, C287A/S183A, S99E, C287A/S99E, T125E, C287A/T125E
and the Ser-Gly linker extension, were constructed by site-directed mutagenesis method in the
full-length expression construct, and were purified by the same method (except for S183E,
S183A, C287A/S183A, S99E, C287A/S99E, T125E, C287A/T125E) as described here for the
wild-type protein.
Caspase-9 S183E, S183A, C287A/S183A, S99E, C287A/S99E, T125E, C287A/T125E
were purified using the same method except 50 mM NaH2PO4 pH 7.0, 300 mM NaCl and 2 mM
imidazole buffer was used to lyse the bacterial cells and wash the HiTrap Ni column. A linear
imidazole gradient from 2 mM to 100 mM was used to elute the protein. All proteins were
further purified by anion exchange chromatography as described above.
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Caspase-9 ∆CARD was expressed from a two-plasmid expression system. Two separate
constructs, one encoding the large subunit, residues 140-305, and the other encoding the small
subunit, residues 331-416, each in the pRSET plasmid, were separately transformed into the
BL21 (DE3) T7 Express strain of E. coli (NEB). The recombinant large and small subunits were
individually expressed as inclusion bodies for subsequent reconstitution. Cultures were grown in
2xYT media supplemented with ampicillin (100 mg/L, Sigma-Aldrich) at 37°C until they reached
an optical density at 600 nm of 0.6. Protein expression was induced with 0.2 mM IPTG. Cells
were harvested after 3 hrs at 37˚C. Cell pellets stored at -20˚C were freeze-thawed and lysed in a
microfluidizer (Microfluidics, Inc.) in 10 mM Tris pH 8.0 and 1 mM EDTA. Inclusion body
pellets were washed twice in 100 mM Tris pH 8.0, 1 mM EDTA, 0.5 M NaCl, 2% Triton, and 1M
urea, twice in 100 mM Tris pH 8.0, 1 mM EDTA and finally resuspended in 6 M guanidine
hydrochloride. Caspase-9 large and small subunit proteins in guanidine hydrochloride were
combined in a ratio of 1:2, large:small subunits, and rapidly diluted dropwise into refolding buffer
composed of 100 mM Tris pH 8.0, 10% sucrose, 0.1% CHAPS, 0.15 M NaCl, and 10 mM DTT,
allowed to stir for one hour at room temperature and then dialyzed four times against 10 mM Tris
pH 8.5, 10 mM DTT, and 0.1mM EDTA buffer at 4˚C. Typically 5 mL of mixed caspase large
and small subunits was diluted to 80 mL in refolding buffer and dialyzed against 5 L of dialysis
buffer. The first and last dialysis steps were allowed to proceed for 4 hours at 4˚C while the
second dialysis proceeded overnight at 4˚C. The dialyzed protein was centrifuged for 15 minutes
at 16,500 x g to remove precipitate and then purified using a HiTrap Q HP ion exchange column
(GE Healthcare) with a linear gradient from 0 to 250 mM NaCl in 20 mM Tris buffer pH 8.5,
with 10 mM DTT. Protein eluted in 20 mM Tris pH 8.5, 100 mM NaCl, and 10 mM DTT buffer
was stored in -80˚C. The identity of the purified caspase-9 ∆CARD was analyzed by SDS-PAGE
and ESI-MS to confirm mass and purity. The ∆CARD-His6x construct was generated by deleting
the CARD (res1-138) from the caspase-9 full-length construct by deletion mutagenesis. ∆CARDHis6x was purified using the same method as wild-type caspase-9.
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Oligomeric-State Determination
Caspase-9 wild-type, full-length and ∆CARD variant protein samples in 20 mM Tris pH
8.5, 110 mM NaCl, and 5 mM DTT were incubated alone (monomer) or with covalent inhibitor
z-VAD-FMK (carbobenzoxy-Val-Ala-Asp-fluoromethylketone, Enzo Life Sciences) (dimer) for
2 hours at room temperature. The oligomeric state of the caspase-9 samples was determined via
gel filtration. 100 µL of 0.5 mg/mL protein sample was loaded onto a Superdex 200 10/300 GL
(GE Healthcare) gel-filtration column. Apo and z-VAD-FMK-incubated protein samples were
eluted with 20 mM Tris pH 8.0, 100 mM NaCl, and 2 mM DTT. Eluted peaks were analyzed by
SDS-PAGE to identify the eluted protein. Four different molecular weight standards from the gelfiltration calibration kit LMW (GE Healthcare) were run in the same conditions and a standard
plot was generated to determine whether the peaks were caspase-9 monomer or dimer.
CARD Expression and Purification
The CARD only construct (amino acids 1-138) in pET23b was made by QuikChange
mutagenesis (Stratagene) using the oligonucleotide primer 5`-CCCAGACCAGTGGACATTGGTTCTGGAGGATTCGGTGATCACCACCACCACCACCACTAAGTCGGTGCTCTTGAG
AGTTTGAGGGGAAATGCAGATTTGG-3`and its reverse compliment on the caspase-9 fulllength gene (Addgene plasmid 11829). These oligo-nucleotide primers insert a 6xHis-tag and a
stop codon after the last amino acid of the CARD domain (Asp138), leaving the remaining
portion of the caspase-9 gene in the plasmid. A separate CARD construct was made to insert a
human rhinovirus-3C (HRV) protease cleavage site (LEVLFQGP) before the 6xHis-tag using the
primers

5’-CTCGGGCTGGAAGTGCTGTTCCAGGGTCCGCACCACCACCACCACCACT-

AAGCCG-3’ (forward) and 5’-ATCACCGAATCCTCCAGAACCAATGTCC-3’ (reverse). Each
construct was transformed into BL21 (DE3) T7 Express strain of E. coli. The cultures were
grown in 2xYT media supplemented with ampicillin (100 mg/L, Sigma-Aldrich) at 37˚C until
they reached an optical density at 600 nm of 0.6. The temperature was reduced to 15˚C and cells
were induced with 1 mM IPTG (Anatrace) to express soluble 6xHis-tagged full-length protein.
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Cells were harvested after 18 hrs. Cell pellets stored at -20˚C were freeze-thawed and lysed in a
microfluidizer (Microfluidics, Inc.) in 50 mM sodium phosphate pH 8.0, 300 mM NaCl, and 2
mM imidazole. Lysed cells were centrifuged at 37,000 x g to remove cellular debris. The filtered
supernatant was loaded onto a 5-mL HiTrap Ni-affinity column (GE Healthcare). The column
was washed with a buffer containing 50 mM sodium phosphate pH 8.0, 300 mM NaCl, 2 mM
imidazole until 280 nm absorbance returned to baseline. The column was washed with 50 mM
phosphate pH 8.0, 300 mM NaCl, 50 mM imidazole and the protein was eluted with 50 mM
phosphate pH 8.0, 300 mM NaCl, 250 mM imidazole. The eluted fraction was diluted 10-fold
into a buffer containing 20 mM Tris pH 8.0 and 2 mM DTT to reduce the salt concentration. This
protein sample was loaded onto a 5 mL Macro-Prep High Q column (Bio-Rad Laboratories, Inc.).
The column was developed with a linear NaCl gradient. Protein eluted in 20 mM Tris pH 8.0, 2
mM DTT, and 130 mM NaCl. Eluted protein was analyzed by SDS-PAGE to assess purity and
stored in -80˚C. For cleavage of the His6x-tag, eluted fractions from the Ni-NTA column was
diluted 2x with 50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA and 1 mM DTT. 100 µg of
hrv3C protease was added per 1 µg of CARD-6xHis and the reaction was incubated for 16h at
4˚C with gentle mixing. The cleavage reaction was filtered through 0.45 µm PVDF. Filtered
protein solution was diluted 6x with Buffer A and loaded onto a HiTrap Q column (GE
Healthcare). The column was developed with a linear NaCl gradient. Caspase-9 CARD (no His
tag) eluted in 20 mM Tris pH 8.0, 130 mM NaCl and 2 mM DTT. Full cleavage was assessed by
running samples on a 16% SDS-PAGE gel.
Thermal Stability and Secondary Structure Analysis by Circular Dichroism
All caspase-9 variants (except for S183E , S183A, C287A/S183A, S99E, C287A/S99E,
T125E, C287A/T125E) and the CARD protein were buffer exchanged via dialysis against 100
mM sodium phosphate pH 7.0, 110 mM NaCl, and 5 mM TCEP and diluted to 7 µM. The
samples were split in half and incubated in the presence or absence of four molar equivalents of
active site ligand VAD-FMK for 3 hours at room temperature. To ensure complete binding of the
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active site ligand to the protein, remaining enzymatic activity was assayed using 300 µM
substrate, LEHD-AFC (N-acetyl-Leu-Glu-His-Asp-7-amino-4-fluorocoumarin), (Enzo Life
Sciences). Once full inhibition was achieved, samples were buffer-exchanged six times with 100
mM phosphate buffer pH 7.0, 100 mM NaCl and 5 mM TCEP using an Amicon Ultracell 3K
concentrator (Millipore) to remove unbound inhibitor. For S183E, S183A, C287A/S183A, S99E,
C287A/S99E, T125E, C287A/T125E variants of caspase-9, prior to thermal denaturation by CD,
the proteins were buffer exchanged with 100 mM phosphate buffer pH 7.5, 110 mM NaCl and 5
mM TCEP using a NAPTM-5 Column (GE Healthcare). For cleavage of the unprocessed caspase9 C287A and S183E variants, 7 µM protein sample was incubated with 3% active caspase-3
protein for two hours at room temperature. Full processing of caspase-9 C287A and S183E by
caspase-3 was determined by SDS-PAGE analysis.
Thermal denaturation of caspase-9 variants and CARD was monitored by loss of CD
signal at 222 nm over a range of 20–90°C. The circular dichroism spectra were monitored from
250-190 nm. Both were performed on a J-720 or J-1150 CD spectrometer (Jasco) with a Peltier
controller. Data were collected four separate times on different days from different batches of
purified proteins. Curves were fit with Origin Software (OriginLab) using sigmoid fit to
determine the melting temperature.
Caspase-3 Expression and Purification
Caspase-3 full-length gene (human sequence) in pET23b (Addgene plasmid 11821
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)

was transformed into BL21 (DE3) T7 Express strain of E. coli and protein expression was
induced with 1 mM IPTG at 30°C for 3 hours 56. The protein was purified as described previously
for caspase-3 21. The eluted protein was stored in -80°C in the buffer in which they eluted. The
identity of purified caspase-3 was assessed by SDS-PAGE and ESI-MS to confirm mass and
purity.
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Native Gel Electrophoresis and Ni-NTA Affinity Isolation Assay to Determine in trans
Interactions
For native gel electrophoresis to diagnose an interaction between caspase-9 ∆CARD and
caspase-9 CARD in trans, full-length caspase-9, caspase-9 ∆CARD and the CARD domain only
were dialyzed twice against 100 mM phosphate pH 7.0 and 2 mM DTT for 90 minutes to rid of
excess salt. Samples were incubated either alone or combined with CARD to achieve a 1:1 ratio
of caspase-9 ∆CARD plus CARD. Each protein sample was diluted to a final concentration of 10
µM in the dialysis buffer. To induce dimerization samples were incubated with 5-fold excess zVAD-FMK. All samples were allowed to incubate at room temperature for one hour. All samples
were mixed with glycerol loading dye and fractionated on a 10% Tris/Glycine pH 8.3
polyacrylamide gel. The oligomeric state of the mixed caspase-9 ∆CARD and CARD samples
were identified by comparison to the apo (monomer) and z-VAD-FMK-bound (dimer) of both the
caspase-9 full-length and caspase-9 ∆CARD protein in addition to the CARD only sample.
For Ni-NTA affinity isolation assay of caspase-9 ∆CARD-His6x (∆CARD, ∆CARD
C287A, ∆CARD+VAD-FMK) with CARD in trans, samples were diluted to 10 µM in binding
buffer (50 mM phosphate pH 8.0, 100 mM NaCl) with 5 mM DTT. To induce dimerization, 20
µM ∆CARD was incubated with 5-fold excess z-VAD-FMK for 1 h at RT. Complete inhibition
was assessed by assaying caspase-9 activity using 300 µM LEHD-AFC. Excess z-VAD-FMK
was removed by buffer exchanging 5x with binding buffer using Amicon Ultra centrifugal filter
10K MWCO (Millipore). Samples were incubated either alone or with CARD to achieve a 1:2
ratio of caspase-9 ∆CARD-His6x plus CARD (no His tag). 100 µL of protein sample was added
to a tube containing 35 µL of HisPur Ni-NTA magnetic beads (ThermoFisher) that were washed
three times in water and twice in binding buffer without DTT. Ni-NTA beads plus caspase-9
∆CARD-His6x and CARD samples were incubated for 3 hours at 4°C with mixing using an endto-end rotator. Supernatant (unbound fraction) was aspirated and the beads were washed three
times with binding buffer to remove any unbound or weakly bound protein (wash fraction).
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Protein elution was then carried out by incubating the Ni-NTA beads with 50 µL elution buffer
(binding buffer + 250 mM imidazole) for 30 minutes at room temperature. The supernatant
(elution fraction) was collected and all fractions were subjected to SDS-PAGE analysis.
Fluorescence Anisotropy
Fluorescence anisotropy was monitored using a SpectraMax M5 plate reader (Molecular
Devices, Inc.) with a fixed excitation wavelength set to 485 nm and an emission wavelength set to
525 nm. Caspase-9 CARD (without the His tag) was labeled with fluorescein isothiocyanate
(FITC) isomer 1 (Sigma) in labeling buffer containing 0.1 M sodium bicarbonate pH 9.0, 100
mM NaCl for 2h at RT. Unreacted FITC was removed by buffer exchange using a NAP5 column
equilibrated in 50 mM Tris (pH 7.5) and 150 mM NaCl. A fixed concentration of FITC-labeled
CARD (25 nM) was titrated into a serially diluted caspase-9 ∆CARD (3 nM – 25 µM). The final
volume of each binding reaction is 100 µL. All measurements were taken at 25˚C after a 1.5 h
incubation at RT.
Activity Assays
For kinetic measurements of caspase activity, 800 nM caspase-9 full-length protein was
diluted in 100 mM MES pH 6.5, 10% PEG 8,000 and 5 mM DTT. Each sample was subjected to
a substrate titration, performed in the range of 0-300 µM fluorogenic substrate, Ac-LEHD-AFC,
(Ex 365/Em 495) which was added to initiate the reaction. Assays were performed in duplicates
at 37°C in 100 µL volumes in 96-well microplate format using a Molecular Devices Spectramax
M5 spectrophotometer. Initial velocities versus substrate concentration were fit to a rectangular
hyperbola using GraphPad Prism (Graphpad Software) to determine kinetic parameters KM and
kcat. Enzyme concentrations were determined by active site titration with quantitative inhibitor zVAD-FMK. Active site titrations were incubated over a period of 3 hours in 100 mM MES pH
6.5, 10% PEG 8,000, and 5 mM DTT. Optimal labeling was observed when protein was added to
z-VAD-FMK solvated in DMSO in 96-well V-bottom plates, sealed with tape, and incubated at
room temperature in a final volume of 200 µL. 90 µL aliquots were transferred to black-well

97

plates in duplicate and assayed with 300 µM substrate. The protein concentration was determined
to be the lowest concentration at which full inhibition was observed.
To test the ability of CARD to activate caspase-9 ∆CARD in trans, 10 µM of ∆CARD
was incubated with CARD at different ratios (1x, 5x and 10x CARD) in minimal activity assay
buffer (100 mM MES pH 6.5, 20% PEG 400 and 5 mM DTT) for 1h at RT. Control reactions
were made using BSA in place of CARD. Samples were diluted to a final concentration of 800
nM ∆CARD using minimal activity assay buffer and LEHDase activity was measured over the
course of 10 min in 100 µL volumes using a Spectramax M5 fluorescence plate reader.
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CHAPTER IV
ACTIVE-SITE ADJACENT PHOSPHORYLATION AT TYR-397 BY c-ABL KINASE
INACTIVATES CASPASE-9

Majority of this chapter is published: Serrano, B.P., Szydlo, H.S., Alfandari, D.R. and Hardy J.A.
Active-Site Adjacent Phosphorylation at Tyr-397 by c-Abl Kinase Inactivates Caspase-9. J. Biol.
Chem. 292:21352-21365 (2017).

Abstract
Caspase-9 is an initiator caspase and plays a central role in activating apoptotic cell
death. Control of caspase-9 and all caspases is tightly regulated by a series of phosphorylation
events enacted by a number of different kinases. Caspase-9 is the most heavily phosphorylated of
all caspases, and is is thus perhaps the most tightly regulated of all caspases. Phosphorylation of
caspase-9 by the non-receptor tyrosine kinase c-Abl, at Y153 reportedly leads to caspase-9
activation. All other phosphorylation events on caspases have been shown to block proteolytic
function by a number of mechanisms, so we undertook a project to understand the molecular
mechanism of caspase-9 activation by phosphorylation. Surprisingly, we observed no evidence
for Y153 phosphorylation under any of the conditions studied, perhaps suggesting that Y153 is
not directly phosphorylated by c-Abl, but by another similarly activated kinase. Instead we
identified a new site of c-Abl phosphorylation, Y397, which is adjacent to the caspase-9 active
site, but as a member of the second shell, not a residue that directly contacts substrate. Our data
indicate that Y397 is the dominant site of c-Abl phosphorylation both in vitro and upon c-Abl
activation in cells. Phosphorylation at the Y397 site inhibits caspase-9 activity. It appears that the
bulk of the added phosphate moiety directly blocks substrate binding. c-Abl is known to play both
proapoptotic and prosurvival roles; these data on c-Abl regulation of caspase-9 suggest that c-Abl
functions in a prosurvival mode.

102

Introduction
Cells undergo constant turnover to maintain normal tissue function and homeostasis. This
is achieved by a delicate and dynamic balance of cellular networks involving cell proliferation
and cell death signaling pathways. Apoptosis or programmed cell death is an essential pathway
that proceeds via a series of biochemical reactions that ultimately result in the controlled
dismantling of cellular components without adverse damage to neighboring cells. Tight regulation
of apoptosis is fundamental to attain cellular homeostasis. Defects in regulation of apoptotic
pathways have been implicated in many diseases that are in nature both proliferative, such as
cancer, and degenerative, like Alzheimer’s and Huntington’s. As such, elements involved in
apoptotic signaling are recognized as attractive drug targets for the development of therapeutics
for apoptosis-related diseases.
Caspases are specialized proteases that mediate the faithful execution of apoptosis.
Caspases cleave protein substrates causing either activation or inhibition which eventually
commits the cell to death. Caspases are extremely specific towards substrates, generally
preferring to cleave after an aspartate1 or glutamate2, and in some cases a phosphoserine3.
Depending on where they act in the apoptotic pathways, caspases are classified as either upstream
initiators (caspase-2, -8 and -9) or downstream executioners (caspase-3, -6 and -7). Because
caspase activity inherently induces apoptosis, caspases are synthesized and held as inactive
zymogens (procaspases). Procaspases contain an N-terminal prodomain region and the highly
homologous caspase core, consisting of a large and a small subunit joined together by an
intersubunit linker. Most procaspases exist predominantly as homodimeric proteins. Upon
apoptosis induction, initiator caspases are recruited to complex protein scaffolds that promote
activation, while executioner caspases depend on initiator caspases to cleave the intersubunit
linker which consequently converts the inactive procaspase into a mature, active form. Once
assembled into an active form, the highly dynamic loops that compose the active site assume a
conformation that allows substrate binding and catalytic cleavage, thereby initiating a cascade of
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reactions that eventually lead to the cell’s demise. Caspases exert such dominant impact on
apoptosis, that any inopportune caspase activation is deleterious to the cell. Thus, caspase
expression and activation are tightly regulated by various mechanisms at different checkpoints in
the cell.
Phosphorylation is recognized to be a critical mediator of apoptosis (reviews4,5). Caspases
form a subset of kinase substrates whose functions are directly affected by phosphorylation
(review6). The initiator caspase-9 (caspase-9), for example, appears to be extremely sensitive to
phosphorylation, having the largest number of phosphorylation sites reported of any caspase
(Figure 4.1A; reviews6–8). This suggests that phosphorylation is a strong regulator of caspase-9
function. This is perhaps because phosphorylation can impact caspase-9 on multiple levels, as
caspase-9 achieves activation in many ways – from cleavage to dimerization to protein-protein
interactions to the formation of the apoptosome. Phosphorylation sites are present in all domains
of caspase-9 (Figure 4.1A) and are targeted by kinases that are involved in cell cycle9,10, cellular
stress11–13 and extracellular signals14,15.
In general, phosphorylation of caspases results in apoptotic suppression, which is a direct
consequence of caspase inhibition. Intriguingly, of all the reported sites of phosphorylation in
caspase-9, Y153 is the only site reported to activate caspase-912. All other sites of
phosphorylation reportedly have led to inactivation (review16). Y153 in caspase-9 is reported to
be phosphorylated by the non-receptor tyrosine kinase c-Abl. c-Abl is activated in response to
various extrinsic and intrinsic signals, which causes it to possess both pro- and anti-apoptotic
roles (review17). c-Abl generally recognizes the sequence I/V/L-Y-X-X-P and phosphorylates a
large number of functionally diverse substrates, in part due to its ability to shuttle between the
cytosol and the nucleus. Interestingly, this nucleocytoplasmic shuttling of c-Abl dictates whether
its activation would promote either cell death or survival. For example, oncogenic forms of c-Abl
exhibit strictly cytoplasmic localization and constitutive activity, while nuclear c-Abl activated by
cellular stress such as DNA damage promotes apoptosis. This pro-apoptotic function of c-Abl has
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been attributed to its phosphorylation of caspase-9 resulting in self-processing and subsequent
activation of caspase-312. We were intrigued by this functional effect of c-Abl on caspase-9,
especially since all other sites were reported to be inhibiting upon phosphorylation. For this
reason we undertook a study of the mechanism of caspase-9 activation by Y153 phosphorylation.
During this study we also identified a new site of phosphorylation.
In the last decade a number of cell-based studies identified sites of phosphorylation in
caspase-9 (review16). Many excellent proteome-wide studies have annotated sites of
phosphorylation in caspase-9 and other caspases. Given the multitude of different cellular
contexts, it has naturally been impossible to perform these large-scale, proteome-wide studies
under all relevant cellular conditions. Thus, although a number of sites have been identified it is
likely that many other sites of phosphorylation by particular kinases have not yet been identified.
Here we report a novel site of phosphorylation in caspase-9 by c-Abl. An active-site adjacent
residue Y397 is phosphorylated by c-Abl both in vitro and intracellularly, leading to caspase-9
inhibition.

Results
Caspase-9 is composed of the caspase activation and recruitment domain (CARD) and
the core which consists of the large and the small subunit. The reported phosphorylation site
Y153 resides in the caspase-9 large subunit (Figure 4.1A, 4.1B). In the dimeric, substrate-bound
structure of caspase-9, the hydroxyl group of Y153 forms an H-bond with D350 in the L2’ loop.
This interaction seems to support the position of L2’ as it correspondingly interacts with L2 and
L4 in the other half of the dimer to form the substrate binding groove and catalytic site (Figure
4.1C). Thus it is conceivable that phosphorylation of Y153 would impact caspase-9 activity.
Phosphorylation of caspases typically leads to inhibition (review6), yet it has been reported that
upon DNA damage, Y153 phosphorylation by c-Abl results in self-processing and promotes
caspase-9 cleavage of caspase-312.
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Figure 4.1. Y153 makes critical contacts with active site loop L2’.
(A) Domain architecture of caspase-9 showing the N-terminal caspase activation and recruitment
domain (CARD) and the core which is composed of a large (Lg) and a small (Sm) subunit connected by
an intersubunit linker. Three cleavage sites in the intersubunit linker are indicated by arrows: E306
(minor, self-cleavage), D315 (major, self-cleavage) and D330 (by caspase-3). Reported phosphorylation
sites are indicated by ℗ in white; the c-Abl phosphorylation site Y153 in the large subunit is
highlighted in yellow. Cognate kinases are indicated with arrows pointing at the phosphorylation site.
(B) Structure of full-length, dimeric caspase-9 showing the phosphorylation site, Y153, as spheres. The
structure shown here was modeled from individual structures of the CARD-deleted caspase-9 (aa 138416; PDB 1JXQ) and the caspase-9 CARD (aa 1-95; PDB 3YGS) from a dimeric complex with Apaf-1
CARD. The region between the CARD and core is not present in either structures and is most likely
highly disordered, hence it was modeled as gray coil. The loops forming the substrate binding groove
(L2, L3 and L4 from one monomer and L2’ from the opposite monomer) are labeled.
(C) Y153 forms an H-bond with D350 in loop L2’, supporting the “up” position of L2’ in order to
properly interact with L2 and L4 and achieve a catalytically competent active site.
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Phosphomimetic Y153E has impaired catalytic efficiency compared to WT caspase-9
To probe for the functional consequence of Y153 phosphorylation in caspase-9, we
generated the glutamate phosphomimetic Y153E. Following overexpression, Y153E remained in
its zymogen (uncleaved) form unlike wild-type (WT) caspase-9, which was expressed as a
mature, cleaved enzyme (Figure 4.2A). Caspase-9 zymogen possesses basal activity and hence
readily undergoes self-processing; however, it seems that the glutamate substitution blocks
function. Unlike the WT zymogen, Y153E lacked the ability to self-process (Figure 4.2B) and did
not exhibit any LEHDase activity (Table 4.1) in the zymogen form. To assess whether the

Figure 4.2. Y153 is an inherently sensitive site.
(A) Caspase-9 Y153 variants (phosphomimetics Y153E, Y153D and non-phosphorylatable Y153F)
remained in the uncleaved zymogen (full-length) state upon overexpression, whereas WT caspase-9
forms the mature, cleaved state upon overexpression. The constitutively two-chain (CT) versions of
caspase-9 are generated by independent translation of the CARD+Large (Lg) and Small (Sm) subunits,
thus all caspase-9 CT variants (CT Y153E, CT Y153F and CT Y153Q) are in the “cleaved” state
following overexpression.
(B) WT caspase-9 zymogen readily undergoes self-processing into the CARD+Large and small
subunits. Full length Y153E is unable to self-process and remains in the zymogen (uncleaved) form,
suggesting it is inherently inactive.
(C) Caspase-3 natively cleaves caspase-9 at D330. WT Caspase-9, catalytic-site inactivated variant
C287A, phosphomimetic Y153E and variants Y153D and Y153F were incubated alone or with caspase3. Cleavage at D330 to generate mature proteins only occurred in the presence of caspase-3, except for
WT which immediately self-processes.
(D) Caspase-9 full-length variants cleaved by caspase-3 (C) were tested in an LEHDase assay. Y153E,
Y153D and Y153F did not gain activity following caspase-3 cleavage.
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observed inhibition was due to its zymogen nature and to assess whether these variants are still
cleavable by other caspases, full-length Y153E was cleaved by caspase-3 (Figure 4.2C). Even
following cleavage to generate the mature form, Y153E remained inactive (Figure 4.2D).
In addition, caspase-9 variants at this position were expressed from a constitutively twochain (CT) construct, which allows independent translation of the CARD+Large and the small
subunits. Even in its fully mature form, CT Y153E remained inactive, suggesting that the
glutamate phosphomimetic inherently inhibits caspase-9 activity (Figure 4.2A, Table 4.1). This
was in contrast to prior reports, in which phosphorylation at Y153 was suggested to promote
caspase-9 self-processing and thereby activation12. To validate that the inhibition was a direct
consequence of the phosphomimetic, an aspartate substitution (Y153D) was made and showed
the same inactivating effect as the glutamate phosphomimetic, while the conservative
phenylalanine substitution mutant (Y153F) had a ~150x decrease in catalytic efficiency (Table
4.1). Both Y153D and Y153F were also uncleaved upon overexpression, suggesting impaired
self-processing abilities (Figure 4.2A).

Table 4.1. Catalytic parameters6 of caspase-9 variants.
KM
Caspase-9 variants
(µM)

kcat
(s-1)

103 x kcat/KM
(µM-1s-1)

1.4 ± 0.1
< 0.01
< 0.01
0.04 ± 0.01
0.78 ± 0.1

3.3
< 0.003
< 0.003
0.02
2.7

WT
609 ± 35
1.8 ± 0.03
Y153E
> 3000
< 0.01
Y153F
> 3000
< 0.01
Y153Q
> 3000
< 0.01
Y397E
961 ± 100
0.57 ± 0.08
6
Values are mean (± SEM) of three trials done on three separate days.

3.0
< 0.003
< 0.003
< 0.003
0.59

Caspase-9 Full-Length (C9 FL)
Wild-type (WT)
Y153E
Y153D
Y153F
Y397F

430 ± 35
> 3000
> 3000
2804 ± 829
338 ± 18

Caspase-9 Constitutively Two-Chain (C9 CT)
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Similar to Y153E, caspase-3 was able to cleave Y153D or F to generate mature enzymes;
however they remained inactive (Figure 4.2C, 4.2D). Moreover, the CT version of Y153F had no
measurable activity, and introducing a polar amide side chain of glutamine (CT Y153Q) did not
rescue activity (Table 4.1, Figure 4.2A). These results are in line with prior observations. This
region where the L2 and L2’ loops interact is extremely sensitive to mutation and posttranslational modification. Substitutions that break the L2-L2’ interaction disrupt caspase
activity18 and phosphorylation of S257, which is also in this region also inactivates caspase-619.
Thus, one might anticipate a priori that should Y153 be phosphorylated, it would be inactivating.
Y397 is the major phosphorylation site in caspase-9 by c-Abl
We performed in vitro phosphorylation using recombinant c-Abl to interrogate the
behavior of the phosphorylated form of caspase-9. Caspase-9 was indeed a substrate of c-Abl, as
both the kinase domain only (KD) and the three domain (SH3-SH2-kinase domain) (3D) forms of
c-Abl resulted in
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P-labeling of caspase-9 zymogen/full-length (as catalytic site inactivated

C287A) in the presence of [γ-32P]-ATP (Figure 4.3). Surprisingly, we did not observe any
phosphorylation in the CARD+Large (CARD+Lg) region where Y153 is located, but rather clear
phosphorylation of the small subunit (Sm) in cleaved, WT caspase-9 (Figure 4.3B, 4.3D). Upon
inspection of all other tyrosine residues in caspase-9 (Y251, Y345, Y363 and Y397), Y397 was
the most highly surface-exposed (Figure 4.4A). In addition, the sequence surrounding Y397
contains a consensus sequence for c-Abl recognition (Figure 4.4B, 4.4C).
To pinpoint the phosphorylated residue or residues, Y153 and Y397 were rendered
unphosphorylatable by substitution of phenylalanine and incubated with active c-Abl. Y153F
substitution did not abolish phosphorylation, as the small subunit was still clearly labeled with 32P
(Figure 4.4D). Y397 appears to be more solvent exposed relative to Y153 hence it is possible that
the competition for Abl recognition and phosphorylation is heavily weighted towards Y397.
However, making Y397 unphosphorylatable (Y397F) did not force phosphorylation of Y153 but
almost completely eliminated caspase-9 phosphorylation (Figure 4.4D).
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Figure 4.3. c-Abl phosphorylates caspase-9 in vitro at the small subunit.
(A) and (C) Recombinant c-Abl constructs used to phosphorylate caspase-9 in vitro. The construct cAbl KD comprises only the kinase domain, while the c-Abl 3D construct contains the SH3-SH2
regulatory/binding domains as well as the kinase domain.
(B) and (D) Caspase-9 catalytic-site inactivated variant C287A (full-length) and WT (cleaved) were
subjected to in vitro phosphorylation by c-Abl KD or 3D in the presence of ATP + [γ-32P]ATP for 2h. cAbl undergoes autophosphorylation/autoactivation upon treatment with ATP. Both forms of c-Abl
phosphorylated caspase-9 in the zymogen (C287A) and cleaved (WT) forms. No phosphorylation in the
CARD+Large region (Y153 site) was detected, but phosphorylation in the small subunit was clearly
visible, as shown in the autoradiograph labeled here and in the succeeding figures as 32P.
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Figure 4.4. Y397 is the predominant site for c-Abl phosphorylation in vitro.
(A) Structure of caspase-9 core showing all the tyrosine residues (yellow spheres). Y397 resides in
loop L4 and is noticeably solvent-exposed, due to crystal contacts in this structure (PDB ID 1JXQ).
(B) Substrate sequence logo for the consensus recognition sequence of c-Abl (downloaded from
PhosphoSitePlus 57)
(C) Sequence of residues surrounding each tyrosine present in caspase-9. Residues in favorable
positions are underlined. Sequence surrounding Y397 conforms well to the consensus sequence for cAbl phosphorylation.
(D) Unphosphorylatable caspase-9 variants (phenylalanine substitutions at putative phosphorylated
tyrosines) in both full-length (FL) and CT versions were subjected to in vitro phosphorylation by cAbl for 2h. The * denotes that FL Y397F was constructed in the background of C287A (catalytic
cysteine inactivated variant) to prevent self-processing since Y397F is active. FL Y153F caspase-9
was still visibly phosphorylated; the CT version of Y153F revealed that the phosphorylation is in the
small subunit. An absence of phosphorylation was observed for Y397F (both FL and CT) and the
double mutant Y153F/Y397F.
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We also tested CARD-deleted versions of
caspase-9

(∆CARD)

to

increase

Y153

accessibility, as the CARD in the full-length is
attached through a highly flexible linker and could
potentially block the Y153 site. Even in the
absence of the CARD, only phosphorylation at the
Sm subunit was observed (Figure 4.5). To
unambiguously identify the phosphorylated site,
we performed LC-MS/MS on peptide fragments
following

ArgC

proteolysis

of

c-Abl-

phosphorylated WT caspase-9 and observed

Figure 4.5. Removal of the CARD in
caspase-9 (∆CARD) did not promote Y153
phosphorylation.
No visible phosphorylation in the large
subunit was observed in both cleaved
versions of WT and ∆CARD caspase-9. Only
the small subunit in both cases was robustly
phosphorylated. An unidentified non-specific
12 kDa band from ∆CARD C287A was also
observed be phosphorylated.

phosphate labeling at Y397 with high confidence
(Figure 4.6A, 4.6B). These results clearly indicate that Y397 is the dominant site for
phosphorylation by c-Abl in vitro.
Phosphorylation of Y397 leads to caspase-9 inhibition
This is the first report of a novel site, Y397, being phosphorylated by c-Abl. As such, it is
imperative to probe whether this phosphorylation imparts functional or structural perturbations to
caspase-9. A modest but statistically significant inhibition of caspase-9 LEHDase activity was
observed when WT was phosphorylated at Y397. In contrast, the activity of the
unphosphorylatable Y397F variant was unchanged even after treatment with c-Abl (Figure 4.7A,
4.7B). Although full inhibition was not achieved under in vitro phosphorylation conditions, a
strong correlation between the levels of phosphorylation and caspase-9 inhibition was observed
(Figure 4.7C). In fact, phosphocapture experiments resulted in samples with enriched levels of
phosphorylated caspase-9 that correspondingly exhibited higher degrees of inhibition (Figure
4.7D), implying that a homogeneous population of phosphorylated caspase-9 would be
completely inhibited.
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Figure 4.6 MS/MS spectra of peptides of derived from c-Abl-phosphorylated 9.
WT 9 was phosphorylated by c-Abl and was digested with Arg C protease which cleaves on the Cterminal side of arginine and lysine residues. Two peptide fragments showed phosphorylation at Y397
with high confidence. In the same analysis the peptides containing Y153 were only observed with
intermediate confidence, nevertheless phosphorylation of Y153 was not indicated by this analysis.
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Figure 4.7. Phosphorylation of Y397 leads to caspase-9 inactivation.
(A) WT Caspase-9 and the unphosphorylatable variant Y397F were subjected to in vitro
phosphorylation by Abl in the presence or absence of ATP for 2h. Phosphorylation of the small
subunit was clearly observed in WT caspase-9 but was essentially absent for caspase-9 Y397F.
Only background levels of phosphorylation were visible in the CARD+Large region. Gels and
corresponding autoradiographs shown are representative of four independent trials performed on
four separate days.
(B) Inhibition of WT and Y397F caspase-9 by phosphorylation. The activities of samples in (A)
after incubation with c-Abl for 2h were measured using the caspase-9 preferred substrate AcLEHD-AFC. WT caspase-9 was moderately inhibited whereas caspase-9 Y397F was insensitive to
c-Abl-mediated inhibition. The reduced LEHDase activity for phosphorylated WT caspase-9 (+
ATP) was statistically different from that of unphosphorylated WT (- ATP) (**P<0.05) as
determined by Student’s t-test. Data shown are means ± SEM from four independent experiments
performed on four separate days.
(C) The level of caspase-9 phosphorylation correlates with the extent of inhibition. Phosphorylation
levels of caspase-9 were determined from [γ-32P]ATP standards exposed on the same
autoradiograph as the Coomassie-stained SDS-PAGE gel (see under Methods, Figure 4.18).
Percent inhibition for phosphorylated caspase-9 (both c-Abl and ATP present) was normalized
against activity in the non-phosphorylated form (with c-Abl but no ATP). Data shown are means ±
SEM from four independent experiments performed on four separate days.
(D) Correlation plot between caspase-9 inhibition and caspase-9 phosphorylation. WT caspase-9
was initially phosphorylated in vitro by c-Abl and was subjected to phosphoprotein enrichment to
capture a greater fraction of phosphorylated caspase-9. Data shown are means ± SD from three
independent experiments performed on three separate days.
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We also observed that phosphorylation of Y397 is reversible; treatment with CIP (Calf Intestinal
Phosphatase) removed phosphorylation with a concomitant rescue in activity (Figure 4.8).

Figure 4.8. Dephosphorylation of caspase-9 relieves inhibition.
(A) c-Abl phosphorylated caspase-9 is dephosphorylated by CIP (Calf Intestinal Phosphatase) for 1h. No
visible phosphorylation remains in the CIP-treated caspase-9, suggesting that phosphorylation by c-Abl is
reversible.
(B) CIP treatment to dephosphorylate caspase-9 leads to recovery of activity. Note: CIP reaction buffer
contains 100 µM ZnCl2, which fully inhibits caspase-9 activity. Even when diluted into caspase-9 activity
assay buffer, caspase-9 is still partially inhibited, hence the large difference in LEHDase activity before and
after CIP treatment.

One of the hallmarks of suppressed apoptosis emanating from caspase-9 inhibition is the
attenuation of the cleavage of downstream substrates caspase-3 and caspase-720. WT Caspase-9
phosphorylated by c-Abl cleaved full-length caspase-7 and caspase-3 more slowly than
unphosphorylated WT caspase-9 (Figure 4.9A, 4.9E). In contrast, there was no significant
difference in caspase-7 or caspase-3 cleavage kinetics by caspase-9 Y397F regardless whether cAbl was active (+ ATP) or not (no ATP) (Figure 4.9B, 4.9F). This recapitulates the previous
finding that Y397F is insensitive to inactivation by c-Abl. Importantly, the degree of caspase-9
phosphorylation also correlates with the decrease of its protein cleavage kinetics (Figure 4.9C,
4.9D for caspase-3 and Figure 4.9G, 4.9H for caspase-7). It is worthwhile to note that Y397F is as
active as WT caspase-9 (Table 4.1), therefore the decrease in caspase-9 activity can be
unambiguously attributed to phosphorylation and not simply due to inherent sensitivity of this
site. Along these lines, we observed a five-fold decrease in catalytic efficiency in the Y397E
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phosphomimetic (Table 4.1) and attenuated protein cleavage kinetics (Figure 4.10A, 4.10B).
Although Y397E is not a perfect surrogate for phosphorylated Y397, it manifests similar
functional outcome to Y397 phosphorylation. Thus one functional effect of Y397
phosphorylation by c-Abl is to diminish caspase-9’s activation of executioner caspases.

Figure 4.9. Phosphorylated caspase-9 exhibits slower protein cleavage kinetics.
(A) WT or (B) Y397F caspase-9 was incubated with c-Abl in the presence or absence of ATP. 1 µM
caspase-9 from the phosphorylation reaction was allowed to cleave 3 µM full-length caspase-3
C163A (catalytic-site inactivated variant) (C3 FL) for 30 min. Cleavage kinetics for each reaction are
plotted as a function of the disappearance of the C3 FL band.
(C) Representative Coomassie-stained gels and corresponding autoradiographs of phosphorylation
reactions used in (A) and (B). Caspase-9 WT is visibly phosphorylated at Y397.
(D) Correlation between caspase-9 phosphorylation as detected by autoradiography in (C) and
inhibition of caspase-3 (C3) cleavage after 30 min. as shown in (A) and (B).
(E) and (F) Caspase-9 WT or Y397F was incubated with c-Abl in the presence or absence of ATP. 1
µM of caspase-9 from the phosphorylation reaction was allowed to cleave 3 µM full-length caspase-7
C186S (catalytic site inactivated variant) (C7 FL) for 30 min. Cleavage kinetics for each reaction are
plotted as a function of the disappearance of the C7 FL band.
(G) Representative Coomassie-stained gel and corresponding autoradiograph of phosphorylation
reactions used in (E) and (F). Caspase-9 WT is phosphorylated at Y397.
(H) Correlation between caspase-9 phosphorylation as detected by autoradiography in (G) and
inhibition of caspase-7 (C7) cleavage after 30 min. as shown in (E) and (F).
Data shown for all of the above experiments are means ± SEM from three independent experiments
done on three separate days.
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Figure 4.10. Caspase-9 Y397E showed attenuated cleavage kinetics of protein substrates.
Cleavage of full-length catalytic site-inactivated variants caspase-3 C163A (A) and caspase-7 C186S
(B) by WT caspase-9, Y397E and Y397F, as shown in Coomassie-stained denaturing gels. The
intensity of the bands from the cleavage assays were quantified and plotted as a function of amount of
full-length substrate protein remaining in the panels on the right. Data shown are means ± SEM of
three independent experiments done on three separate days.

Model for caspase-9 inhibition by Y397 phosphorylation
The substrate binding site of active, dimeric caspases consists of highly mobile loops L2, L3, L4 from one monomer and L2’ from the opposite monomer - which, upon substrate
binding, assume a properly ordered conformation to perform catalytic cleavage. Y397 is situated
in loop L4 of caspase-9 (Figure 4.1A, 4.11B). In the substrate-bound structure, Y397 participates
in the hydrophobic network along with I396 and W362 to engage the hydrophobic P4 residue
(Figure 4.11A). Modeling a phosphotyrosine in place of Y397, it appears that both the added bulk
and charge of phosphoY397 would directly impact substrate binding. Being situated in a highly
mobile loop, the phosphotyrosine could be envisioned to reach into the substrate-binding cavity,
essentially creating steric and electrostatic clashes with other subsite residues (Figure 4.11B).
This would either directly obstruct the incoming substrate from binding, or prevent the loop
bundle from assuming an ordered conformation keeping the active site in an unproductive state,
or both.
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A

B

Figure 4.11. Models for 9 inhibition by phosphorylation at Y397.
(A) A diagram of the interactions of 9 residues in the active site with the irreversible peptide inhibitor
Z-EVD-Dcbmk (benzoxycarbonyl-Glu-Val-Asp-dichlorobenzylmethyl ketone) was generated using
Ligplot58. The substrate peptide residues are labeled P4, P3, P2 and P1. Broken lines indicate H-bonds.
Half-circles (
) indicate hydrophobic interactions within 5 Å of 9 residues. Y397 takes part in a
hydrophobic network to stabilize the side chain in the P4 position in the only extant structure of 9 (PDB
ID 1JXQ) bound to a tripeptide capped at the N-terminus with a carboxybenzyl moiety. In the structure
the carboxybenzyl occupies the S4 pocket which binds hydrophobic residues in the 9 recognition sites.
(B) Y397 is in the highly mobile L4 loop, in close proximity to the substrate-binding cavity and loops
L2 and L2’. A phosphotyrosine in this position (p-Y397) could create steric clashes and potentially
prevent substrate binding by blocking access to the active site cavity, or by preventing the active site
loops from achieving the catalytically competent conformation. Modeling of the phosphotyrosine was
performed in Coot59 using PDB 1JXQ.
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Y397 is phosphorylated in cells upon direct c-Abl activation
In vitro phosphorylation coupled with the use of unphosphorylatable protein variants has
allowed identification of putative residues phosphorylated by kinases. However alternative
specificity of kinases towards substrates in vitro has been reported in isolated cases21. The lack of
regulatory elements normally present intracellularly has been suggested to contribute to altered
phosphorylation. To determine whether Y397 was a bona fide cellular site of phosphorylation,
recombinant WT caspase-9 was added into HEK 293T lysates supplemented with [γ-32P]ATP and
orthovanadate, a phosphatase inhibitor. This resulted in visible phosphorylation of the
CARD+Large (Figure 4.12A, Figure 4.13A, no Abl). Given that there are other kinases readily
activated by addition of ATP and treatment of orthovanadate, and that caspase-9 has multiple
phosphorylation sites in this region9,11,13–15,22,23, we were not surprised by this observation.
Phosphorylation of the small subunit in WT caspase-9 in the absence of c-Abl was not evident,
which could either be due to low titers of endogenous c-Abl in HEK 293T, or because c-Abl was
not sufficiently activated, or both. Since the activation state of c-Abl was not known, the lysates
were supplemented with recombinant c-Abl to allow in trans activation of c-Abl. This resulted in
distinct phosphorylation of the small subunit in WT caspase-9, whereas Y397F exhibited
negligible levels of small subunit phosphorylation (Figure 4.12A, 4.12B, 4.13B). For both WT
and Y397F, the CARD+Large region appeared to retain its phosphorylation state. Addition of a cAbl inhibitor, Imatinib, abrogated the phosphorylation of the small subunit but not that of the
CARD+Large (Figure 4.12A). This implies that the phosphorylation observed for the small
subunit was predominantly due to c-Abl, while that for the CARD+Large was not, and could be
reliant on the action of other kinases.
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Figure 4.12. Caspase-9 is phosphorylated at Y397 by activated c-Abl in HEK 293T lysates.
(A) Recombinant caspase-9 was phosphorylated in HEK 293T lysates. Lysates were supplemented with
20 nM c-Abl, 200 µM orthovanadate and 1 mM ATP + [γ-32P]ATP to ensure in trans activation of cAbl. Where indicated, lysates were also treated with the c-Abl inhibitor Imatinib (200 µM) 30 min prior
to addition of c-Abl. WT or Y397F caspase-9 (30 µg) were added to lysates to allow caspase-9
phosphorylation. WT but not Y397F caspase-9 showed phosphorylation in the small (Sm) subunit,
which was not visible with Imatinib-treated lysates. In some trials, the small subunit of Y397F also
appears to be labeled albeit at a significantly lower level than that of WT (Supplemental Figure S4.4B).
The phosphorylation observed for CARD+Large appeared to be c-Abl-independent, since Imatinib did
not eliminate its phosphorylation. The band was confirmed to correspond to 32P-labeled CARD+Lg
since it was not present in samples containing only lysates and [γ-32P]ATP (Figure 4.14)
(B) Band intensities corresponding to a phosphorylated small subunit in WT and Y397F show that
Y397F is significantly less phosphorylated (student’s t-test indicates data is statistically significant
***P<0.05 at 99% confidence). Data shown are means ± SEM from three independent experiments
performed on three separate days.

Figure 4.13. Phosphorylation of recombinant caspase-9 in HEK 293T lysates.
(A) Recombinant WT caspase-9 was incubated with HEK 293T lysates with and without added c-Abl (20
nM) over the course of 4h. The CARD+Large (CARD+Lg) region of caspase-9 is phosphorylated even
without adding c-Abl. Only when c-Abl was added was there visible phosphorylation of the small (Sm)
subunit.
(B)Phosphorylation states of WT caspase-9 and Y397F in lysates. The small subunit is clearly
phosphorylated in WT and weakly phosphorylated in Y397F.
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Figure 4.14. Negative control reactions in lysates.
WT caspase-9 is phosphorylated in the CARD+Lg region in the absence of activated c-Abl. The bands
were verified to correspond to caspase-9 since a reaction containing only HEK293T lysates and ATP did
not show 32P-labeling at the corresponding molecular weight of the caspase-9 CARD+Lg.

We then proceeded to interrogate caspase-9 phosphorylation in cells upon activation of
endogenous c-Abl. HEK 293T cells were treated with DPH, a known direct activator of c-Abl24,
along with the phosphatase inhibitor orthovanadate. This led to c-Abl activation, as manifested by
phosphorylation of c-Abl at Y41225. In addition, CrkII, a well-known physiological substrate of cAbl26, was phosphorylated only upon treatment of DPH. The presence of active, phosphorylated
c-Abl

and

phosphorylated

CrkII

were

confirmed

by

immunoblot

against

the

phosphorylatedresidues p-Y412 (for c-Abl) and p-Y221 (for CrkII) (Figure 4.15A). The c-Abl
inhibitor Imatinib abolished these phosphorylation events, demonstrating that c-Abl is indeed
activated by DPH and vanadate (Figure 4.15A).
In order to probe caspase-9 phosphorylation by c-Abl, HEK 293T cells were transfected
with FLAG-tagged caspase-9 catalytic site-inactivated variant C287A and the unphosphorylatable
C287A/Y397F variant. Transfected cells were then treated with DPH/vanadate to induce c-Abl
activation (Figures 4.15B, 4.16A, 4.16B, panels labeled Total). Immunoprecipitated caspase-9
C287A was robustly tyrosine-phosphorylated as assessed by phosphotyrosine immunoblot
(Figures 4.15B, 4.16A, 4.16B; panels labeled IP:FLAG). Together these data indicate that
caspase-9 is a bona fide substrate of c-Abl. While phosphorylation was not entirely eliminated in
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the unphosphorylatable variant C287A/Y397F, the level of phosphorylation was significantly
weaker than in C287A, although the total amount of immunoprecipitated caspase-9 was the same
in both transfected conditions (Figure 4.15B, 4.15C). Moreover, transfected cells treated with
DMSO showed weak tyrosine phosphorylation of both C287A and C287A/Y397F, the
phosphorylation levels of which are comparable to that of C287A/Y397F in DPH/vanadatetreated cells (Figure 4.16A). This strongly supports the model that Y397 is the predominant site
for c-Abl phosphorylation upon its activation by DPH and is the dominant site of c-Abl
phosphorylation in cells.

Figure 4.15. Activation of c-Abl leads to caspase-9 phosphorylation at Y397 intracellularly.
(A) c-Abl is activated by 5-(1,3-diaryl-1H-pyrazol-4-yl)hydantoin (DPH) in synergy with orthovanadate
treatment. HEK 293T cells were treated with DMSO, the known c-Abl activating compound DPH +
orthovandate, or Imatinib for 2h. Lysates were probed for active c-Abl as assessed by immunoblot (IB).
Active c-Abl is phosphorylated at Y412. DPH/vanadate treatment clearly resulted in c-Abl activation,
as manifested by phosphorylation at Y412 and downstream phosphorylation of a well-known c-Abl
substrate, CrkII.
(B) Caspase-9 is phosphorylated at Y397 by active c-Abl intracellularly. HEK 293T cells were
transfected with vector alone (p3xFLAG-CMV™-14), catalytic site-inactivated caspase-9 (C9 C287A3xFLAG or) or the unphosphorylatable variant (C9 C287A/Y397F-3xFLAG). 24h post-transfection,
cells were treated with DPH/vanadate for 2h, harvested and lysed. Immunoblot of total proteins
confirmed c-Abl activation and caspase-9 expression. Caspase-9 was immunoprecipitated from lysates
with an anti-FLAG antibody and probed with anti-phosphotyrosine (p-Tyr) and anti-caspase-9 by
immunoblotting. Cells transfected with C287A/Y397F showed significantly lower levels of
phosphotyrosine in uncleaved caspase-9 compared with those transfected with C287A, although the
levels of immunoprecipitated caspase-9 in both C287A and C287A/Y397F were similar.
(C) Relative abundance of phosphotyrosine (p-Tyr) in caspase-9 C287A and C287A/Y397F. Band
intensities of p-Tyr were normalized against corresponding band intensities of caspase-9 in the
immunoprecipitates. Student’s t-test indicates data is statistically significant *P<0.05 at 99%
confidence. Data shown are means of three independent experiments done on three separate days.
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Figure 4.16. Independent trials of caspase-9 phosphorylation in cells by active c-Abl.
(A) Caspase-9 shows basal tyrosine phosphorylation in the absence of active c-Abl.
Both caspase-9 C287A and C287A/Y397F in DMSO-treated cells showed weak tyrosine phosphorylation,
the levels of which were similar to that of C287A/Y397F in DPH/vanadate-treated cells, suggesting that
this basal phosphorylation is independent of c-Abl activity.
(B) Another independent trial showing that cells transfected with C287A/Y397F are less abundant in
tyrosine phosphorylated-caspase-9 than those transfected with C287A.

Discussion
It is clear from the data presented here that Y397 is a bona fide site of phosphorylation
intracellularly, as was predicted by in vitro phosphorylation studies using purified proteins. There
has been some suggestion in the literature that in vitro phosphorylation of kinase substrates
sometimes differs from in cellular phosphorylation21,27,28. We have not previously observed
irregular phosphorylation of caspase substrates by any of the kinases we have studied19,29,30. Once
again in this work, we found that in vitro phosphorylation by c-Abl accurately reflected the
intracellular phosphorylation specificity we observed. This fidelity between in vitro and cellbased observations is probably due to caspase-9 being a direct substrate of c-Abl. Our data from
multiple kinase:caspase pairs suggest that when the appropriate kinase is studied, in vitro and
cellular phosphorylation patterns are conserved19,29,30.
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While it is clear that Y397 is a bona fide site of c-Abl phosphorylation of caspase-9, one
of the most surprising aspects of our work is the fact that the reported sites on caspase-9,
particularly Y153, was not observed to be phosphorylated by c-Abl either using purified proteins
or intracellularly and was not activated by c-Abl as previously reported. This could be for a
number of reasons. First, the study that identified Y153 phosphorylation as activating did not
investigate the functional impact of substitutions at Y153 on proteolytic activity, but assumed that
Y153F caspase-9 was proteolytically active12. In this work, we have shown that Y153F is
intrinsically inactive. The intrinsic lack of activity led to the interpretation that Y153F transfected
cells were less susceptible to cell death due to phosphorylation by c-Abl12, when in fact, cells
should have been rendered less susceptible to cell death due to the lack of proteolytic activity in
Y153F caspase-9. Second, it is important to note that Y397 is contained within a much more ideal
c-Abl recognition site than Y153 is. Second, c-Abl phosphorylation of caspase-9 at Y153 was
reported after induction of DNA damage12. c-Abl is known to shuttle between the cytosol and the
nucleus31 and DNA damage activates the nuclear c-Abl32,33. It is possible that c-Abl activated by
DNA damage has an altered sequence specificity or recognizes caspase-9 in complex with
cofactors that direct phosphorylation to Y153, or prefers to phosphorylate Y153 in caspase-9 in a
different conformational state. We are only able to speculate on the altered specificity or complex
formation, but we have evidence that the conformational state is not likely to contribute
significantly to the ability of c-Abl to recognize caspase-9. We found that neither caspase-9 in the
zymogen nor in the cleaved state was phosphorylated at Y153 (Figure 4.3B, 4.3D) in vitro.
Fourth, cases of multisite phosphorylation on proteins resulting in antagonistic effects have been
reported34,35, so it is possible that two sites in caspase-9 are differentially phosphorylated by c-Abl
in vivo. Finally, and most probably, it is also possible that c-Abl activated by DNA damage
activates another kinase that is responsible for Y153 phosphorylation. The fact that Y397 is
contained within a more ideal c-Abl recognition site than Y153 may also suggest that Y153
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phosphorylation is achieved not by c-Abl directly, but by a different kinase that is activated by cAbl or by the same stimuli that activate c-Abl.
Y397 is present in the L4 loop, which forms the side of the substrate-binding groove in
caspases. This site is a privileged location for regulation in that is adjacent to but does not directly
interact with substrate. No phosphorylatable tyrosines are present in the L4 loops of other
caspases (Figure 4.17A, 4.17B) so phosphorylation by c-Abl and inhibition by this active-site
adjacent mechanism is likely to be unique to caspase-9. Thus Y397 may provide a chemical
handle for development of compounds that inhibit caspase-9 specifically. Interestingly, in
caspase-6, C264 which is also in the L4 loop, is palmitoylated36. The functional impact of this
palmitoylation has not been fully uncovered but it is tempting to speculate that like caspase-9
Y397 phosphorylation, caspase-6 C264 palmitoylation may result in loss of activity.

Figure 4.17. Y397 is unique to caspase-9.
(A) Sequence alignment of loop L4 of apoptotic caspases. Only caspase-9 contains the
phosphorylatable tyrosine at any position in the L4 loop.
(B) Structure alignment of caspases -3, -6, -7, -8 and -9 highlighting the active site loop bundle.
Residues corresponding to sites Y153 and Y397 are shown in sticks. A tyrosine in Y153 site is
present in all caspase structures shown, while only caspase-9 has a tyrosine in position Y397.
(C) Other apoptotic caspases were incubated with c-Abl in the presence of ATP + [γ-32P]ATP to
assess the ability of c-Abl to phosphorylate them. Caspase-9 clearly appears to be the preferred
substrate of c-Abl over other caspases in vitro. Caspase-8 is weakly phosphorylated at both its large
and small subunits. The following caspase variants were used: caspase-3 CT C163A, WT caspase-6
CT, caspase-7 CT C186S, caspase-8 ∆DED and WT caspase-9 CT. CT refers to Constitutively TwoChain caspase construct.
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The L4 has the most diverse sequence among the active site loops in the apoptotic caspases thus
posttranslational or targeted modification of L4 could be an amenable method of inhibition as it
might confer added specificity for each caspase.
While the full impacts of Y397 phosphorylation are not known it is tempting to speculate
about the functional impact of this phosphorylation event. A prevalent consequence of
phosphorylation is to impact protein-protein interactions. Phosphorylation can either disrupt or
promote binding and in some cases even create a new binding interface. The region where Y397
resides,

395

GIYK398, in L4 of caspase-9 is involved in crystal contacts37, which may suggest that

this region could potentially be involved in protein-protein binding under native conditions as
well. Caspase-9 is activated by recruitment to the apoptosome via CARD-CARD interactions
with Apaf-138. Recently, a structure of the human apoptosome revealed that a monomer of
caspase-9 core (p20/p10) is “parked” on the apoptosome hub, likely in a dynamic manner,
independent of the other caspase-9 dimer/s undergoing activation within the CARD-CARD
ring39. Monomeric caspase-9 cores were also reported to bind to the apoptosome by forming
heterodimer with the Apaf-1 nucleotide oligomerization domain (NOD) via the caspase-9 small
(p10) subunit40. In addition, the apoptosome of C. elegans formed from CED4 and CED3
(homologues of Apaf-1 and caspase-9, respectively) shows that the L2’ region of CED3 directly
interacts with the oligomerized CED4 and is crucial in the formation of a functional
holoenzyme41. These observations imply that in addition to the CARD, other regions in caspase-9
interact with the apoptosome and potentially influence its activation. Perhaps the Y397 region of
the small subunit is involved in direct interactions with the apoptosome, such that
phosphorylation of Y397 would impact these interactions.
c-Abl has been reported to play both pro-apoptotic and anti-apoptotic/pro-survival roles.
The fact that caspase-9 is inhibited by c-Abl phosphorylation at Y397 suggests that this molecular
event contributes to the pro-survival nature of c-Abl. Whereas c-Abl activation by DNA damage
is known to induce cell death, hyperactive cytoplasmic kinase activities of c-Abl and Abl fusion
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proteins are recognized for their oncogenic potential42,43. Overexpression and activation of c-Abl
has been detected in certain breast, colon and lung cancer carcinoma, and in some cases
melanoma (review43). A prime example is BCR-Abl fusion kinase, whose loss of autoinhibition
and increased catalytic activity is highly persistent in chronic myelogenous leukemia (CML)
(reviews44,45). Besides deregulation and hyperactivity, the expanded diversity of Abl substrates
due to altered specificities is thought to be another driving force towards oncogenicity46,47. Thus
Abl phosphorylation of pro-apoptotic proteins with a loss-of-function consequence is consistent
with c-Abl’s anti-apoptotic/pro-survival function. Targeting an initiator caspase such as caspase-9
serves as an efficient route to execute an upstream block in apoptosis signaling.
The dynamic crosstalk between caspases and kinases enables their co-regulation, which is
essential for cellular homeostasis. In many cases kinases are regulated by proteolysis by the very
caspases they phosphorylate (reviews6,48). The cellular outcome, whether promotion or
suppression of apoptosis, is dictated by which functional impact overcomes or precedes the other:
caspase phosphorylation or kinase cleavage. We did not observe any apparent cleavage of c-Abl
by caspase-9 in vitro. One possibility is that caspase-9 only exhibits basal or much lower levels of
activity whereas the kinase activity of c-Abl is heavily favored under in vitro phosphorylation
conditions. It is also possible that c-Abl is simply not a preferred substrate of caspase-9.
However, the case might be different intracellularly since c-Abl was shown to be cleaved by
caspase-8 and caspase-3 causing its transformation to an active state49 and/or its relocation to the
nucleus50. Given that c-Abl exerts dual yet opposing functions in apoptosis, one could infer that
the molecular dialogue between c-Abl and caspase-9 would especially be more relevant in cell
death signaling. We also observed that among apoptotic caspases, caspase-9 is the most preferred
substrate of c-Abl (Figure 4.15C); we envision that exploiting this interaction could be a suitable
approach to specifically control caspase-9 function.
More phosphorylation sites have been reported in caspase-9 than in any other caspase
(reviews6–8). Perhaps this is simply due to the fact that more effort has focused on caspase-9, or
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because there is a need for additional regulation of caspase-9. The latter is more likely, as
caspase-9’s upstream function requires exquisite control to prevent any inopportune amplification
of apoptotic signals. Given the rapid rate of proteomics advancement, we expect more
phosphorylation sites to be reported on caspases under different cellular conditions. In the study
of the interactions of kinase with their substrates, it is often insufficient to rely solely on cellbased assays, particularly when the intrinsic activity of mutant enzymes has not been assessed.
Accurately identifying functionally relevant sites and elucidating the mechanism of
phosphoregulation requires complementary cellular, biochemical and structural interrogation, as
was done in this case.
Our recent data elucidating Y397 phosphorylation adds to the growing list of caspase
phosphoregulation (see Chapter V, Table 5.1). Our results clearly demonstrate that Y397 in
caspase-9 is a bona fide and the dominant site of phosphorylation by c-Abl intracellularly. An
active-site adjacent residue, Y397 does not seem to participate in strong molecular interactions
with residues within the substrate-binding pocket or with the substrate itself, but phosphorylation
transforms this site to one that directly inhibits substrate binding. This is the first report of a novel
c-Abl phosphorylation site unique to caspase-9, and targeting Y397 may serve as an alternative
approach for the specific control of caspase-9. Our results suggest that phosphorylation of
caspase-9 by c-Abl is an important mechanism by which c-Abl fulfills its survival role to escape
apoptosis. The next studies prompted by these findings are to determine the level of caspase-9
phosphorylation at Y397 in cancer cells where c-Abl is overexpressed and hyperactive as it may
provide possible avenues for caspase-kinase co-therapies in cancer and other proliferative
diseases.
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Materials and Methods
DNA constructs
The caspase-9 full-length wild-type (C9FL WT) expression construct (gift of Guy
Salvesen) consists of the human caspase-9 gene (amino acids 1-416) with C-terminal 6x His tag
in pET23b54. The caspase-9 constitutively two-chain (C9 CT) construct consists of an E. coli
codon-optimized synthetic gene (GenScript) built for expression of the CARD+Large subunit
(amino acids 1-315) and separate expression of the small subunit (amino acids 316-416 plus
6xHis) which was under the control of a second ribosome binding site. The Caspase-9 ΔCARD
expression construct was made by deleting the CARD in the C9FL construct by deletion
mutagenesis and inserting a start codon before the first amino acid (Val-139) of the large subunit.
Caspase-3 full-length wild-type expression construct (gift of Guy Salvesen) consists of the human
caspase-3 gene (amino acids 1-279 plus 6x His) in pET23b 55. Caspase variants encoding amino
acid substitutions were generated by point mutagenesis. Bacterial expression constructs for the cAbl kinase domain (c-Abl kinase) (residues 229-511) in pET28a, c-Abl SH3-SH2-kinase domains
(c-Abl 3D) (residues 46-515) in pET28a and YopH phosphatase in pCDFDuet-1 were gifts from
Markus Seeliger56 (Stony Brook University School of Medicine, NY). Both c-Abl constructs have
a TEV protease-cleavable 6xHis tag at the N-termini. For caspase-9 expression in HEK 293T
cells, caspase-9 FL C287A or FL C287A/Y397F gene was subcloned between HindIII and
BamHI sites of the p3xFLAG-CMV™-14 vector (Sigma), producing a C-terminally 3xFLAGtagged caspase-9 expression construct.
Expression and Purification of Proteins
Purification of caspase-9 proteins. Caspase-9 (FL, CT and ΔCARD expression
constructs) in pET23b were individually transformed into the BL21(DE3) E. coli strain. Cells
were grown in 2xYT media with 100 µg/mL of Ampicillin at 37˚C with shaking until OD600=1.2.
The temperature was lowered to 15˚C and protein expression was induced with 1 mM IPTG for 3
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h. Cells were harvested by centrifugation at 4,700 x g for 10 min at 4˚C. Thawed cells were
resuspended in a buffer containing 50 mM sodium phosphate pH 7.0, 300 mM NaCl, 2 mM
imidazole and lysed by use of a microfluidizer (Microfluidics, Inc.). Cell lysate was clarified by
centrifugation at 37,000 x g for 1 h at 4˚C. The supernatant was then loaded onto a HiTrap Niaffinity column (GE Healthcare). Proteins were eluted using a linear imidazole gradient from 2100 mM. Fractions containing caspase-9 were pooled, diluted eight-fold in 20 mM Tris pH 8.5, 5
mM DTT and loaded onto a HiTrap Q-column (GE Healthcare). Proteins were eluted using a
linear NaCl gradient from 0-275 mM. Caspase-9 eluted in buffer with 180 mM NaCl. Peak
fractions were analyzed by SDS-PAGE for purity and stored in -80˚C until further use.
Purification of caspase-3. Full-length caspase-3 (wild-type or the catalytic site
inactivated variant C163S expression constructs) in pET23b were individually transformed into
the BL21(DE3) strain of E. coli. Cultures were grown in 2xYT media supplemented with 100
µg/mL ampicillin at 37˚C with shaking until OD600=0.8. The temperature was lowered to 30˚C
and protein expression as induced by 1 mM IPTG for 3 h. Cells were harvested by centrifugation
at 4,700 x g for 10 min at 4˚C. Cells were freeze-thawed, resuspended in lysis buffer (50 mM
sodium phosphate pH 8,300 mM NaCl, 2 mM imidazole) and lysed by use of a microfluidizer.
Lysed cells were centrifuged at 30,600 x g for 50 min at 4˚C to remove cellular debris. The
supernatant was loaded onto a HiTrap Ni-NTA column. The column was then washed with 50
mM imidazole in lysis buffer and proteins were eluted with 250 mM in lysis buffer. The eluent
was diluted six-fold with buffer A (20 mM Tris pH 8.0, 3 mM DTT) and loaded onto a HiTrap Qcolumn. Proteins were eluted using a linear gradient from 0 – 500 mM NaCl. Caspase-3 eluted in
buffer A with 250 mM NaCl. Peak fractions were analyzed by SDS-PAGE for purity and stored
in -80˚C until use.
Purification of c-Abl kinase. c-Abl kinase was purified according to a method developed
by Seeliger, et al56. Briefly, the expression constructs for c-Abl in pET28a and for YopH in
pCDFDuet were co-transformed in BL21(DE3) E. coli cells. Cells were grown in 2xYT media
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supplemented with kanamycin (50 µg/mL) and streptomycin (50 µg/mL) at 37˚C with shaking
until OD600=1.2. The temperature was lowered to 18˚C and protein expression was induced with
0.2 mM IPTG for 16h. Cells were harvested by centrifugation at 4,700 x g at 4˚C and stored in 80˚C until use. Thawed cells were resuspended in lysis buffer (50 mM Tris pH 8.0, 500 mM
NaCl, 5% glycerol, 25 mM imidazole), lysed by passing through a microfluidizer and centrifuged
at 37,000 x g for 1h at 4˚C. The supernatant was loaded onto a 5-mL HiTrap Ni-affinity column.
Proteins were eluted using a linear gradient of 25 – 250 mM imidazole in lysis buffer. Fractions
containing c-Abl were pooled and treated with TEV protease to cleave the His-tag (1 mg of TEV
per 25 mg of crude kinase). Cleavage proceeded at 4˚C for 16 h while dialyzing against 20
volumes of buffer A (20 mM Tris pH 8.0, 100 mM NaCl, 5% glycerol and 1 mM DTT). The
dialysate was diluted two-fold with buffer A and loaded onto a HiTrap Q column. The column
was developed using a linear gradient of 100-350 mM NaCl in buffer A. c-Abl eluted in buffer A
with 200 mM NaCl. Peak fractions were analyzed by SDS-PAGE for purity and stored in -80˚C
until use.
In vitro phosphorylation and dephosphorylation of caspase-9
Autophosphorylation of c-Abl. c-Abl (20 µM) was incubated in kinase activity buffer (50
mM Tris-Cl pH 7.5, 20 mM MgCl2, 0.1 mM EDTA, 0.5 mM EGTA, 5 mM β-glycerophosphate,
1 mM Na3VO4) and allowed to autoactivate in the presence of 250 µM ATP spiked with [γ32

P]ATP (10 µCi/µL, Perkin Elmer) for 2 h at 30˚C.
Phosphorylation of caspase-9. Caspase-9 (50 µM) was incubated with 1 µM of

autoactivated c-Abl in kinase activity buffer with 1 mM ATP with [γ-32P]ATP for 4 h at 30˚C. For
phosphorylation of caspase-9 in HEK 293T lysates, 20 nM of c-Abl was incubated first with the
lysates (150 µg total protein) with or without Imatinib (200 µM, Sigma) for 30 min. Caspase-9,
WT or Y397F, (30 µg) was then added and the reaction was allowed to proceed for 4h at 30˚C.
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Dephosphorylation of caspase-9. Phosphorylation reactions were treated with calf
intestinal alkaline phosphatase (CIP)(NEB) (10 U for every 10 µg of incorporated phosphate).
The reaction was incubated at 30˚C for 1 h. Removal of phosphates was confirmed by the loss of
band intensity in the phosphorimage.
Phosphoenrichment. c-Abl-phosphorylated caspase-9 WT (100 µM) was bufferexchanged into a loading buffer (TALON® PMAC kit, Clontech) using a NAP™5 desalting
column (GE Healthcare). The buffer-exchanged protein solution was then mixed with TALON®
PMAC magnetic beads (Clontech) for 1 h at 4˚C. The beads were washed twice with loading
buffer and phosphorylated proteins were eluted stepwise from the beads using 250 mM sodium
phosphate pH 7.2, 0.5 M NaCl. Protein concentrations of eluted fractions were estimated using a
BCA (bicinchoninic acid) assay kit (PierceTM, Thermo Scientific).
All reactions were stopped by addition of SDS-PAGE sample dye and boiling for 10 min.
Proteins were resolved by denaturing SDS-PAGE. Phosphorimages were obtained using Typhoon
FLA 7000 (GE Healthcare) and bands were quantified using ImageQuant TL software (GE
Healthcare). Amount of phosphate incorporated was quantified from an ATP standard curve on
the same phosphorimage (Figure 4.18).

Figure 4.18. [γ-32P]ATP standards allow quantification of phosphorylation levels in caspase-9.
Representative Coomassie-stained gel and corresponding phosphorimage of casp-9 phosphorylation by the
three domain (3D) c-Abl kinase in the presence of [γ-32P]ATP with ATP standards on the same
phosphorimage. The intensity of the standards allowed phosphorylation levels in casp-9 and c-Abl to be
accurately quantified.
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Caspase-9 activity assay
Caspase-9 was diluted in caspase-9 activity assay buffer (100 mM MES pH 6.5, 10%
PEG 8000, 5 mM DTT) to a final concentration of 800 nM. For determination of catalytic
parameters, a substrate titration was performed in the range of 0 - 3 mM fluorogenic substrate AcLEHD-AFC (Ex 365 / Em 495) (Enzo Life Sciences). Enzyme concentrations were determined
by active-site titration using a quantitative inhibitor z-VAD-FMK (Enzo Life Sciences). The rate
of LEHD cleavage (LEHDase) was measured using a Spectramax M5 fluorescence plate reader
(Molecular Devices). For caspase-9 activity assays after phosphorylation, 1.5 µM of caspase-9
and 1 mM substrate were used.
Protein Cleavage assays
Self-cleavage. Zymogen forms of caspase-9 (WT, Y153E, Y153D and Y153F) (3 µM)
were allowed to undergo self-cleavage in a minimal activity assay buffer (100 mM MES pH 6.5,
20% PEG 400, 5 mM DTT) at 37˚C over the course of 2 h.
Cleavage by caspase-3. Caspase-3 WT (20 nM) was prepared in caspase-3 activity assay
buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 5 mM CaCl2, 10% PEG 400, 2 mM DTT). Fulllength, uncleaved caspase-9 (catalytic site inactivated variant C287A or phosphomimetics Y153E
and Y153D, or Y153F) (5 µM) was added and the reaction was incubated at 37˚C for times
indicated.
Cleavage of caspase-3 and caspase-7 by caspase-9. Caspase-9 WT or Y397F (50 µM)
was initially phosphorylated by c-Abl. Phosphorylated (WT) and unphosphorylated (Y397F)
caspase-9 was then diluted to 1 µM in caspase-9 minimal activity buffer after which each of the
catalytic site inactivated variants of caspase-3 C163S or caspase-7 C186A were added to a final
concentration of 3 µM and incubated at 32˚C. Aliquots were taken at different time points within
30 min.
All cleavage reactions were stopped by addition of SDS-PAGE sample buffer and boiling
for 10 min. Bands were quantified by densitometry using ImageLab software (BioRad).
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Mammalian Cell culture, transfections and preparation of extracts
HEK 293T cells were grown in RPMI media supplemented with 10% fetal bovine serum,
2 mM glutamine, 50 I.U. penicillin, 50 µg/mL streptomycin and 2 mM sodium pyruvate. Cells
were incubated at 37°C in a humidified atmosphere maintained at 5% CO2. Cells were transiently
transfected with either empty vector (p3xFLAG-CMV-14) or caspase-9 (C9 C287A-3xFLAG or
C9 C287A/Y397F-3xFLAG) using the X-tremeGENE HP DNA transfection reagent (Roche)
according to manufacturer instructions.
After 24 h of expression, transfected cells were washed with 1x PBS and lysed with 1x
Modified Barth’s Saline (MBS)-TritonX pH 7.8 containing 5 mM HEPES pH 7.8, 176 mM NaCl,
1 mM KCl, 1mM MgSO4, 2.5 mM NaHCO3, 1% Triton-X100 and supplemented with Halt™
protease and phosphatase inhibitor cocktail (Thermo Scientific). Lysates were clarified by
centrifugation for 30 min at 16,100 x g at 4˚C.
Activation of c-Abl in HEK 293T
Transfected HEK 293T cultures grown to ~90% confluency were treated with 20 µM 5(1,3-diaryl-1H-pyrazol-4-yl)hydantoin (DPH) (Sigma) and 100 µM sodium orthovanadate
(Sigma) for 2 h. For untreated cells, DMSO was added in place of DPH. To determine the
inhibition of endogenous c-Abl, HEK 293T cells were initially treated with 20 µM of Imatinib
mesylate (Sigma) for 16h prior to DPH treatment. Activation was assessed by monitoring
autophosphorylation of c-Abl at Y412 and phosphorylation of known c-Abl substrate CrkII by
immunoblot.
Immunoprecipitation and Immunoblotting
3xFLAG-tagged caspase-9 from lysates of transfected cells were immunoprecipitated
using anti-FLAG® M2 Affinity Gel (Sigma). The beads with covalently linked antibody were
incubated with the lysates for 16 h at 4˚C using an end-to-end rotator. Beads were washed three
times with 1x MBS-TritonX buffer with Halt™ protease and phosphatase inhibitor cocktail
(Thermo Scientific). Immunoprecipitates were eluted with non-denaturing Laemmli buffer, after
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which 5 mM DTT (final concentration) was added and the solution was boiled for 5 min. Total
lysates and immunoprecipitates were loaded onto a 5-22 % SDS-PAGE and electroblotted to a
PVDF membrane. Total lysates were probed with antibodies against the following: FLAG
(mouse, clone M2, Millipore), phosphoY412 c-Abl (rabbit, Cell Signaling Technologies (CST)),
phosphoY221 CrkII (rabbit, CST), caspase-9 (rabbit, CST) and cyclophilin A (rabbit, CST) which
served as a loading control. Antibody-antigen complexes were probed with anti-phosphotyrosine
(mouse, 4G10 Platinum, Millipore) and anti-caspase-9 (mouse, Proteintech). All primary
antibodies were used at 1:1000 dilution. Prior to immunoblotting with anti-caspase-9, the
membrane was stripped using a stripping buffer pH 2.2 (20 mM glycine, 0.1% (w/v) SDS, 1%
Tween) for 1h then washed sequentially with 1x PBS and 1xTBST. Stripping was confirmed by
probing with a secondary antibody and visualizing no bands after substrate incubation. The
following HRP-conjugated secondary antibodies were used (all from Jackson Immunoresearch):
goat anti-mouse IgG, goat anti-mouse IgG light chain-specific, goat anti-rabbit IgG.
Immunoreactive bands were were detected by enhanced chemiluminescence using an X-ray film
and by visualizing in ChemiDoc XRS+ (BioRad). For detection by X-ray fil, secondary
antibodies were diluted 1:5000; for detection by ChemiDoc XRS+, secondary antibodies were
diluted 1:50,000.
Protein Digestion and LC-MS/MS
In-solution digestion. Caspase-9 (50 µM) was phosphorylated by c-Abl (1 µM) with 1
mM ATP for 4h at 30˚C. After phosphorylation, 5 mM DTT (final concentration) was added and
incubated at 30˚C for 20 min. Cysteine alkylation was then performed by treatment of the sample
with 8 mM iodoacetamide (Sigma). The tube was covered with foil to prevent light-mediated
reactions and the reaction was agitated using an end-to-end rotator for 15 min at RT. Unreacted
iodoacetamide was quenched by adding 5 mM DTT for 15 min at RT. Half of this reaction (~100
µg caspase-9) was diluted in the same volume of Arg-C incubation buffer (50 mM Tris pH 7.7, 5
mM CaCl2 and 2 mM EDTA). 1 µg of Arg-C protease (sequencing grade, Promega) in 50 µL
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activation buffer (5 mM Tris-Cl pH 7.7, 5 mM DTT, 200 µM EDTA) was then added to the
reaction. Digestion was allowed to proceed for 16h at 37˚C. The reaction was stopped by adding
10% formic acid to a final concentration of 0.5%. Final pH was confirmed to be ≤ 2.0. Arg-C was
removed using a Microcon® spin filter column MWCO 10K (Millipore) centrifuged at 16,100 x
g for 15 min. Peptide concentration was estimated by absorbance at 280 nm using a NanoDropTM
2000c spectrophotometer (Thermo Scientific). Digested proteins were diluted with 1% formic
acid to contain 2 µg of peptides.
LC-MS/MS. Protein digests were diluted in 0.1% formic acid in water (solvent A) and
were analyzed on an Orbitrap FusionTM mass spectrometer (Thermo Scientific) coupled to an
Easy-nLC 1000 (Thermo Scientific) ultra high-pressure liquid chromatography (UHPLC) pump.
Analytical LC separations were performed on a FortisBIO C18 nano-flow column (150 mm x 75
µm, 1.7 µm (Fortis Technologies Ltd.)) at a flow rate of 225 nL/min. The following step gradient
was used: 0-40% solvent B (0.1% formic acid in acetonitrile) for the first 90 min then 40-85% B
for 90-95 min. Total run time was set to 130 min. MS1 spectra were collected on a positive
polarity mode with a scan range from m/z 350-1500 at a resolution of 120,000 with an automated
gain control (AGC) target of 400,000 and a maximum injection time of 50 ms. The most intense
ions were selected for MS/MS. A dynamic exclusion window of 60 s with a mass tolerance of
±10 ppm was used to exclude precursors. MS2 precursors were isolated with a quadrupole mass
filter, fragmented by electron transfer dissociation (ETD) and detected by an ion trap mass
analyzer. MS2 was operated with an AGC target of 50,000 and a maximum injection time of 100
ms. MS/MS analysis workflow was created with Proteome Discoverer v1.4 (Thermo Scientific).
Assignment of MS/MS spectra was performed using the SEQUEST algorithm utilizing the
FASTA sequence for human caspase-9 (UniProt ID P55211). SEQUEST searches were
performed with a 10 ppm precursor mass tolerance and 0.5 Da fragment mass tolerance while
requiring peptide termini to have ArgC protease specificity and allowing up to three missed
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cleavages. Carbamidomethylation of cysteine residues (+57.021 Da) and phosphorylation of
tyrosine residues (+79.966) were set as dynamic modifications.
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CHAPTER V
CASPASE-9 PHOSPHORYLATION BY PKA AND c-ABL:
BLOCKING THE APOPTOTIC CASCADE

The power to control cellular signaling pathways has been one of the driving concepts in
therapeutic intervention and drug development aimed at finding cures for deadly and severely
debilitating human diseases. A retrospective examination of the basis of the pathogenesis of these
diseases would reveal a fundamental signaling pathway that almost always contributes to the
progression, or even accounts for that disease. A prominent critical pathway is apoptosis or
programmed cell death, a mechanism utilized by multicellular organisms to achieve tissue
homeostasis and ensure survival by safely disposing unwanted, harmful or unneeded cells.
Diseases associated with defective apoptosis include cancer, neurodegeneration, cardiovascular
diseases and autoimmune disorders. The past few decades have seen continuous efforts to unravel
the many layers of how the cell expertly controls this very complex pathway, resulting in a
breathtaking wealth of knowledge about apoptotic signaling. The attractive idea that one would
be able to control cell death as a means to treat cancer or neurodegeneration has prompted
numerous studies involving core apoptotic components that can either serve as targets or, those
that could potentially be elevated to the clinic as biological therapeutics.
Many elements coordinate to ensure the faithful execution of apoptosis, but caspases
have solicited much interest as appealing therapeutic targets not only because of the great extent
of their killing potential, but also the distinctive property of possessing various switches that
allow them to be turned on or off. One particular molecular switch that controls caspase function
is phosphorylation. While the functional phenotype (suppression or induction of apoptosis)
resulting from phosphorylation of caspases has been known in most cases, key molecular details
that would explain the functional consequences of phosphorylation have been nearly completely
lacking. This dissertation presented detailed structural and mechanistic investigations of caspase-
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9 regulation by phosphorylation in order to provide information that will aid in designing
therapeutic strategies for apoptosis-associated diseases.
Phosphorylation at S183 and Y397 Directly Inhibits Caspase-9
In Chapter I, we put forth the many aspects in caspase-9 phosphorylation that needs to be
addressed in order to fully harness the mechanism of phosphoregulation for therapeutic purposes.
One of the major findings of this work is that phosphorylation of caspase-9 at two dominant sites,
S183 and Y397, abides by the common theme of phosphorylation, directly inhibiting a caspase’s
catalytic function. S183 is phosphorylated by PKA, while Y397 is acted upon by c-Abl kinase.
Two previous findings prompted us to investigate caspase-9 phosphorylation by PKA and c-Abl.
One was the prior report and conclusion that phosphorylation of three sites (S99, S183 and S95)
in caspase-9 was redundant and nonessential to caspase-9 inhibition1. The second was that among
the many reported phosphorylation of caspase-9, only phosphosphorylation by c-Abl at Y153
apparently leads to self-activation and promotes apoptosis2. Our experience with studying
multiple caspase:kinase3,4 pairs led us to hypothesize that contrary to what was reported,
phosphorylation by PKA and c-Abl would directly inhibit caspase-9 function. The data in this
dissertation have shown that assertion to be true.
Chapter II presents comprehensive studies to elucidate the molecular mechanism of
caspase-9 inhibition by PKA. One crucial detail that emerged was that caspase-9 was directly
inhibited by PKA phosphorylation. Using phosphomimetics, in vitro phosphorylation and sitespecific phosphoincorporation, we identified S183 as the predominant site of caspase-9
phosphorylation leading to inhibition. This finding is noteworthy because it contradicts the prior
conclusion of Martin et al.1 about the non-functional or silent effect of PKA phosphorylation in
caspase-9 inhibition. We are able to explain why Martin et al. misinterpreted their data leading to
an erroneous conclusion. Specifically, as is common in many cell-biological studies, they
neglected to biochemically assess the catalytic function of the mutants they used in their studies.
Because the variants they used were inherently inactive, but were assumed to be active, the
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conclusions drawn by their paper were faulty. Our results clearly showed that a phosphorylation
of S183 was enough to render caspase-9 catalytically inactive. In Chapter IV, we employed the
same strategies from Chapter II to explore the activating effect of c-Abl phosphorylation on
caspase-9 as previously reported2. While we were thrilled with the prospect of exploiting a unique
activating mechanism in caspase-9, our results pointed two major findings, both of which were
contrary to what was previously reported. First, we uncovered that Y153 is not the major site of
phosphorylation by c-Abl, rather we discovered a novel site of phosphorylation in caspase-9,
Y397, which was observed to be robustly phosphorylated both in vitro and intracellularly.
Second, phosphorylation of Y397 by c-Abl does not activate but inhibits caspase-9 activity. In the
paper by Raina et al.2, the conclusion that phosphorylation by c-Abl activates caspase-9 was again
based on the erroneous assumption that the unphosphorylatable mutant Y153F was active. They
attributed the observed suppression of apoptosis to the absence of phosphorylation in Y153. In
fact, our biochemical assays clearly show that Y153F has severely impaired catalytic activity, and
would explain the attenuated apoptosis in cells expressing Y153F.
It was evident that our results were not in total agreement with what was previously
reported. We provided an updated interpretation of the previous results, citing the importance of
performing structural and biochemical analyses to complement cell-based assays. While cellbased assays are essential in discerning the biological relevance of phosphorylation, conclusions
derived from these assays can be misleading, most especially when the intrinsic activities of
caspase-9 variants were not assessed and taken into account. Such was the case for both papers on
PKA and c-Abl phosphorylation. In addition, structural analysis of caspase-9 S183 and Y153
would have instantly provided a snapshot of the possible functional effect of phosphorylation.
S183 is involved in critical interactions within conserved residues in the active site, while Y153
contacts with the L2 loop to support the active site loop bundle. Based on these, one would have
predicted that phosphorylation of S183 and Y153 would be inactivating, and not silent or
activating, respectively. Based on this theme, we recommend to other investigators probing
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capsase or caspase-kinase interaction that in the future, the phosphomimetic and
unphosphorylatable versions of all caspases be functionally assessed before any cell-based assays
with mutant proteins are undertaken.
Structural analyses allowed us to expound on the molecular details of how
phosphorylation of S183 and Y397 directly inhibits caspase-9 activity. One detail that particularly
stood out is the proximity of these two residues to the substrate-binding groove (Figure 2.1B,
4.11B), which seems to be a hotspot for phosphorylation in other caspases as well3,4. We have
presented models that would explain the mechanism of inhibition by phosphorylation at S183 and
Y397. Both models suggest that phosphorylation of these sites prevent substrate binding through
different but related mechanisms. S183 phosphorylation disorients the active site loop bundle,
while Y397 phosphorylation reaches into and blocks the substrate-binding pocket.
Our results that phosphorylation by PKA and c-Abl leads to caspase-9 inhibition suggest
an anti-apoptotic/prosurvival role of these kinases. This is particularly relevant in deciphering the
relationship between c-Abl and caspase-9. c-Abl has been reported to play dual yet opposing
roles in apoptotic signaling, depending on its cellular localization. Our observation that caspase-9
is inhibited by c-Abl phosphorylation suggests that this molecular event contributes to the
prosurvival nature of c-Abl, which is consistent with c-Abl’s anti-apoptotic function in the
cytosol where majority of caspase-9 cellular pool are found. Phosphorylation of caspase-9 by
PKA and c-Abl therefore act as upstream block in the apoptotic cascade.
Structural Impacts of Phosphorylation on Caspase-9
A significant finding in Chapter II was that S183 phosphorylation by PKA appears to
utilize two different mechanisms of inhibiting caspase-9, depending on its conformational state.
Phosphorylation of S183 while caspase-9 is in its latent/zymogen state directly prevents substrate
binding, but in its mature/fully cleaved state, S183 phosphorylation triggers the disassembly of
caspase-9 by unfolding its catalytic core. This supports our previous assertion that
phosphorylation can differentially exert its influence throughout the different stages in caspase-
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9’s life cycle. Another fascinating observation was that S183 is distal from the caspase-9
large:small interface, thus the unfolding and disassembly likely proceeds through allosteric
mechanism. To our knowledge this is the first report of such allosteric mechanism of inhibition in
caspases. The most intriguing detail in S183 phosphorylation is our observation that upon
phosphorylation-induced unfolding, caspase-9 formed ordered aggregates, the morphology of
which were visualized through electron microscopy (Figure 2.9, 2.10). While the existence and
possible function of caspase-9 ordered aggregates in vivo remain in question, we offered two
possible scenarios that would explain why phosphorylated caspase-9 might engage such a
mechanism (see Discussion in Chapter II). One is the possibility that the disassembly of the
catalytic core is a surefire way to completely block the apoptotic cascade. Our results point to the
idea that phosphorylated S183 is completely inhibited and more importantly, non-activatable,
even as caspase-9 was directed to the apoptosome. Within the apoptosome, activation by cleavage
of caspase-9 occurs. Cleaved caspase-9 phosphorylated at S183E is severely unstable. This leads
to its unfolding and eventually being disengaged from the apoptosome because it is no longer
structurally intact, and possibly gets directed to proteasomal degradation. The second scenario
involves these ordered aggregates as a mechanism to hold caspase-9 in its latent/inactive state
until caspase-9 gets dephosphorylated and reactivated, a mechanism analogous to that of
functional aggregates. Both scenarios are appealing from a therapeutic and a mechanistic
viewpoint. Phosphorylation-mediated unfolding and degradation suggests crosstalk between
phosphorylation and ubiquitination pathways, thus providing an additional node of possible
therapeutic intervention to control apoptosis. The notion that caspase-9 forms higher order
structures apart from the apoptosome and more importantly, with an opposite function, i.e.
deactivating, adds another layer in the hierarchical nature of caspase-9 structure and function.
In our experiments, ordered aggregates were derived from the phosphomimetic S183E.
What would aid in thorough investigations of the mechanism of formation of these ordered
aggregates is to use a phosphorylated version of S183. While we have successfully generated
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phosphoS183 using site-specific phosphoincorporation in E. coli, the extremely low expression
levels of the phosphocaspase has limited the amount of material to perform aggregation and
subsequent experiments. We recently constructed an MBP-fused phosphocaspase-9, which was
observed to significantly boost caspase-9 expression. It would then be interesting to take S183phosphorylated caspase-9, subject it to aggregation and test whether dephosphorylation would
resolubilize and reactivate caspase-9. If so, then it would strengthen our hypothesis of the nature
and function of these ordered aggregates. The next phase would be to determine the structure of
caspase-9 aggregates by cryo-EM to identify critical interactions within caspase-9 domains or
among caspase-9 molecules.
We also probed and characterized the interaction between the caspase-9 CARD and
catalytic core. This physical interaction influences the stability and activity of caspase-9, but is
dictated by the geometry of the active site and the conformational states of the enzyme. The
region of binding between the CARD and core is still unknown, but would greatly benefit from
structural studies such as X-ray crystallography and small-angle X-ray scattering. While
numerous structures are available for other apoptotic caspases, to date there are only six
structures of non-apoptosome-bound caspase-9 in the PDB. In addition, there is no available
structure of the full-length caspase-9, only that of the catalytic core (∆CARD)5–8 or the CARD9,10,
alone or in complex with other proteins or domains. It would be helpful to obtain a crystal
structure of the full-length caspase-9. Since in almost all crystal structures, the caspase-9 core is a
homodimer, we envision that full-length caspase-9 will crystallize as a dimer as well. What would
be most interesting is whether the interaction between the CARD and catalytic core would be
present in the structure of the full-length caspase-9 with an active-site ligand bound.
Caspase-9-Kinase Interplay
Crosstalk between caspases and kinases is important in their co-regulation, and the
cellular outcome of either promotion or suppression of apoptosis is dictated by whether caspase
phosphorylation or kinase cleavage takes precedence over the other. Typically caspases cleave
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the very kinase that phosphorylates them; such cases were observed in caspase-7 with PAK24 and
caspase-8 with Src11. In our studies on caspase-9 phosphorylation by PKA and c-Abl, we did not
observe any cleavage of either kinase by caspase-9. This observation could be explained by the
relatively low activity of caspase-9 in in vitro conditions. A good model to test whether caspase-9
would cleave PKA and c-Abl is monitor kinase cleavage using caspase-9 in the presence of Apaf1, cytochrome c and dATP, which may accurately reflect an active caspase-9 in the apoptosome.
Should kinase cleavage be observed, the next study would be to determine whether PKA and cAbl prefers to phosphorylate caspase-9 in a specific conformational state, i.e, apoptosome-bound
and cleaved caspase-9 or free caspase-9 in zymogen state.
Alternatively, it is also likely is that the cross talk between caspase-9 and its cognate
kinases is heavily weighted towards phosphorylation. A reason for this assumption is that unlike
other caspase:kinase pairs (review12), no cognate kinase has been reported to be a substrate of
caspase-9. In fact, sequence analyses predicted no caspase-9 cleavage site in PKA. c-Abl is
cleaved by both caspase-313,14 and caspase-814, and while it may be feasible caspase-9 likewise
cleaves c-Abl intracellularly, the caspase cleavage sequences present in c-Abl are not preferred by
caspase-9. Thus it appears that for both PKA and c-Abl (and possibly all other cognate kinases of
caspase-9), phosphorylation-mediated inhibition of caspase-9 would always prevail over kinase
cleavage. A complete understanding of this relationship would be critical in the development of
caspase-kinase co-therapies. For example, in cancer and tumor applications, turning on an
upstream apoptotic caspase like caspase-9 while turning off any inhibition coming from a specific
kinase could potentially result in maximum killing of targeted cells.
Specificity of Phosphorylation by PKA and c-Abl among Apoptotic Caspases
A notable observation in Chapter IV was that caspase-9 is the most preferred caspase
substrate of c-Abl. In addition, the phosphorylated residue, Y397 is a site that is only present in
caspase-9 and not in other apoptotic caspases. This provides multiple potential strategies for the
specific control of caspase-9, either by targeting c-Abl or by exploiting the Y397 site to develop
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inhibitors that will specifically target caspase-9. In contrast to the specificity displayed by c-Abl
towards caspase-9, other apoptotic caspases including caspase-8, -10, -3, -6, and -7 contain the
PKA phosphorylation motif surrounding the S183 site. Surprisingly, caspase-9 is the only
reported caspase substrate of PKA. It would be interesting to explore if these caspases are also
phosphorylated by PKA and whether they are similarly inhibited by the same the mechanisms as
those observed in caspase-9. If other caspases were found to be PKA substrates, this suggests that
PKA could have the upper hand in putting a break in the apoptotic pathways by phosphorylating
and inhibiting multiple caspases, a mechanism which may be exploited by cells in many cancers
and tumor types where PKA is overexpressed15,16.
Other Sites of Phosphorylation in Caspase-9
Caspase-9 contains the greatest number of phosphorylation sites among caspases,
highlighting the need for additional regulation of caspase-9. In the major chapters of this
dissertation, we only focused on two sites of phosphorylation, S183 and Y397, and already
uncovered many layers that govern phosphoregulation of caspase-9. In the Appendix, we present
initial studies on other phosphorylation sites within the CARD and core (S99, T125, S144, S195)
and intersubunit linker (S302, S307 and S310) using phosphomimetics in an attempt to identify
which sites would also inhibit caspase-9 function. We found that in most cases, phosphomimetics
did not directly inhibit catalytic activity, which strongly suggests that phosphorylation of these
residues affect caspase-9 function at a different level. Two particular phosphorylation sites are of
interest – S307 and T125. Our results showed that phosphomimetic S307E is ~40x less active
than WT, although it is capable of self-processing/autoactivation. In this case, phosphorylation
appears to permit zymogen activation of caspase-9, but prevents it from achieving a fully active
state. T125 is the site that is targeted by multiple kinases17–19 to inhibit caspase-9 intracellularly.
In our phosphomimetic studies, T125E is as active as WT and binding assays showed that it does
not prevent caspase-9 from being recruited by Apaf-1. The exact mechanism of how T125
phosphorylation inhibit caspase-9 function remains to be seen. T125 sits in the potentially flexible
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region between the CARD and the large subunit. Reported exosites in caspases seem to cluster in
the prodomain-adjacent region, such as the

38

KKKK41 patch20 and S304 in caspase-7 and a

putative hydrophobic exosite patch in caspase-6 composed of

55

FFW57

21

. In light of these

observations, one might wonder if there are also exosites in caspase-9 that reside in the
prodomain-adjacent region (such as T125 and S99) and whether phosphorylation would influence
exosite binding. Assessing the ability of T125E and S99E to cleave caspase-9 substrates and
comparing it with that of WT is a good place to start exploring this exosite concept.
Diverse Molecular Mechanisms of Phosphorylation-Mediated Caspase Inhibition
Prior to this work, only one mechanism of caspase-9 phosphoregulation (mediated by
CK2) has been elucidated. The work presented in this dissertation now adds three distinct
mechanisms of caspase-9 phosphoregulation to the growing list of molecular mechanisms of
phosphorylation-mediated caspase inhibition (Table 5.1). Some of these mechanisms operate by
inhibiting the early stages of caspase activation, particularly zymogen activation. The conversion
of caspases from a zymogen to a cleaved (mature) state to gain maximal activity is achieved by
cleavage at the intersubunit linker, either by the self-processing or by the action of another
caspase. Phosphorylation of residues adjacent or within the cleavage site(s) in the intersubunit
linker has been shown to block linker cleavage, as observed in casp-322, -811,23 and -924. Recently,
phosphorylation of casp-7 at a prodomain-adjacent S30 was observed to block interaction with
caspase-9, leading to failure of casp-7 cleavage and activation4. Phosphorylation also impacts the
catalytic activity of mature caspases. The mobile nature of the active site loops allows the kinase
facile access to phosphorylation sites that are in close proximity to or within the substrate-binding
pocket. Phosphorylation of these residues appears to be a robust way to directly inhibit catalytic
function either by blocking substrate binding through steric clash, as observed in casp-7 S2394, or
by disorienting the substrate-binding loops, thus making them incompetent to bind substrate, as in
casp-6 S257 and caspase-9 S1833,25. Another is through an active site-adjacent mechanism, as in
Y397 in caspase-9, in which a residue in close proximity to the active site is able to reach into the
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susbtrate binding pocket to block substrate binding26. We also observed an intriguing allosteric
mechanism of phosphoregulation in caspase-9 wherein phosphorylation of S183 in the mature
form is sufficient to disassemble the caspase-9 core despite S183 being distal from the large:small
interface25. We expect that more distinct mechanisms will be added in this growing list.

Table 5.1 Molecular mechanisms of phosphorylation-mediated caspase inhibition.
Molecular Mechanism

Caspase

Site

Kinase

Preventing zymogen activation

Caspase-3
Caspase-8
Caspase-9

T174, S176
Y380
S310 (S348 murine)

CK222
Src11,23
CK224

Blocking protein-protein interactions

Caspase-7

S30

PAK24

Disorienting substrate-binding loops

Caspase-9
Caspase-6

S183
S257

PKA25
Ark53

Directly blocking substrate binding

Caspase-7

S239

PAK24

Core disruption & formation of ordered
aggregates

Caspase-9

S183

PKA25

Active-site adjacent

Caspase-9

Y397

c-Abl26

Many molecular questions still abound concerning caspase phosphoregulation. Of these,
we consider two important questions, which when addressed, will greatly aid in our
understanding about caspase phosphorylation and how it influences the apoptotic pathways. First,
what degree of phosphorylation of caspases is sufficient to switch on or off their function, and is
there a threshold of phosphorylation level that would lead to either suppression or induction of
apoptosis? And second, what phosphatases are associated with these phosphorylation events that
will ensure reversibility of phosphorylation in order to regain balance between cell death and
survival?
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APPENDIX
INTERROGATION OF OTHER PHOSPHORYLATION SITES IN CASPASE-9

The use of glutamate as a phosphomimetic has allowed us to widely investigate
functional effects arising from phosphorylation. Glutamate is typically an acceptable surrogate for
a phosphoSer and phosphoThr, imparting both the bulk and negative charge similar to a
phosphate moiety. Besides the ease by which it can be constructed by site-directed mutagenesis,
one particular advantage of using a phosphomimetic is the ability to obtain homogeneously
“labeled” samples, whereas in vitro reactions typically do not achieve 100% phosphorylation.
Thus the intrinsic functional effect of phosphorylation can readily be examined and explicitly
attributed to that modification. In this section, we employed phosphomimetics to interrogate
residues that were not directly inactivating upon phosphorylation, but could influence other
aspects of caspase-9 structure and function such as oligomerization, protein-protein interactions
and cleavage.
Phosphorylation in CARD and Catalytic Core Domains
The CARD and catalytic core of caspase-9 contain the greatest number of
phosphorylation sites (Figure 1.5, 1.6). In Chapter II, we identified S183 as the predominant site
of phosphorylation that leads to inactivation of caspase-9 by PKA via allosteric mechanisms. In
Chapter IV, Y397 was determined to be a novel site of inactivation upon c-Abl phosphorylation.
Along with S183, two other sites were phosphorylated by PKA – S99 and S195, however
phosphorylation of these sites was reported to be dispensable to caspase-9 inhibition1, and we
make the same observation (Chapter II, Figure 2.2F) . Other sites that reside in the CARD and
core regions are S144, which was observed to be phosphorylated by the atypical PKC ζ under
hyperosmotic stress, and T125, a site phosphorylated by multiple kinases including ERK1,22,
DYRK1A3 and CDK14. In some cases, T107 is reported to be phosphorylated along with T125,
albeit in low levels2,4. Caspase-9 in cell extracts that were phosphorylated on either S144 or T125
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showed diminished self-processing upon incubation with Apaf-1 and cytochrome c. In addition, a
decrease in both casp-3 cleavage and DEVDase activity in these cell extracts were observed,
suggesting that S144- or T125-phosphorylated caspase-9 failed to cleave and activate
downstream caspases. These results initially point towards a direct inactivation of caspase-9
activity upon phosphorylation.
Phosphomimetic versions S99E, S195E, S144E, and T125E were constructed,
overexpressed and purified from E. coli. In contrast to previous reports where phosphorylation
was

inhibitory

to

caspase-9

activity,

all

phosphomimetic variants (S99E, S195E, S144E
and

T125E)

displayed

LEHDase

activity.

Following overexpression, these variants were in
fully

mature/cleaved

forms

(Figure

A.1),

indicating that the variants were capable of selfactivation/cleavage.

Moreover,

their

catalytic

parameters against caspase-9 substrate LEHD
showed that they were active (Table A.1).

Figure A.1. WT and phosphomimetic
versions
of
caspase-9.
Following
overexpression all variants were in the fully
mature/cleaved state.

Table A.1. Catalytic parameters9 of WT caspase-9 and phosphomimetic variants using substrate AcLEHD-AFC.
KM

kcat

103 x kcat / KM

(µM)

(s-1)

(µM-1s-1)

430 ± 35

1.4 ± 0.10

3.3

S99E

1280 ± 295

0.97 ± 0.10

0.80

T125E

509 ± 47

1.38 ± 0.40

2.7

S144E

280 ± 85

0.72 ± 0.15

2.6

S195E

440 ± 85

0.90 ± 0.10

2.1

Caspase-9 variant
WT

9

Values are mean (± SEM) of three trials done on three separate days.

The observation that there was no direct hit to the catalytic activity of these caspase-9
variants could simply imply non-functional or silent phosphorylation, an idea that has been
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debated in the phosphorylation field5,6. Although it is appealing to assign these sites as nonfunctional, knowing the multifaceted nature of caspase-9 regulation led us to further probe how
phosphorylation of these sites, besides affecting catalytic activity, could influence caspase-9
activation. Prior work in our group has clearly shown that phosphorylation of one site does not
necessarily alter catalytic activity, yet impacts a different aspect of caspase function. This was
evident in casp-7 phosphorylation by PAK2, where phosphorylation of S30 and phosphomimetic
S30E had no effect in activity but was found to significantly attenuate procasp-7 cleavage and
activation by caspase-97.
Exploring Apaf-1 CARD:caspase-9 CARD Interactions
From Chapter III it was clear that S99E and T125E did not abolish the interactions
between the CARD and catalytic core of caspase-9 (Chapter II, Figure 3.10). We then explored
whether S99E and T125E could disrupt the interaction between caspase-9 CARD and Apaf-1
CARD. This CARD:CARD interaction is paramount to the initial step of caspase-9 activation in
the apoptosome; any event that breaks this interaction will be an upstream block in the caspase-9
activation cascade. S99 and T125 are located in the potentially flexible linker preceding the large
subunit (Chapter I, Figure 1.6). These residues do not appear to directly participate in Apaf-1
CARD:caspase-9 CARD interactions, based on the available structures of the CARD:CARD
complex, both in isolation8,9 and in the apoptosome10–14. However, we reasoned that the flexible
nature of the S99 and T125 and the altered properties of the residues due to the glutamate
substitution could prevent interaction with Apaf-1 CARD since CARD:CARD interactions are
driven by electrostatics. In addition, there are other charged surfaces outside of CARD:CARD
binding interface that remain exposed9 which could potentially interact with E99 or E125. Gel
mobility shift assays show that the migration of S99E and T125E clearly shifted upon incubation
with Apaf-1 CARD, suggesting that the CARD:CARD interactions are still intact in these
caspase-9 variants (Figure A.2A). In the presence of Apaf-1 CARD, full-length caspase-9 has
been observed to form two species – a heterotetramer composed of a homodimer of caspase-9
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with two Apaf-1 CARD bound, and a high molecular weight oligomer/complex (~300-400 kDa)9.
It was suggested that the high molecular weight complex is formed due to additional interactions
outside of the CARD:CARD binding interface, possibly between the caspase-9 catalytic core and
the CARD:CARD platform. Along with the formation of these oligomers was a marked elevation
in caspase-9 activity. A similar increase in activity was observed with WT caspase-9 and T125E
when bound to Apaf-1 CARD. Strikingly, S99E failed to exhibit this increase in activity (Figure
A.2B). S99E itself was less active than WT (Table A.1), and a similar diminished activity was
also observed with the phosphorylated version, phosphoS99 (Chapter II, Figure 2.3B). Thus it
seems that S99E has enough intrinsic activity to undergo self-processing but is resistant to
enhancement even in the presence of an activating scaffold. Studies such as testing the activities
of S99E and T125E or the phosphorylated versions (using site-specific phosphoincorporation) in
the presence of a reconstituted apoptosome will provide additional insights into how
phosphorylation of S99 and T125 inhibits caspase-9 activity as reported.

Figure A.2. S99E and T125E are able to interact with Apaf-1 CARD.
(A) Gel mobility shift assay of WT caspase-9, and phosphomimetic variants S99E and T125E in the
presence of two-fold excess Apaf-1 CARD. Clear migration shifts were observed for all caspase-9
variants, suggesting an interaction with Apaf-1 CARD.
(B) Change in caspase-9 activity after incubation with Apaf-1 CARD. Elevated LEHDase activity was
observed in WT caspase-9 and T125E while S99E did not display any change in activity.

156

Utilizing Phosphomimetics to Explore Potential Exosites
One recently explored mechanism that dictates caspase function is that caspases possess
exosites critical to substrate recognition and binding. Due the negative charge that the phosphate
moiety imparts on a residue, phosphorylation can alter binding interfaces, either promoting
interactions by creating a new interface, or abrogating interactions by introducing charge
repulsion. Thus one strategy to explore the presence of exosites in caspases is through
phosphorylation. In casp-7, S30 was uncovered to be an exosite for binding with caspase-9.
Phosphorylation of S30 abrogated binding of caspase-9 to procasp-7, leading to an attenuation of
procasp-7 cleavage by caspase-9. This cleavage is paramount to casp-7 activation. However S30E
had no direct effect on the DEVDase activity of the fully mature/cleaved casp-77. In light of these
observations, we examined whether S144 and S195 sites in caspase-9 also serve as exosites that
are utilized by caspase-9 to bind and turnover protein substrates.
Both S144 and S195 are on the surface of helices in the catalytic core that could
potentially be binding surfaces in caspase-9 (Figure 1.6B, A.3). Both sites are adjacent to charged
patches in the catalytic core and substitution of both S144 and S195 to glutamate increases the
surface area of these charged patches (Figure A.3).

Figure A.3. Electrostatic potential map of catalytic core of caspase-9 monomer.
Surface representation of caspase-9 highlighting the changes in electrostatic potential in S195E (left)
and S144E (right) when substituted with glutamate (E195 and E144, respectively). Cartoon
representation in the middle shows the location of S144 and S195 in the caspase-9 monomer.
Electrostatic potential maps were created using Pymol.
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Caspase-9 phosphomimetic variants S144E and S195E exhibited WT-like LEHDase
activities (Table A.1). We assessed whether S144E and S195E would impact the cleavage of
protein substrates. Being an initiator caspase, it is extremely important that caspase-9 fulfills its
function of cleaving downstream executioner caspases. Caspase-9 should also be able to undergo
self-processing in the apoptosome, as it has emerged that uncleavable versions of caspase-9 could
not be efficiently activated in the apoptosome15.
S144E, S195E and the double glutamate variant S144E/S195E were tested in their ability
to cleave the zymogen caspase-9 variant C287A (Figure A.4) to represent the ability of caspase-9
to perform in trans cleavage of other procaspase-9 enzymes. The rate of cleavage of caspase-9
C287A was similar for WT and S144E. S195E cleaved C287A slightly faster than WT, while the
double mutant S144E/S195E displayed similar cleavage kinetics to WT. These data suggest that
the phosphomimetic variants tested were capable of in trans caspase-9 processing.

Figure A.4. Phosphomimetic S144E, S195E and S144E/S195E do not block in trans caspase-9
processing.
Full-length, zymogen caspase-9 C287A (catalytic site-inactivated) was cleaved with S144E, S195E and
S144E/S195E variants for 2h. All variants cleaved C287A with comparable kinetics.

S195E was further tested in cleaving of executioner caspases casp-3 and -7. If caspase-9 utilizes
S195 to bind and cleave casp-3 or casp-7, then the glutamate phosphomimetic S195E would
display either faster or slower protein cleavage kinetics. However, there was no significant
difference in its cleavage kinetics compared to WT caspase-9 (Figure A.5).
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Figure A.5. Cleavage of procasp-3 and procasp-7 by caspase-9 S195E.
(A) Full-length, zymogen casp-3 (catalytic site-inactivated C163S), or (B) full-length zymogen casp-7
(catalytic site-inactivated C186A) was cleaved by WT caspase-9 or S195E for 2h. No significant
difference in cleavage kinetics was observed between WT and S195E.

While phosphorylation of S144 and S195 reportedly led to caspase-9 inhibition in cell extracts,
our assays showed no difference in protein cleavage activities between WT and the
phosphomimetics. The mechanism for the reported inhibition of caspase-9 upon phosphorylation
of these residues remains to be explained.
Phosphorylation of the Intersubunit Linker
Procaspase-9 is cleaved at three sites in the intersubunit linker. The major site for selfprocessing and cleavage by casp-8 is D315 in caspase-9 while minor processing occurs at E306.
Caspase-9 D330 is the recognition and cleavage site for casp-3. Cleavage of the linker is an
activating event for all caspases because it allows the critical L2 and L2’ loops to sample the “up”
conformation to stabilize the active site loop bundle. As an initiator caspase, no upstream caspase
in the intrinsic pathway cleaves the caspase-9 linker, hence it undergoes processing and activation
once incorporated in the apoptosome. Although it has been observed that cleavage of procaspase9 is not necessary for catalytic activity, cleavage plays an integral part of caspase-9 regulation in
various ways. First, the initial cleavage at D315 yields the p35 CARD+Large subunit and the p12
small subunit. The neo-N-terminal of the p12 subunit generates the IAP binding motif
(316ATPF319) that is recognized by the BIR3 domain of XIAP, the apoptotic suppressor that traps
caspase-9 in its monomeric state by binding to this epitope and blocking the dimerization
interface, preventing caspase-9 activation. However, the second cleavage at D330 removes the
IAP binding motif and partially relieves XIAP inhibition and allow caspase-9 activation. Second,
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it was reported that cleaved caspase-9 has a weaker affinity for the apoptosome than procaspase9/zymogen, causing procaspase-9 to displace any auto-activated/cleaved caspase-9 from the
apoptosome. This process of recruitment-activation-displacement of caspase-9 in the apoptosome
is hypothesized to function as a molecular timer, with the intracellular concentration of
procaspase-9 setting the duration of the timer to process executioner caspases as caspase-9
substrates16. If this model is accurate, then cleavage of the intersubunit linker is critical, since
without cleavage, procaspase-9 might remain bound to the apoptosome and cause the molecular
timer to be suspended. Third, uncleavable versions of caspase-9 (E306A/D315A/D330A) were
observed to be inefficiently activated by the apoptosome, attributing the drastic reduction in
activity to the reduced ability of uncleavable caspase-9 to form homodimers15. Fourth, although
the form in which caspase-9 functions outside of the apoptosome is still unknown, activated
caspase-9 has been observed to be cleaved17.
Phosphorylation of caspase substrates has been reported to alter their tendency to undergo
cleavage by caspases (reviews18,19). This effect, whether promotion or protection against cleavage
is commonly observed when phosphorylation is very near the caspase cleavage site. Caspase-9
has three phosphorylation sites in the intersubunit linker (Figure A.6A). These three sites are both
adjacent to each other and neighbors the natural cleavage sites E306 and D315 (Figure A.6B). All
three sites – S302, S307 and S310 – are reported to be phosphorylated by the kinase CK2 (casein
kinase 220,21). CK2 recognizes the minimal consensus sequence S-X-X-D/E/pS/pT (where pS and
pT are phosphoSer and phosphoThr, respectively). Close inspection of these three sites revealed
that the sequences surrounding these sites conform to the CK2 recognition sequence. Since these
sites are adjacent to the linker cleavage sites in caspase-9, phosphorylation could prevent or
promote self-cleavage of caspase-9. Phosphomimetic versions (S302E, S307E and S310E) were
expressed in the full-length construct. Following overexpression, we observed that all
phosphomimetic variants were in the fully mature/cleaved form, indicating that phosphomimicry
most likely does not block caspase-9 self-cleavage. One interesting observation was the cleavage

160

Figure A.6. Caspase-9 intersubunit linker phosphomimetic variants.
(A) Caspase-9 domains showing phosphorylation sites at intersubunit linker by CK2.
(B) The phosphorylation sites are adjacent to self-cleavage sites (E306 and D315, indicated by
arrows) of caspase-9.
(C) Following overexpression, all phosphomimetic variants are in fully cleaved/mature form. S310E
shows a distribution of two cleavage fragments.
(D) Catalytic parameters of linker variants using substrate LEHD-AFC. The catalytic efficiency of
S307E is drastically reduced.

pattern of S310E. The predominant cleavage happens at D315, with a little (< 5%) processing
observed at E306, and both fragments co-elute over the course of an ion exchange gradient. This
fraction and co-elution were consistently observed in all our preparations of active caspase-9
variants. Intriguingly, S310E appears to promote cleavage at E306 (Figure A.6C, first lane in
S310E), generating the E306 cleavage fragment greater than 5% that can be separated from the
D315 fragment on an ion exchange gradient. The relevance of this cleavage pattern is still
unknown but there was a moderate decrease in LEHDase activity observed for S310E (Figure
A.6D).
The most striking observation among the linker variants was the dramatically reduced
activity of S307E. It was able to auto-/self-process yet its catalytic efficiency is ~ 40x less than
WT (Figure A.6C, A.6D). The fact that S307E was able to self-process yet exhibits a diminished
catalytic activity suggests that phosphorylation affects the mature/cleaved form more severely
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than the zymogen. We have yet to explore the mechanism by which S307E is inactivating, but we
surmise that the long linker of caspase-9 can reach into its substrate-binding groove, and a
phosphorylated S307 could either destabilize the active site loop bundle or occlude the substrate
from binding, or both. The linker region of caspases have been shown to perform conformational
acrobatics that contribute to the activation and catalytic function of caspases22,23. Casp-6 has a
relatively long linker compared to other executioner caspases which allows for intramolecular
cleavage24. In the structure of procasp-8 obtained by NMR, it was observed that the intact linker
sits within the vicinity of the active site and forms intramolecular contacts with residues in the
active site loop bundle23. Thus is it conceivable that the longer linker of caspase-9 would
similarly be able to form these interactions with the active site loops and that phosphorylation of
S307 would perturb critical interactions within the active site necessary for catalytic activity.
Phosphorylation of the intersubunit linker near cleavage sites in caspases has been
reported to prevent zymogen activation, either by self-processing or by cleavage by other
caspases. Casp-3 is phosphorylated by CK2 at T174 and S176, blocking linker cleavage by casp-8
and caspase-920. Casp-8 is phosphorylated by Src kinase at Y380, preventing its maturation and
activation in the DISC25,26. In murine caspase-9, phosphorylation of S348, which corresponds to
S310 in human, also prevents auto/self-processing. However, our results showed that the
corresponding phosphomimetics for the phosphorylation sites in the linker were still capable of
self-processing since they were in the fully cleaved/mature form following overexpression
(Figure A.6C). It would be worthwhile to study whether these phosphomimetics block cleavage
of caspase-9 by other caspases including casp-3 and casp-8, which naturally cleave caspase-9. In
addition, the phosphate moiety is in itself a glutamate mimic19,27,28, thus it could potentially create
new cleavage sites in caspase-9 that can be recognized by other caspases.
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